Thus	O
,	O
FGF6	B-GP
is	O
increased	B-Positive_regulation
in	O
PIN	O
and	O
prostate	B-DS
cancer	I-DS
and	O
can	O
promote	O
the	O
proliferation	O
of	O
the	O
transformed	O
prostatic	O
epithelial	O
cells	O
via	O
paracrine	O
and	O
autocrine	O
mechanisms	O
.	O

Isolation	O
and	O
characterization	O
of	O
the	O
major	O
form	O
of	O
human	O
MUC18	O
cDNA	O
gene	O
and	O
correlation	O
of	O
MUC18	B-GP
over	B-Gene_expression
-	I-Gene_expression
expression	I-Gene_expression
in	O
prostate	B-DS
cancer	I-DS
cell	O
lines	O
and	O
tissues	O
with	O
malignant	O
progression	O
.	O

We	O
therefore	O
conclude	O
that	O
MUC18	B-GP
expression	B-Gene_expression
is	O
increased	B-Positive_regulation
during	O
prostate	B-DS
cancer	I-DS
initiation	O
(	O
high	O
grade	O
PIN	O
)	O
and	O
progression	O
to	O
carcinoma	O
,	O
and	O
in	O
metastatic	O
cell	O
lines	O
and	O
metastatic	O
carcinoma	O
.	O

We	O
have	O
found	O
that	O
Cdc6	B-GP
expression	B-Gene_expression
is	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	I-Negative_regulation
in	O
prostate	B-DS
cancer	I-DS
as	O
detected	O
by	O
semiquantitative	O
reverse	O
transcriptase	O
-	O
PCR	O
of	O
prostate	O
cell	O
lines	O
and	O
laser	O
-	O
captured	O
microdissected	O
prostate	O
tissues	O
.	O

Furthermore	O
,	O
a	O
100	O
-	O
fold	O
reduction	B-Negative_regulation
in	O
the	O
transcription	O
efficiency	O
of	O
the	O
Cdc6	B-GP
promoter	I-GP
-	I-GP
luciferase	I-GP
construct	I-GP
was	O
noted	O
in	O
the	O
metastatic	O
PC3	B-DS
cells	O
compared	O
with	O
that	O
in	O
BPH	O
-	O
1	O
cells	O
.	O

Sustained	O
increase	B-Positive_regulation
of	O
the	O
c	B-GP
-	I-GP
myc	I-GP
gene	I-GP
product	I-GP
was	O
detectable	O
in	O
PC	B-DS
-	I-DS
3	O
but	O
not	O
in	O
DU	O
-	O
145	O
cells	O
.	O

Concurrently	O
,	O
we	O
demonstrated	O
BN	O
-	O
dependent	O
activation	B-Positive_regulation
of	O
the	O
transcription	B-GP
factor	I-GP
Elk	I-GP
-	I-GP
1	O
and	O
significant	O
increase	O
of	O
cell	O
proliferation	O
in	O
both	O
prostate	B-DS
cancer	I-DS
cell	O
lines	O
.	O

Electronic	O
profiling	O
of	O
publicly	O
available	O
expressed	O
sequence	O
tag	O
databases	O
identified	O
a	O
gene	O
,	O
cysteine	O
-	O
rich	O
secretoryprotein	O
-	O
3	O
(	O
CRISP	B-GP
-	I-GP
3	O
),	O
that	O
is	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
in	O
prostate	B-DS
cancer	I-DS
,	O
and	O
of	O
which	O
the	O
expression	O
is	O
relatively	O
prostate	O
-	O
specific	O
.	O

Cdc25B	B-GP
is	O
frequently	O
overexpressed	B-Gene_expression
in	O
human	O
prostate	B-DS
cancer	I-DS
tissues	O
(	O
29	O
of	O
30	O
;	O
97	O
%).	O

MEK5	B-GP
overexpression	B-Gene_expression
is	O
associated	O
with	O
metastatic	O
prostate	B-DS
cancer	I-DS
,	O
and	O
stimulates	O
proliferation	O
,	O
MMP	O
-	O
9	O
expression	O
and	O
invasion	O
.	O

The	O
overexpression	B-Gene_expression
of	O
Bax	O
inhibitor	O
-	O
1	O
(	O
BI	B-GP
-	I-GP
1	O
)	O
in	O
prostate	O
carcinoma	O
and	O
prostate	B-DS
cancer	I-DS
cell	O
lines	O
was	O
confirmed	O
by	O
using	O
Northern	O
blot	O
and	O
Western	O
blot	O
analyses	O
.	O

These	O
observations	O
suggest	O
that	O
U19	O
is	O
growth	O
inhibitory	O
and	O
tumor	O
suppressive	O
and	O
that	O
the	O
disruption	O
of	O
androgen	O
-	O
dependent	O
growth	O
inhibition	O
via	O
U19	B-GP
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
is	O
commonly	O
associated	O
with	O
prostate	B-DS
cancer	I-DS
progression	O
.	O

First	O
,	O
a	O
comprehensive	O
serial	O
immunohistochemical	O
analysis	O
of	O
primary	O
and	O
metastatic	O
prostate	B-DS
cancer	I-DS
samples	O
showed	O
increased	B-Positive_regulation
stage	O
-	O
specific	O
expression	B-Gene_expression
of	O
IL	B-GP
-	I-GP
11Ralpha	I-GP
during	O
disease	O
progression	O
.	O

We	O
have	O
shown	O
previously	O
that	O
although	O
AP	O
-	O
2	O
is	O
expressed	O
highly	O
in	O
normal	O
prostatic	O
epithelium	O
,	O
its	O
expression	O
is	O
lost	O
in	O
high	O
-	O
grade	O
prostatic	O
intraepithelial	O
neoplasia	O
and	O
prostate	B-DS
cancer	I-DS
,	O
suggesting	O
that	O
loss	B-Negative_regulation
of	O
AP	B-GP
-	I-GP
2	O
plays	O
a	O
role	O
in	O
prostate	O
cancer	O
development	O
.	O

The	O
interaction	O
between	O
FADD	O
and	O
caspase	O
-	O
8	O
was	O
inhibited	O
,	O
but	O
abrogation	B-Negative_regulation
of	O
JNK	O
activity	O
or	O
HIPK3	B-GP
expression	B-Gene_expression
was	O
found	O
to	O
restore	O
this	O
interaction	O
and	O
increased	O
the	O
sensitivity	O
of	O
DU	B-DS
145	I-DS
cells	O
to	O
Fas	O
receptor	O
-	O
mediated	O
apoptosis	O
.	O

In	O
clinical	O
prostate	B-DS
cancer	I-DS
specimens	O
from	O
patients	O
with	O
varying	O
grades	O
of	O
disease	O
,	O
the	O
stained	O
tissue	O
sections	O
showed	O
high	O
levels	B-Positive_regulation
of	O
SREBP	B-GP
-	I-GP
1	I-GP
protein	I-GP
compared	O
with	O
noncancerous	O
prostate	O
tissue	O
.	O

In	O
summary	O
,	O
the	O
LNCaP	O
xenograft	O
model	O
of	O
human	O
prostate	B-DS
cancer	I-DS
as	O
well	O
as	O
clinical	O
specimens	O
of	O
prostate	O
cancer	O
demonstrated	O
an	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
SREBPs	B-GP
and	O
their	O
downstream	O
effector	O
genes	O
during	O
progression	O
to	O
androgen	O
independence	O
.	O

CBX7	B-GP
overexpression	B-Gene_expression
in	O
LNCaP	B-DS
cells	O
resulted	O
in	O
a	O
slight	O
growth	O
advantage	O
in	O
both	O
androgen	O
-	O
dependent	O
and	O
-	O
independent	O
conditions	O
.	O

Cytochrome	B-GP
P450	I-GP
1B1	I-GP
(	I-GP
CYP1B1	I-GP
),	O
a	O
dioxin	O
inducible	O
member	O
of	O
the	O
CYP	O
supergene	O
family	O
,	O
is	O
overexpressed	B-Gene_expression
in	O
various	O
human	O
malignancies	O
including	O
prostate	B-DS
cancer	I-DS
.	O

Increased	B-Positive_regulation
expression	B-Gene_expression
of	O
osteopontin	B-GP
contributes	O
to	O
the	O
progression	O
of	O
prostate	B-DS
cancer	I-DS
.	O

Increased	B-Positive_regulation
expression	B-Gene_expression
of	O
type	B-GP
2	I-GP
3alpha	I-GP
-	I-GP
hydroxysteroid	I-GP
dehydrogenase	I-GP
/	I-GP
type	I-GP
5	I-GP
17beta	I-GP
-	I-GP
hydroxysteroid	I-GP
dehydrogenase	I-GP
(	I-GP
AKR1C3	I-GP
)	O
and	O
its	O
relationship	O
with	O
androgen	O
receptor	O
in	O
prostate	B-DS
carcinoma	I-DS
.	O

Transfection	O
-	O
mediated	O
WWOX	O
overexpression	O
in	O
DU145	B-DS
cells	O
suppressed	O
colony	O
growth	O
(	O
P	O
=	O
0	O
.	O
0012	O
),	O
and	O
WWOX	B-GP
overexpression	B-Gene_expression
by	O
infection	O
with	O
Ad	O
-	O
WWOX	O
virus	O
induced	O
apoptosis	O
through	O
a	O
caspase	O
-	O
dependent	O
mechanism	O
and	O
suppressed	O
cell	O
growth	O
.	O

Together	O
,	O
our	O
data	O
suggest	O
that	O
strong	O
Tiam1	B-GP
overexpression	B-Gene_expression
relative	O
to	O
the	O
corresponding	O
benign	O
epithelial	O
cells	O
is	O
a	O
new	O
and	O
independent	O
predictor	O
of	O
decreased	O
DFS	O
for	O
patients	O
with	O
prostate	B-DS
cancer	I-DS
.	O

Out	O
of	O
seven	O
isoforms	O
of	O
gal8	O
,	O
the	O
proto	O
isoform	O
gal8e	B-GP
and	O
our	O
newly	O
discovered	O
proto	O
isoform	O
gal8g	B-GP
were	O
upregulated	B-Positive_regulation
in	O
LNCaP	B-DS
cells	O
compared	O
to	O
PrEC	O
,	O
whereas	O
the	O
two	O
tandem	O
-	O
repeat	O
isoforms	O
gal8a	O
and	O
gal8b	O
were	O
equally	O
expressed	O
in	O
these	O
cells	O
.	O

Increased	B-Positive_regulation
expression	B-Gene_expression
of	O
cyclin	B-GP
B1	I-GP
sensitizes	O
prostate	B-DS
cancer	I-DS
cells	O
to	O
apoptosis	O
induced	O
by	O
chemotherapy	O
.	O

We	O
present	O
here	O
for	O
the	O
first	O
time	O
that	O
signal	B-GP
transducers	I-GP
and	I-GP
activators	I-GP
of	I-GP
transcription	I-GP
3	O
(	O
Stat3	O
),	O
which	O
is	O
constitutively	O
activated	B-Positive_regulation
in	O
a	O
wide	O
variety	O
of	O
human	O
cancers	O
,	O
including	O
prostate	B-DS
cancer	I-DS
,	O
interacts	O
with	O
PKCepsilon	O
.	O

Clinical	O
data	O
showed	O
that	O
the	O
levels	B-Gene_expression
of	O
interleukin	B-GP
-	I-GP
4	O
(	O
IL	O
-	O
4	O
)	O
are	O
significantly	O
elevated	B-Positive_regulation
in	O
serum	O
of	O
patients	O
with	O
ablation	O
resistant	O
prostate	B-DS
cancer	I-DS
.	O

Overexpression	B-Gene_expression
of	O
IL	B-GP
-	I-GP
4	O
increases	O
the	O
sensitivity	O
of	O
androgen	O
-	O
sensitive	O
LNCaP	O
prostate	B-DS
cancer	I-DS
cells	O
in	O
response	O
to	O
androgen	O
stimulation	O
and	O
enhances	O
the	O
growth	O
of	O
LNCaP	O
cells	O
both	O
in	O
the	O
presence	O
and	O
absence	O
of	O
androgen	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Loss	B-Negative_regulation
of	O
BRCA2	B-GP
promotes	O
prostate	B-DS
cancer	I-DS
cell	O
invasion	O
through	O
up	O
-	O
regulation	O
of	O
matrix	O
metalloproteinase	O
-	O
9	O
.	O

Consistently	O
,	O
PI3	B-GP
-	I-GP
kinase	I-GP
inhibition	B-Negative_regulation
with	O
a	O
dominant	O
-	O
negative	O
mutant	O
or	O
MAPK	O
/	O
ERK	O
activation	O
with	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutant	O
reduced	O
MMP	O
-	O
9	O
levels	O
and	O
prevented	O
migration	O
and	O
invasion	O
in	O
wild	O
-	O
type	O
PC	B-DS
-	I-DS
3	O
cells	O
.	O

Hyaluronan	B-GP
synthase	I-GP
3	O
overexpression	B-Gene_expression
promotes	O
the	O
growth	O
of	O
TSU	O
prostate	B-DS
cancer	I-DS
cells	O
.	O

AMACR	O
was	O
the	O
best	O
single	O
marker	O
of	O
prostate	B-DS
cancer	I-DS
but	O
in	O
7	O
of	O
the	O
59	O
total	O
cases	O
the	O
expression	O
of	O
AMACR	O
was	O
not	O
significantly	O
elevated	O
while	O
PSGR	B-GP
and	O
/	O
or	O
PSGR2	O
were	O
substantially	O
elevated	B-Positive_regulation
.	O

Reduction	B-Negative_regulation
of	O
AR	B-GP
expression	B-Gene_expression
in	O
the	O
two	O
androgen	O
-	O
sensitive	O
prostate	B-DS
cancer	I-DS
cell	O
lines	O
,	O
LNCaP	O
and	O
LAPC4	O
,	O
significantly	O
decreased	O
AR	O
-	O
mediated	O
transcription	O
and	O
cell	O
growth	O
.	O

Downregulation	B-Negative_regulation
of	O
protein	B-GP
kinase	I-GP
C	O
suppresses	O
induction	O
of	O
apoptosis	O
in	O
human	O
prostatic	B-DS
carcinoma	I-DS
cells	O
.	O

PKC	O
isozyme	O
analysis	O
revealed	O
that	O
chronic	O
PDBu	O
treatment	O
caused	O
downregulation	B-Negative_regulation
of	O
PKC	B-GP
-	I-GP
alpha	I-GP
and	I-GP
-	I-GP
epsilon	I-GP
in	O
DU	B-DS
-	I-DS
145	I-DS
cells	O
.	O

Antisense	O
bcl	O
-	O
2	O
oligodeoxynucleotides	O
decreased	B-Negative_regulation
Bcl	B-GP
-	I-GP
2	I-GP
protein	I-GP
levels	O
and	O
significantly	O
inhibited	O
PC	B-DS
-	I-DS
3	O
cell	O
growth	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O

Experimental	O
work	O
in	O
various	O
prostate	B-DS
cancer	I-DS
models	O
revealed	O
that	O
the	O
androgen	B-GP
receptor	I-GP
is	O
frequently	O
upregulated	B-Positive_regulation
and	O
implicated	O
in	O
tumor	O
progression	O
.	O

EPCR	B-GP
expression	B-Gene_expression
is	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
both	O
at	O
the	O
mRNA	O
and	O
protein	O
levels	O
in	O
invasive	O
prostate	O
DU	B-DS
-	I-DS
145	I-DS
and	O
PC	O
-	O
3	O
cells	O
in	O
comparison	O
to	O
normal	O
prostate	O
epithelial	O
cells	O
(	O
PrEC	O
)	O
and	O
less	O
-	O
invasive	O
LNCaP	O
cells	O
.	O

In	O
conclusion	O
,	O
we	O
provide	O
an	O
explanation	O
for	O
telomerase	O
inhibition	O
after	O
androgen	B-GP
receptor	I-GP
blockade	B-Negative_regulation
in	O
LNCaP	B-DS
cells	O
and	O
we	O
also	O
report	O
activation	B-Positive_regulation
of	O
the	O
p53	B-GP
pathway	O
in	O
LNCaP	O
cells	O
and	O
in	O
-	O
vitro	O
sensitivity	O
to	O
bicalutamide	O
of	O
low	O
confluent	O
androgen	O
-	O
insensitive	O
DU145	O
cells	O
.	O

Reactivation	B-Positive_regulation
of	O
androgen	B-GP
receptor	I-GP
-	I-GP
regulated	I-GP
TMPRSS2	I-GP
:	O
ERG	B-GP
gene	I-GP
expression	B-Gene_expression
in	O
castration	O
-	O
resistant	O
prostate	B-DS
cancer	I-DS
.	O

Moreover	O
,	O
as	O
observed	O
in	O
the	O
clinical	O
samples	O
,	O
ERG	B-GP
expression	B-Gene_expression
was	O
fully	O
restored	B-Positive_regulation
in	O
the	O
VCaP	B-DS
xenografts	O
that	O
relapsed	O
after	O
castration	O
,	O
coincident	O
with	O
AR	B-GP
reactivation	B-Positive_regulation
.	O

We	O
observed	O
that	O
re	O
-	O
expression	O
of	O
AR	O
in	O
the	O
AR	O
-	O
negative	O
cells	O
PC3	B-DS
decreases	O
anchorage	O
-	O
independent	O
growth	O
and	O
Matrigel	O
invasiveness	O
of	O
PC3	O
-	O
AR	O
cells	O
where	O
plasma	O
membrane	O
interaction	O
between	O
AR	O
and	O
EGFR	O
led	O
to	O
an	O
interference	O
with	O
downstream	O
signalling	O
and	O
internalization	O
of	O
activated	B-Positive_regulation
EGFR	B-GP
.	O

M12	B-DS
cells	O
,	O
like	O
many	O
other	O
human	O
cancer	O
cells	O
,	O
contain	O
constitutively	O
activated	B-Positive_regulation
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
STAT3	B-GP
).	O

Strikingly	O
,	O
IFN	O
-	O
gamma	O
-	O
induced	O
apoptosis	O
and	O
growth	O
inhibition	O
of	O
M12	B-DS
cells	O
were	O
associated	O
with	O
persistent	O
suppression	B-Negative_regulation
of	O
the	O
constitutive	O
tyrosine	O
-	O
phosphorylated	O
STAT3	B-GP
(	O
pY	O
-	O
STAT3	O
).	O

In	O
this	O
study	O
,	O
while	O
demonstrating	O
suppressed	B-Negative_regulation
levels	O
of	O
Tm1	B-GP
in	O
the	O
prostate	B-DS
cancer	I-DS
cell	O
lines	O
LNCaP	O
,	O
PC3	O
,	O
and	O
DU	O
-	O
145	O
compared	O
to	O
normal	O
prostate	O
epithelial	O
cell	O
primary	O
isolates	O
(	O
PrEC	O
),	O
a	O
novel	O
splice	O
variant	O
of	O
the	O
TPM2	O
gene	O
was	O
identified	O
.	O

Prostate	O
cancer	O
bony	O
metastases	O
show	O
increased	B-Positive_regulation
expression	B-Gene_expression
of	O
the	O
PTH	B-GP
receptor	I-GP
(	O
PTH	B-GP
-	I-GP
IR	I-GP
)	O
and	O
PTH	B-GP
promotes	O
the	O
growth	O
and	O
invasiveness	O
of	O
prostate	B-DS
cancer	I-DS
cells	O
in	O
bone	O
.	O

A	O
broad	O
spectrum	O
of	O
tumor	O
derived	O
cell	O
lines	O
,	O
from	O
varied	O
tissue	O
sources	O
and	O
blood	O
samples	O
from	O
patients	O
having	O
confirmed	O
prostate	B-DS
carcinoma	I-DS
,	O
all	O
scored	O
positive	B-Positive_regulation
for	O
expression	B-Gene_expression
of	O
PTI	B-GP
-	I-GP
1	O
,	O
while	O
corresponding	O
normal	O
tissues	O
or	O
blood	O
samples	O
were	O
negative	O
.	O

miR	O
488	O
*	O
inhibits	B-Negative_regulation
androgen	B-GP
receptor	I-GP
expression	B-Gene_expression
in	O
prostate	B-DS
carcinoma	I-DS
cells	O
.	O

Here	O
we	O
show	O
that	O
an	O
increase	B-Positive_regulation
in	O
the	O
level	O
of	O
expression	B-Gene_expression
of	O
Bcl	B-GP
-	I-GP
2	O
in	O
the	O
human	O
prostate	B-DS
carcinoma	I-DS
cell	O
line	O
LNCaP	O
observed	O
in	O
response	O
to	O
hormone	O
withdrawal	O
is	O
further	O
augmented	O
by	O
TNF	O
-	O
alpha	O
treatment	O
,	O
and	O
this	O
effect	O
is	O
abated	O
by	O
inhibitors	B-Negative_regulation
of	O
NF	B-GP
-	I-GP
kappa	I-GP
B	O
.	O

For	O
example	O
,	O
some	O
studies	O
showed	O
that	O
CLU	B-GP
expression	B-Gene_expression
is	O
increased	B-Positive_regulation
in	O
advanced	O
stages	O
of	O
prostate	B-DS
cancer	I-DS
and	O
that	O
suppression	B-Negative_regulation
of	O
CLU	B-GP
expression	B-Gene_expression
sensitizes	O
prostate	O
cancer	O
cells	O
to	O
chemotherapeutic	O
drugs	O
killing	O
.	O

Accordingly	O
,	O
a	O
meta	O
-	O
analysis	O
of	O
available	O
microarray	O
data	O
shows	O
that	O
CLU	B-GP
mRNA	I-GP
is	O
significantly	O
downregulated	B-Negative_regulation
in	O
prostate	B-DS
cancer	I-DS
tissue	O
compared	O
to	O
normal	O
prostate	O
in	O
14	O
out	O
of	O
15	O
independent	O
studies	O
.	O

Consistently	O
,	O
CLU	B-GP
expression	B-Gene_expression
was	O
found	O
to	O
be	O
significantly	O
reduced	B-Negative_regulation
in	O
untreated	O
and	O
hormone	O
-	O
refractory	O
human	O
prostate	B-DS
carcinomas	I-DS
.	O

In	O
PC	B-DS
-	I-DS
3	O
cells	O
,	O
adhesion	O
molecule	O
expression	O
,	O
analyzed	O
by	O
immunoblotting	O
,	O
was	O
unaffected	O
by	O
LA	O
,	O
while	O
a	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
c	B-GP
-	I-GP
met	I-GP
(	O
up	O
to	O
28	O
%)	O
was	O
observed	O
after	O
24	O
h	O
of	O
treatment	O
but	O
which	O
did	O
not	O
hold	O
up	O
over	O
time	O
(	O
48	O
-	O
144	O
h	O
).	O

Our	O
findings	O
demonstrate	O
the	O
efficacy	O
of	O
LA	O
in	O
upregulating	B-Positive_regulation
E	B-GP
-	I-GP
cadherin	I-GP
,	O
β	O
-	O
and	O
γ	B-GP
-	I-GP
catenin	I-GP
in	O
LNCaP	B-DS
cells	O
.	O

In	O
BPH	B-DS
samples	O
there	O
was	O
a	O
significant	O
correlation	O
between	O
CD38	O
loss	O
(	O
mean	O
21	O
%	O
of	O
acini	O
)	O
and	O
HLA	B-GP
-	I-GP
DR	I-GP
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
(	O
mean	O
20	O
%;	O
P	O
&	O
lt	O
;	O
0	O
.	O
001	O
).	O

The	O
absence	B-Negative_regulation
of	O
CD38	B-GP
and	O
presence	O
of	O
HLA	O
-	O
DR	O
expression	O
in	O
prostatic	O
epithelium	O
is	O
consistent	O
in	O
BPH	B-DS
and	O
tissue	O
surrounding	O
tumour	O
,	O
and	O
strongly	O
related	O
to	O
gland	O
atrophy	O
.	O

R	O
-	O
etodolac	O
,	O
a	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
inhibits	O
the	O
progression	O
of	O
CWRSA6	O
androgen	O
-	O
independent	O
and	O
LuCaP	O
-	O
35	O
androgen	O
-	O
dependent	O
prostate	B-DS
cancer	I-DS
xenograft	O
growth	O
through	O
downregulation	B-Negative_regulation
of	O
cyclin	B-GP
D1	I-GP
expression	B-Gene_expression
via	O
the	O
PPARgamma	O
pathway	O
.	O

Constitutive	O
activation	O
of	O
MAPK	O
/	O
ERK	O
inhibits	O
prostate	B-DS
cancer	I-DS
cell	O
proliferation	O
through	O
upregulation	B-Positive_regulation
of	O
BRCA2	B-GP
.	O

Overexpressing	B-Gene_expression
PKIB	B-GP
in	O
prostate	B-DS
cancer	I-DS
promotes	O
its	O
aggressiveness	O
by	O
linking	O
between	O
PKA	O
and	O
Akt	O
pathways	O
.	O

DHT	O
-	O
induced	O
E2F	B-GP
-	I-GP
1	I-GP
protein	I-GP
and	O
mRNA	O
expressions	O
was	O
also	O
inhibited	B-Negative_regulation
by	O
BMP	O
-	O
2	O
,	O
suggesting	O
that	O
BMP	O
-	O
2	O
inhibits	O
DHT	O
-	O
induced	O
growth	O
of	O
LNCaP	B-DS
cells	O
through	O
a	O
decrease	B-Negative_regulation
in	O
E2F	B-GP
protein	I-GP
expression	B-Gene_expression
and	O
suppression	B-Negative_regulation
of	O
E2F	B-GP
activity	O
by	O
hypophosphorylation	O
of	O
Rb	O
.	O

Dual	O
blockade	B-Negative_regulation
of	O
PKA	B-GP
and	O
NF	B-GP
-	I-GP
κB	I-GP
inhibits	O
H2	O
relaxin	O
-	O
mediated	O
castrate	O
-	O
resistant	O
growth	O
of	O
prostate	B-DS
cancer	I-DS
sublines	O
and	O
induces	O
apoptosis	O
.	O

Immunohistochemical	O
analysis	O
of	O
tissue	O
microarrays	O
in	O
combination	O
with	O
multispectral	O
quantitative	O
imaging	O
comparing	O
RLN2	O
levels	O
in	O
patients	O
with	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
),	O
prostatic	B-DS
intraepithelial	I-DS
neoplasia	I-DS
,	O
and	O
CaP	O
determined	O
that	O
RLN2	B-GP
is	O
significantly	O
upregulated	B-Positive_regulation
in	O
CaP	O
vs	O
BPH	O
(	O
p	O
=	O
0	O
.	O
002	O
).	O

In	O
human	O
prostate	B-DS
cancer	I-DS
cells	O
,	O
knockdown	B-Negative_regulation
of	O
ILK	B-GP
expression	B-Gene_expression
with	O
siRNA	O
,	O
or	O
inhibition	B-Negative_regulation
of	O
ILK	B-GP
activity	O
,	O
results	O
in	O
significant	O
inhibition	B-Negative_regulation
of	O
HIF	B-GP
-	I-GP
1alpha	I-GP
and	O
VEGF	B-GP
expression	B-Gene_expression
.	O

Inhibition	B-Negative_regulation
of	O
ILK	B-GP
activity	O
also	O
inhibits	O
prostate	B-DS
tumor	I-DS
angiogenesis	O
and	O
suppresses	O
tumor	O
growth	O
.	O

GRP78	B-GP
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
is	O
associated	O
with	O
androgen	O
receptor	O
status	O
,	O
Hsp70	O
-	O
Hsp90	O
client	O
proteins	O
and	O
castrate	O
-	O
resistant	O
prostate	B-DS
cancer	I-DS
.	O

In	O
keeping	O
with	O
our	O
clinical	O
data	O
,	O
activation	B-Positive_regulation
of	O
AR	B-GP
by	O
dihydrotestosterone	O
(	O
DHT	O
)	O
potently	O
activated	B-Positive_regulation
GRP78	B-GP
expression	B-Gene_expression
in	O
both	O
LNCaP	B-DS
and	O
LNCaP	O
-	O
CR	O
cells	O
.	O

TRPV6	O
and	O
prostate	B-DS
cancer	I-DS
:	O
cancer	O
growth	O
beyond	O
the	O
prostate	O
correlates	O
with	O
increased	B-Positive_regulation
TRPV6	B-GP
Ca2	O
+	O
channel	O
expression	B-Gene_expression
.	O

In	O
vitro	O
and	O
in	O
vivo	O
xenograft	O
experiments	O
in	O
NOD	O
/	O
SCID	O
mice	O
further	O
demonstrated	O
that	O
SOX2	O
increased	O
the	O
apoptosis	O
-	O
resistant	O
properties	O
of	O
DU145	B-DS
cells	O
with	O
decreased	O
function	O
of	O
store	O
-	O
operated	O
Ca	O
(	O
2	O
+)	O
entry	O
and	O
reduced	B-Negative_regulation
expression	B-Gene_expression
of	O
Orai1	B-GP
at	O
both	O
mRNA	O
and	O
protein	O
levels	O
,	O
suggesting	O
a	O
potential	O
mechanism	O
that	O
contributes	O
to	O
the	O
anti	O
-	O
apoptotic	O
property	O
of	O
SOX2	O
.	O

These	O
data	O
suggest	O
that	O
blocking	B-Negative_regulation
TSPO	B-GP
function	O
in	O
tumor	O
cells	O
induces	O
cell	O
death	O
and	O
denotes	O
a	O
survival	O
role	O
for	O
TSPO	O
in	O
prostate	B-DS
cancer	I-DS
and	O
provides	O
the	O
first	O
evidence	O
for	O
the	O
use	O
of	O
benzodiazepines	O
in	O
prostate	O
cancer	O
therapeutics	O
.	O

Increased	B-Positive_regulation
levels	B-Gene_expression
of	O
plasma	B-GP
haemoxygenase	I-GP
-	I-GP
1	O
in	O
prostate	B-DS
cancer	I-DS
.	O

PDLIM4	B-GP
mRNA	I-GP
and	O
protein	B-Gene_expression
-	I-Gene_expression
expression	I-Gene_expression
levels	O
were	O
reduced	B-Negative_regulation
in	O
LNCaP	O
,	O
LAPC4	O
,	O
DU145	O
,	O
CWR22	O
,	O
and	O
PC3	O
prostate	B-DS
cancer	I-DS
cells	O
.	O

Compared	O
with	O
BPH	B-DS
,	O
the	O
PCa	O
patients	O
showed	O
decreased	B-Negative_regulation
expressions	B-Gene_expression
of	O
miR	B-GP
-	I-GP
98	I-GP
,	O
let	O
-	O
7d	O
and	O
let	O
-	O
7g	O
,	O
and	O
decreased	B-Negative_regulation
expressions	B-Gene_expression
of	O
miR	B-GP
-	I-GP
96	I-GP
,	O
miR	B-GP
-	I-GP
182	I-GP
and	O
miR	B-GP
-	I-GP
183	I-GP
,	O
with	O
statistically	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
(	O
P	O
&	O
lt	O
;	O
0	O
.	O
05	O
).	O

With	O
the	O
treatment	O
of	O
9	O
-	O
cis	O
RA	O
,	O
the	O
NKX3	B-GP
.	I-GP
1	I-GP
promoter	I-GP
activity	O
was	O
increased	B-Positive_regulation
in	O
reporter	O
gene	O
assay	O
and	O
NKX3	B-GP
.	I-GP
1	O
expression	B-Gene_expression
was	O
enhanced	B-Positive_regulation
at	O
both	O
mRNA	O
and	O
protein	O
levels	O
in	O
LNCaP	B-DS
cells	O
.	O

Our	O
results	O
demonstrated	O
that	O
9	O
-	O
cis	O
RA	O
as	O
a	O
differentiating	O
agent	O
can	O
arrest	O
prostate	B-DS
cancer	I-DS
cells	O
in	O
G	O
(	O
1	O
)	O
phase	O
and	O
reduce	O
cell	O
mitosis	O
,	O
and	O
upregulate	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
human	B-GP
homeobox	I-GP
gene	I-GP
NKX3	I-GP
.	I-GP
1	O
,	O
which	O
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
prostate	O
differentiation	O
and	O
to	O
act	O
as	O
a	O
tumor	O
suppressor	O
gene	O
in	O
the	O
prostate	O
.	O

Our	O
findings	O
indicate	O
that	O
bcl	B-GP
-	I-GP
2	O
expression	B-Gene_expression
is	O
augmented	B-Positive_regulation
following	O
androgen	O
ablation	O
and	O
is	O
correlated	O
with	O
the	O
progression	O
of	O
prostate	B-DS
cancer	I-DS
from	O
androgen	O
dependence	O
to	O
androgen	O
independence	O
.	O

A	O
novel	O
component	O
of	O
the	O
ubiquitin	O
pathway	O
,	O
ubiquitin	B-GP
carboxyl	I-GP
extension	I-GP
protein	I-GP
1	O
is	O
overexpressed	B-Gene_expression
in	O
prostate	B-DS
cancer	I-DS
.	O

Using	O
this	O
approach	O
we	O
found	O
an	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
ubiquitin	B-GP
carboxyl	I-GP
extension	I-GP
protein	I-GP
1	O
(	O
UBCEP	B-GP
-	I-GP
1	O
)	O
mRNA	O
in	O
prostate	B-DS
carcinoma	I-DS
cells	O
compared	O
to	O
the	O
normal	O
glandular	O
epithelium	O
of	O
the	O
prostate	O
proper	O
.	O

Up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
c	B-GP
-	I-GP
Jun	I-GP
-	I-GP
NH2	I-GP
-	I-GP
kinase	I-GP
pathway	O
contributes	O
to	O
the	O
induction	O
of	O
mitochondria	O
-	O
mediated	O
apoptosis	O
by	O
alpha	O
-	O
tocopheryl	O
succinate	O
in	O
human	O
prostate	B-DS
cancer	I-DS
cells	O
.	O

In	O
the	O
adjacent	O
prostate	B-DS
adenocarcinoma	I-DS
glands	O
,	O
the	O
beta	B-GP
1C	I-GP
variant	I-GP
was	O
dramatically	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	I-Negative_regulation
in	O
27	O
of	O
34	O
(	O
79	O
%)	O
analyzed	O
cases	O
,	O
whereas	O
the	O
expression	O
and	O
distribution	O
of	O
its	O
wild	O
-	O
type	O
counterpart	O
,	O
beta	O
1A	O
,	O
remained	O
unchanged	O
.	O

Our	O
findings	O
indicate	O
a	O
significant	O
reduction	B-Negative_regulation
in	O
p27Kip1	B-GP
immunoreactivity	O
in	O
HGPIN	O
(	O
P	O
&	O
lt	O
;	O
0	O
.	O
0001	O
)	O
and	O
prostate	B-DS
cancer	I-DS
(	O
P	O
&	O
lt	O
;	O
0	O
.	O
0001	O
)	O
compared	O
with	O
the	O
benign	O
tissue	O
.	O

Resveratrol	O
-	O
and	O
EGCG	O
-	O
induced	O
apoptosis	O
is	O
associated	O
with	O
a	O
significant	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
CK2	B-GP
activity	O
and	O
protein	O
expression	B-Gene_expression
in	O
both	O
the	O
ALVA	B-DS
-	I-DS
41	I-DS
and	O
PC	O
-	O
3	O
cells	O
.	O

Overexpression	B-Gene_expression
of	O
CK2alpha	B-GP
protected	O
prostatic	B-DS
cancer	I-DS
cells	O
against	O
resveratrol	O
-	O
and	O
EGCG	O
-	O
induced	O
apoptosis	O
.	O

The	O
frequencies	O
of	O
loss	O
for	O
areas	O
known	O
to	O
be	O
frequently	O
deleted	B-Negative_regulation
in	O
prostate	B-DS
cancer	I-DS
,	O
such	O
as	O
6q	B-GP
,	O
8p	O
,	O
or	O
13q	O
,	O
were	O
not	O
different	O
between	O
the	O
two	O
groups	O
.	O

The	O
study	O
suggests	O
that	O
IGF	O
-	O
II	O
has	O
a	O
role	O
in	O
regulating	O
AR	O
expression	O
in	O
prostate	B-DS
cancer	I-DS
cells	O
,	O
and	O
that	O
the	O
action	O
of	O
anti	O
-	O
androgens	O
is	O
mediated	O
partly	O
by	O
an	O
ability	O
to	O
suppress	B-Negative_regulation
IGF	B-GP
-	I-GP
II	I-GP
expression	B-Gene_expression
.	O

Isosilybin	O
B	O
(	O
10	O
-	O
90	O
microM	O
)	O
treatment	O
decreased	B-Negative_regulation
the	O
AR	B-GP
and	O
prostate	B-GP
specific	I-GP
antigen	I-GP
(	O
PSA	B-GP
)	O
levels	B-Gene_expression
in	O
LNCaP	O
,	O
22Rv1	O
and	O
LAPC4	O
cells	O
,	O
but	O
not	O
in	O
non	O
-	O
neoplastic	O
human	O
prostate	O
epithelial	O
PWR	B-DS
-	I-DS
1E	I-DS
cells	O
.	O

Hepatocyte	O
growth	O
factor	O
up	B-Positive_regulation
-	I-Positive_regulation
regulates	I-Positive_regulation
the	O
expression	B-Gene_expression
of	O
the	O
bone	B-GP
morphogenetic	I-GP
protein	I-GP
(	I-GP
BMP	I-GP
)	I-GP
receptors	I-GP
,	O
BMPR	B-GP
-	I-GP
IB	I-GP
and	O
BMPR	B-GP
-	I-GP
II	I-GP
,	O
in	O
human	O
prostate	B-DS
cancer	I-DS
cells	O
.	O

In	O
a	O
murine	O
prostate	O
tumour	O
model	O
,	O
infusion	O
of	O
recombinant	O
HGF	O
resulted	O
in	O
an	O
increase	B-Positive_regulation
in	O
the	O
levels	B-Gene_expression
of	O
both	O
BMPR	B-GP
-	I-GP
IB	I-GP
and	O
BMPR	B-GP
-	I-GP
II	I-GP
transcript	I-GP
in	O
prostate	B-DS
tumours	I-DS
.	O

In	O
conclusion	O
,	O
HGF	O
up	B-Positive_regulation
-	I-Positive_regulation
regulates	I-Positive_regulation
the	O
expression	B-Gene_expression
of	O
the	O
bone	B-GP
morphogenetic	I-GP
protein	I-GP
receptors	I-GP
,	O
BMPR	B-GP
-	I-GP
IB	I-GP
and	O
BMPR	B-GP
-	I-GP
II	I-GP
,	O
in	O
prostate	B-DS
cancer	I-DS
cells	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

3	O
,	O
3	O
'-	O
diindolylmethane	O
induction	B-Positive_regulation
of	O
p75NTR	O
-	O
dependent	O
cell	O
death	O
via	O
the	O
p38	B-GP
mitogen	I-GP
-	I-GP
activated	I-GP
protein	I-GP
kinase	I-GP
pathway	O
in	O
prostate	B-DS
cancer	I-DS
cells	O
.	O

Furthermore	O
,	O
siRNA	O
knockdown	O
of	O
the	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
protein	O
prevented	O
induction	B-Positive_regulation
of	O
p75	B-GP
(	O
NTR	B-GP
)	O
by	O
DIM	O
in	O
the	O
PC	B-DS
-	I-DS
3	O
prostate	O
cell	O
line	O
.	O

Activation	B-Positive_regulation
of	O
mitogen	B-GP
-	I-GP
activated	I-GP
protein	I-GP
kinase	I-GP
pathway	O
by	O
the	O
antiandrogen	O
hydroxyflutamide	O
in	O
androgen	O
receptor	O
-	O
negative	O
prostate	B-DS
cancer	I-DS
cells	O
.	O

In	O
the	O
CM	O
of	O
BPH	B-DS
stromal	O
cells	O
,	O
IGFBP	B-GP
-	I-GP
2	O
levels	B-Gene_expression
were	O
dramatically	O
reduced	B-Negative_regulation
to	O
less	O
than	O
20	O
%	O
of	O
normal	O
(	O
P	O
&	O
lt	O
;	O
0	O
.	O
001	O
).	O

Northern	O
blot	O
analysis	O
of	O
mRNA	O
from	O
normal	O
and	O
BPH	B-DS
stromal	O
cells	O
demonstrated	O
a	O
5	O
-	O
fold	O
decrease	B-Negative_regulation
in	O
IGFBP	B-GP
-	I-GP
2	I-GP
mRNA	I-GP
(	O
P	O
&	O
lt	O
;	O
0	O
.	O
001	O
)	O
and	O
a	O
4	O
-	O
fold	O
increase	B-Positive_regulation
in	O
IGFBP	B-GP
-	I-GP
5	I-GP
mRNA	I-GP
(	O
P	O
&	O
lt	O
;	O
0	O
.	O
01	O
)	O
in	O
BPH	O
compared	O
to	O
normal	O
cells	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
a	O
role	O
for	O
increased	O
DHT	O
levels	O
in	O
the	O
prostate	O
through	O
increased	B-Positive_regulation
activity	O
of	O
the	O
SRD5A2	B-GP
locus	I-GP
in	O
prostate	B-DS
cancer	I-DS
progression	O
,	O
in	O
a	O
subset	O
of	O
patients	O
.	O

Inhibition	B-Negative_regulation
of	O
telomerase	B-GP
with	O
human	O
telomerase	O
reverse	O
transcriptase	O
antisense	O
increases	O
the	O
sensitivity	O
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
-	O
induced	O
apoptosis	O
in	O
prostate	B-DS
cancer	I-DS
cells	O
.	O

hTERT	O
AS	O
PS	O
-	O
ODN	O
can	O
significantly	O
inhibit	O
telomerase	O
activity	O
by	O
downregulating	B-Negative_regulation
the	O
hTERT	B-GP
mRNA	I-GP
and	O
protein	O
expression	B-Gene_expression
,	O
and	O
inhibition	O
of	O
telomerase	O
with	O
hTERT	O
antisense	O
can	O
enhance	O
TNF	O
-	O
alpha	O
-	O
induced	O
apoptosis	O
of	O
PC3	B-DS
cells	O
.	O

Inhibition	B-Negative_regulation
of	O
the	O
Akt	B-GP
,	O
cyclooxygenase	B-GP
-	I-GP
2	O
,	O
and	O
matrix	O
metalloproteinase	O
-	O
9	O
pathways	O
in	O
combination	O
with	O
androgen	O
deprivation	O
therapy	O
:	O
potential	O
therapeutic	O
approaches	O
for	O
prostate	B-DS
cancer	I-DS
.	O

Previous	O
studies	O
by	O
us	O
and	O
others	O
,	O
with	O
androgen	O
-	O
sensitive	O
prostate	B-DS
cancer	I-DS
cell	O
lines	O
,	O
have	O
demonstrated	O
that	O
androgen	O
deprivation	O
results	O
in	O
activation	B-Positive_regulation
/	O
overexpression	O
of	O
Akt	O
,	O
COX	B-GP
-	I-GP
2	O
,	O
and	O
MMP	O
-	O
9	O
in	O
cells	O
.	O

R	O
-(+)	O
equol	O
and	O
S	O
-(-)	O
equol	O
inhibited	O
motility	O
and	O
invasion	O
in	O
PC3	O
and	O
DU145	B-DS
cells	O
,	O
while	O
the	O
most	O
strong	O
effect	O
was	O
observed	O
in	O
PC3	O
cells	O
by	O
R	O
-(+)	O
equol	O
,	O
which	O
might	O
regulated	O
by	O
the	O
activation	B-Positive_regulation
of	O
estrogen	B-GP
receptor	I-GP
-	I-GP
alpha	I-GP
.	O

Induction	B-Positive_regulation
of	O
p27	B-GP
(	O
kip1	B-GP
)	O
by	O
2	O
,	O
4	O
,	O
3	O
',	O
5	O
'-	O
tetramethoxystilbene	O
is	O
regulated	O
by	O
protein	O
phosphatase	O
2A	O
-	O
dependent	O
Akt	O
dephosphorylation	O
in	O
PC	O
-	O
3	O
prostate	B-DS
cancer	I-DS
cells	O
.	O

These	O
results	O
suggest	O
that	O
TMS	O
may	O
inhibit	O
the	O
cell	O
cycle	O
through	O
induction	B-Positive_regulation
of	O
p27	B-GP
(	O
kip1	B-GP
),	O
leading	O
to	O
apoptotic	O
cell	O
death	O
in	O
PC	O
-	O
3	O
prostate	B-DS
cancer	I-DS
cells	O
.	O

Our	O
results	O
support	O
ongoing	O
therapeutic	O
attempts	O
of	O
EGFR	B-GP
inhibition	B-Negative_regulation
in	O
subgroups	O
of	O
patients	O
with	O
prostate	B-DS
cancer	I-DS
.	O

We	O
also	O
found	O
that	O
the	O
expression	B-Gene_expression
of	O
tumour	B-GP
necrosis	I-GP
factor	I-GP
receptor	I-GP
2	I-GP
and	I-GP
death	I-GP
receptor	I-GP
3	O
(	O
DR3	B-GP
)	O
was	O
increased	B-Positive_regulation
in	O
PC3	B-DS
cells	O
,	O
and	O
the	O
expression	B-Gene_expression
of	O
FAS	B-GP
and	O
DR3	B-GP
was	O
increased	B-Positive_regulation
in	O
SW620	O
cells	O
by	O
co	O
-	O
culture	O
with	O
NK	O
-	O
92	O
cells	O
.	O

Evaluation	O
of	O
alterations	O
in	O
the	O
level	O
of	O
the	O
five	O
major	O
electrophoretic	O
fractions	O
of	O
serum	O
proteins	O
(	O
albumin	O
,	O
alpha	O
1	O
-,	O
alpha	O
2	O
-,	O
beta	O
-	O
and	O
gamma	O
-	O
globulin	O
)	O
in	O
18	O
patients	O
with	O
prostatic	B-DS
cancer	I-DS
prior	O
to	O
and	O
following	O
cryoprostatectomy	O
disclosed	O
:	O
(	O
i	O
)	O
a	O
progressive	O
increase	B-Positive_regulation
in	O
the	O
level	O
of	O
alpha	B-GP
2	I-GP
-	I-GP
and	I-GP
beta	I-GP
-	I-GP
globulin	I-GP
and	O
the	O
incidence	O
of	O
patients	O
possessing	O
statistically	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
elevations	O
in	O
these	O
proteins	O
with	O
a	O
progression	O
of	O
the	O
stage	O
of	O
their	O
malignancy	O
;	O
(	O
ii	O
)	O
a	O
significant	O
decrease	B-Negative_regulation
in	O
albumin	B-GP
,	O
alpha	O
2	O
-	O
and	O
beta	O
-	O
globulin	O
and	O
increase	B-Positive_regulation
in	O
alpha	B-GP
1	I-GP
-	I-GP
and	I-GP
gamma	I-GP
-	I-GP
globulin	I-GP
from	O
their	O
preoperative	O
levels	O
following	O
cryoprostatectomy	O
in	O
patients	O
with	O
metastatic	O
disease	O
(	O
stage	O
III	O
)	O
in	O
association	O
with	O
a	O
favorable	O
clinical	O
response	O
;	O
(	O
iii	O
)	O
an	O
overall	O
significant	O
decrease	B-Negative_regulation
in	O
albumin	B-GP
and	O
alpha	B-GP
2	I-GP
-	I-GP
globulin	I-GP
and	O
increase	B-Positive_regulation
in	O
alpha	B-GP
1	I-GP
-	I-GP
globulin	I-GP
from	O
their	O
preoperative	O
levels	B-Gene_expression
and	O
(	O
iv	O
)	O
a	O
general	O
association	O
of	O
decreases	O
in	O
albumin	O
(	O
83	O
%	O
of	O
the	O
patients	O
)	O
and	O
alpha	O
2	O
-	O
globulin	O
(	O
92	O
%)	O
and	O
gamma	O
-	O
globulin	O
(	O
75	O
%)	O
with	O
a	O
favorable	O
clinical	O
response	O
following	O
cryoprostatectomy	O
.	O

Trefoil	B-GP
factor	I-GP
3	O
is	O
overexpressed	B-Gene_expression
in	O
human	O
prostate	B-DS
cancer	I-DS
.	O

These	O
studies	O
validate	O
that	O
TFF3	B-GP
is	O
overexpressed	B-Gene_expression
in	O
a	O
subset	O
of	O
primary	O
and	O
metastic	O
prostate	B-DS
cancers	I-DS
.	O

Furthermore	O
,	O
E1	O
induced	O
a	O
twofold	O
increase	B-Positive_regulation
in	O
connexin	B-GP
43	I-GP
(	O
Cx43	B-GP
),	O
whereas	O
forskolin	O
caused	O
a	O
50	O
%	O
reduction	B-Negative_regulation
in	O
Cx32	B-GP
expression	B-Gene_expression
in	O
RWPE	B-DS
-	I-DS
1	O
cells	O
.	O

Here	O
we	O
demonstrate	O
that	O
arsenite	O
induces	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
HIF	B-GP
-	I-GP
1alpha	I-GP
but	O
not	O
HIF	B-GP
-	I-GP
1beta	I-GP
subunit	I-GP
in	O
DU145	O
human	O
prostate	B-DS
carcinoma	I-DS
cells	O
.	O

The	O
differentiation	O
-	O
related	O
gene	O
1	O
,	O
Drg1	B-GP
,	O
is	O
markedly	O
upregulated	B-Positive_regulation
by	O
androgens	O
in	O
LNCaP	O
prostatic	B-DS
adenocarcinoma	I-DS
cells	O
.	O

Basal	O
levels	B-Gene_expression
and	O
adrenocorticotropic	B-GP
hormone	I-GP
(	O
ACTH	B-GP
)-	O
induced	O
increments	B-Positive_regulation
(	O
delta	O
-	O
values	O
)	O
of	O
serum	O
cortisol	O
,	O
dehydroepiandrosterone	O
(	O
DHA	O
),	O
dehydroepiandrosterone	O
sulfate	O
(	O
DHAS	O
),	O
4	O
-	O
androstene	O
-	O
3	O
,	O
17	O
-	O
dione	O
(	O
A4	O
),	O
and	O
17	O
-	O
hydroxyprogesterone	O
(	O
170HP	O
);	O
basal	O
testosterone	O
(	O
T	O
),	O
luteinizing	B-GP
hormone	I-GP
(	O
LH	O
),	O
serum	O
ASAT	O
,	O
gamma	O
-	O
GT	O
,	O
and	O
albumin	O
were	O
measured	O
in	O
prostatic	B-DS
cancer	I-DS
patients	O
before	O
and	O
after	O
6	O
months	O
of	O
treatment	O
with	O
LH	O
-	O
RH	O
-	O
agonist	O
,	O
with	O
flutamide	O
,	O
and	O
with	O
LH	O
-	O
RH	O
-	O
agonist	O
+	O
flutamide	O
,	O
respectively	O
.	O

These	O
events	O
result	O
in	O
increased	O
accumulation	B-Positive_regulation
of	O
AR	B-GP
and	O
thus	O
enhanced	O
growth	O
of	O
prostate	B-DS
cancer	I-DS
cells	O
at	O
low	O
levels	O
of	O
androgen	O
.	O

About	O
50	O
%	O
of	O
prostate	B-DS
cancers	I-DS
have	O
TMPRSS2	O
-	O
ERG	O
fusions	O
with	O
concurrent	O
ERG	B-GP
overexpression	B-Gene_expression
.	O

Inhibition	O
of	O
ligand	O
-	O
mediated	O
HER2	B-GP
activation	B-Positive_regulation
in	O
androgen	B-DS
-	I-DS
independent	I-DS
prostate	I-DS
cancer	I-DS
.	O

Similarly	O
,	O
activation	B-Positive_regulation
of	O
the	O
AR	B-GP
by	O
phosphorylated	O
protein	O
kinase	O
B	O
,	O
Akt	O
,	O
has	O
also	O
been	O
reported	O
in	O
prostate	B-DS
cancer	I-DS
.	O

Overexpression	B-Gene_expression
of	O
manganese	O
superoxide	B-GP
dismutase	I-GP
in	O
DU145	O
human	O
prostate	B-DS
carcinoma	I-DS
cells	O
has	O
multiple	O
effects	O
on	O
cell	O
phenotype	O
.	O

DU145	O
human	O
prostate	B-DS
carcinoma	I-DS
cells	O
were	O
transfected	O
with	O
the	O
cDNA	O
for	O
manganese	O
superoxide	O
dismutase	O
(	O
MnSOD	O
),	O
and	O
two	O
clones	O
overexpressing	B-Gene_expression
MnSOD	B-GP
activity	O
were	O
subsequently	O
characterized	O
by	O
comparison	O
with	O
parental	O
and	O
plasmid	O
control	O
-	O
transfected	O
cells	O
.	O

Our	O
results	O
suggest	O
novel	O
mechanisms	O
by	O
which	O
MnSOD	B-GP
overexpression	B-Gene_expression
may	O
modulate	O
the	O
malignant	O
phenotype	O
,	O
with	O
potential	O
applications	O
in	O
developing	O
new	O
therapies	O
for	O
prostate	B-DS
cancer	I-DS
.	O

Overexpression	B-Gene_expression
of	O
p45	B-GP
-	I-GP
sErbB3	I-GP
in	O
the	O
osteolytic	O
prostate	B-DS
cancer	I-DS
cell	O
line	O
PC	O
-	O
3	O
converted	O
its	O
phenotype	O
from	O
bone	O
lysing	O
to	O
bone	O
forming	O
upon	O
injection	O
into	O
the	O
femurs	O
of	O
immunodeficient	O
mice	O
.	O

L	O
-	O
mimosine	O
blocks	O
cell	O
proliferation	O
via	O
upregulation	B-Positive_regulation
of	O
B	B-GP
-	I-GP
cell	I-GP
translocation	I-GP
gene	I-GP
2	O
and	O
N	B-GP
-	I-GP
myc	I-GP
downstream	I-GP
regulated	I-GP
gene	I-GP
1	O
in	O
prostate	B-DS
carcinoma	I-DS
cells	O
.	O

Immunoblot	O
assays	O
indicated	O
that	O
hypoxia	O
and	O
L	O
-	O
mimosine	O
stabilized	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
α	O
(	O
HIF	O
-	O
1α	O
)	O
and	O
induced	B-Positive_regulation
Btg2	B-GP
and	O
Ndrg1	B-GP
protein	I-GP
expression	B-Gene_expression
,	O
but	O
downregulated	O
protein	O
levels	O
of	O
cyclin	O
A	O
in	O
both	O
PC	O
-	O
3	O
and	O
LNCaP	B-DS
cells	O
.	O

L	O
-	O
mimosine	O
treatment	O
decreased	B-Negative_regulation
cyclin	B-GP
D1	I-GP
protein	O
in	O
PC	O
-	O
3	O
cells	O
,	O
but	O
not	O
in	O
LNCaP	B-DS
cells	O
.	O

Dimethyloxalylglycine	O
,	O
a	O
pan	O
-	O
prolyl	O
hydroxylase	O
inhibitor	O
,	O
also	O
induced	B-Positive_regulation
Btg2	B-GP
and	O
Ndrg1	B-GP
protein	I-GP
expression	B-Gene_expression
in	O
LNCaP	B-DS
cells	O
.	O

L	O
-	O
mimosine	O
enhanced	B-Positive_regulation
expression	B-Gene_expression
of	O
Btg2	B-GP
and	O
Ndrg1	B-GP
,	O
which	O
attenuated	O
cell	O
proliferation	O
of	O
the	O
PC	O
-	O
3	O
and	O
LNCaP	O
prostate	B-DS
carcinoma	I-DS
cells	O
.	O

These	O
results	O
showed	O
fisetin	O
could	O
inhibit	O
the	O
metastatic	O
ability	O
of	O
PC	B-DS
-	I-DS
3	O
by	O
reducing	B-Negative_regulation
MMP	B-GP
-	I-GP
2	O
and	O
MMP	B-GP
-	I-GP
9	O
expressions	B-Gene_expression
through	O
suppressing	O
phosphoinositide	O
3	O
-	O
kinase	O
/	O
Akt	O
(	O
PI3K	O
/	O
Akt	O
)	O
and	O
JNK	O
signaling	O
pathways	O
.	O

The	O
expression	B-Gene_expression
of	O
the	O
p75	B-GP
neurotrophin	I-GP
receptor	I-GP
(	O
p75NTR	B-GP
)	O
is	O
diminished	B-Negative_regulation
in	O
epithelial	O
cells	O
during	O
progression	O
of	O
prostate	B-DS
cancer	I-DS
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Hence	O
,	O
re	O
-	O
expression	O
of	O
the	O
p75NTR	O
appears	O
to	O
partially	O
reverse	O
de	O
-	O
differentiation	O
of	O
prostate	B-DS
cancer	I-DS
cells	O
by	O
up	B-Positive_regulation
-	I-Positive_regulation
regulating	I-Positive_regulation
the	O
expression	B-Gene_expression
of	O
CRABPI	B-GP
for	O
localized	O
sequestration	O
of	O
retinoids	O
that	O
are	O
available	O
to	O
newly	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
RAR	B-GP
-	I-GP
beta	I-GP
,	O
RXR	O
-	O
alpha	O
,	O
and	O
RXR	O
-	O
beta	O
.	O

Ubiquitous	O
mitochondrial	B-GP
creatine	I-GP
kinase	I-GP
is	O
overexpressed	B-Gene_expression
in	O
the	O
conditioned	O
medium	O
and	O
the	O
extract	O
of	O
LNCaP	O
lineaged	O
androgen	O
independent	O
cell	O
lines	O
and	O
facilitates	O
prostate	B-DS
cancer	I-DS
progression	O
.	O

uMtCK	B-GP
was	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
in	O
AIPC	O
cells	O
and	O
in	O
human	O
prostate	B-DS
cancer	I-DS
tissues	O
at	O
WHO	O
grade	O
III	O
.	O

Exogenous	O
uMtCK	O
in	O
LNCaP	B-DS
cells	O
surprisingly	O
contributed	B-Positive_regulation
to	O
overproduction	B-Gene_expression
of	O
ROS	B-GP
,	O
activation	O
of	O
Akt	O
signaling	O
pathway	O
and	O
more	O
aggressive	O
phenotypes	O
including	O
androgen	O
independence	O
development	O
.	O

Quercetin	O
-	O
induced	O
growth	O
inhibition	O
and	O
cell	O
death	O
in	O
prostatic	B-DS
carcinoma	I-DS
cells	O
(	O
PC	O
-	O
3	O
)	O
are	O
associated	O
with	O
increase	B-Positive_regulation
in	O
p21	B-GP
and	O
hypophosphorylated	B-GP
retinoblastoma	I-GP
proteins	I-GP
expression	B-Gene_expression
.	O

Androgen	O
-	O
sensitive	O
LNCaP	O
prostate	B-DS
cancer	I-DS
cells	O
engineered	O
to	O
stably	O
overexpress	B-Gene_expression
CDK6	B-GP
display	O
increased	O
expression	O
of	O
the	O
prostate	O
-	O
specific	O
antigen	O
and	O
enhanced	O
growth	O
in	O
the	O
presence	O
of	O
dihydrotestosterone	O
.	O

Arsenite	O
induces	B-Positive_regulation
p70S6K1	B-GP
activation	B-Positive_regulation
and	O
HIF	B-GP
-	I-GP
1alpha	I-GP
expression	B-Gene_expression
in	O
prostate	B-DS
cancer	I-DS
cells	O
.	O

We	O
have	O
also	O
shown	O
that	O
arsenite	O
specifically	O
induces	B-Positive_regulation
HIF	B-GP
-	I-GP
1alpha	I-GP
,	O
but	O
not	O
HIF	O
-	O
1beta	O
,	O
protein	O
levels	O
in	O
prostate	B-DS
cancer	I-DS
cells	O
in	O
a	O
mTOR	O
-	O
dependent	O
manner	O
.	O

Quinazoline	O
-	O
based	O
alpha	O
1	O
-	O
adrenoceptor	O
antagonists	O
induce	O
prostate	B-DS
cancer	I-DS
cell	O
apoptosis	O
via	O
TGF	O
-	O
beta	O
signalling	O
and	O
I	B-GP
kappa	I-GP
B	I-GP
alpha	I-GP
induction	B-Positive_regulation
.	O

Treatment	O
of	O
the	O
androgen	O
-	O
independent	O
human	O
prostate	B-DS
cancer	I-DS
cells	O
PC	O
-	O
3	O
with	O
doxazosin	O
resulted	O
in	O
a	O
strong	O
caspase	B-GP
-	I-GP
3	O
activation	B-Positive_regulation
within	O
24	O
h	O
,	O
whereas	O
tamsulosin	O
,	O
a	O
sulphonamide	O
-	O
based	O
alpha	O
1	O
-	O
adrenoceptor	O
antagonist	O
,	O
had	O
no	O
significant	O
apoptotic	O
effect	O
against	O
prostate	O
cancer	O
cells	O
.	O

[	B-Gene_expression
Overexpression	I-Gene_expression
of	O
human	B-GP
tumor	I-GP
metastasis	I-GP
-	I-GP
related	I-GP
gene	I-GP
TMSG	I-GP
-	I-GP
1	O
suppresses	O
cell	O
proliferation	O
and	O
invasion	O
of	O
a	O
highly	O
metastatic	B-DS
prostate	I-DS
cancer	I-DS
cell	O
line	O
PC	O
-	O
3M	O
-	O
1E8	O
in	O
vitro	O
].	O

The	O
compound	O
investigated	O
is	O
present	O
in	O
a	O
herbal	O
preparation	O
extracted	O
from	O
Boswellia	O
serrata	O
oleo	O
-	O
gum	O
-	O
resin	O
,	O
it	O
inhibits	O
the	O
growth	O
of	O
chemotherapy	O
-	O
resistant	O
human	O
PC	O
-	O
3	O
prostate	B-DS
cancer	I-DS
cells	O
in	O
vitro	O
and	O
induces	O
apoptosis	O
as	O
shown	O
by	O
activation	B-Positive_regulation
of	O
caspase	B-GP
3	O
and	O
the	O
induction	O
of	O
DNA	O
fragmentation	O
.	O

OC	B-GP
expression	B-Gene_expression
is	O
elevated	B-Positive_regulation
in	O
prostate	B-DS
tumor	I-DS
cells	O
and	O
in	O
prostate	O
and	O
bone	O
stromal	O
cells	O
interdigitating	O
with	O
both	O
localized	O
and	O
metastatic	O
prostate	O
epithelium	O
.	O

Angiogenic	O
cytokines	O
such	O
as	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
have	O
been	O
identified	O
in	O
prostate	B-DS
cancer	I-DS
cells	O
and	O
tumours	O
,	O
and	O
androgens	O
appear	O
to	O
stimulate	B-Positive_regulation
VEGF	B-GP
.	O

Overexpression	B-Gene_expression
of	O
12	B-GP
/	I-GP
15	I-GP
-	I-GP
lipoxygenase	I-GP
,	O
an	O
ortholog	O
of	O
human	O
15	O
-	O
lipoxygenase	O
-	O
1	O
,	O
in	O
the	O
prostate	B-DS
tumors	I-DS
of	O
TRAMP	O
mice	O
.	O

We	O
critically	O
review	O
the	O
recent	O
advances	O
in	O
prostate	B-DS
cancer	I-DS
immunohistochemistry	O
,	O
including	O
the	O
introduction	O
of	O
newer	O
basal	O
cell	O
markers	O
such	O
as	O
p63	O
and	O
the	O
discovery	O
of	O
the	O
overexpression	B-Gene_expression
of	O
alpha	B-GP
-	I-GP
methylacyl	I-GP
coenzyme	I-GP
A	I-GP
racemase	I-GP
(	O
AMACR	O
)	O
in	O
prostate	O
cancer	O
.	O

The	O
proportion	O
of	O
PSA	B-GP
-	I-GP
ACT	I-GP
is	O
increased	B-Positive_regulation
in	O
prostate	B-DS
cancer	I-DS
(	O
PCa	O
),	O
but	O
immunologic	O
determination	O
of	O
PSA	O
-	O
ACT	O
is	O
hampered	O
by	O
a	O
background	O
produced	O
by	O
nonspecific	O
adsorption	O
of	O
ACT	O
to	O
the	O
solid	O
phase	O
.	O

However	O
,	O
in	O
this	O
issue	O
of	O
the	O
JCI	O
,	O
Sharma	O
et	O
al	O
.	O
show	O
that	O
RB1	B-GP
loss	B-Negative_regulation
is	O
a	O
late	O
event	O
in	O
human	O
prostate	B-DS
cancer	I-DS
that	O
is	O
coincident	O
with	O
the	O
emergence	O
of	O
castrate	O
-	O
resistant	O
metastatic	O
disease	O
.	O

Elevated	B-Positive_regulation
serum	O
chromogranin	B-GP
A	O
precedes	O
prostate	O
-	O
specific	O
antigen	O
elevation	O
and	O
predicts	O
failure	O
of	O
androgen	O
deprivation	O
therapy	O
in	O
patients	O
with	O
advanced	O
prostate	B-DS
cancer	I-DS
.	O

The	O
gene	O
array	O
revealed	O
decreased	B-Negative_regulation
expression	B-Gene_expression
of	O
ADAMTS1	B-GP
,	O
ephrin	B-GP
-	I-GP
A5	I-GP
,	O
fibronectin	B-GP
1	O
,	O
and	O
neuropilin	B-GP
1	O
in	O
LNCaP	O
-	O
19	O
compared	O
to	O
LNCaP	B-DS
,	O
while	O
expression	B-Gene_expression
of	O
midkine	O
and	O
VEGF	B-GP
were	O
increased	B-Positive_regulation
.	O

Increased	B-Positive_regulation
expression	B-Gene_expression
of	O
bone	B-GP
morphogenetic	I-GP
protein	I-GP
-	I-GP
7	O
in	O
bone	O
metastatic	B-DS
prostate	I-DS
cancer	I-DS
.	O

(	O
3	O
)	O
Of	O
the	O
2	O
,	O
272	O
men	O
,	O
284	O
had	O
elevated	B-Positive_regulation
PSA	B-GP
levels	O
and	O
prostate	B-DS
carcinoma	I-DS
was	O
detected	O
in	O
62	O
men	O
.	O

Overexpression	B-Gene_expression
of	O
clusterin	B-GP
in	O
LNCaP	B-DS
cells	O
confers	O
resistance	O
to	O
both	O
androgen	O
ablation	O
and	O
chemotherapy	O
.	O

In	O
contrast	O
to	O
previous	O
findings	O
by	O
others	O
,	O
PPAR	O
-	O
gamma	O
ligands	O
did	O
not	O
induce	B-Positive_regulation
PPAR	B-GP
-	I-GP
gamma	I-GP
expression	B-Gene_expression
in	O
EC	O
or	O
PC	B-DS
-	I-DS
3	O
.	O

Low	O
COX	O
-	O
2	O
expression	O
in	O
PC	B-DS
-	I-DS
3	O
was	O
up	O
-	O
regulated	O
by	O
serum	O
,	O
and	O
15d	O
-	O
PGJ	O
(	O
2	O
)	O
blocked	B-Negative_regulation
serum	O
-	O
induced	O
COX	B-GP
-	I-GP
2	O
expression	B-Gene_expression
and	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
present	O
study	O
showed	O
that	O
PPAR	B-GP
-	I-GP
gamma	I-GP
activation	B-Positive_regulation
can	O
be	O
an	O
important	O
regulator	O
of	O
COX	O
-	O
2	O
in	O
prostate	O
cells	O
and	O
may	O
be	O
an	O
important	O
target	O
for	O
prostate	B-DS
cancer	I-DS
chemoprevention	O
.	O

Overexpression	B-Gene_expression
of	O
HER2	B-GP
has	O
independent	O
prognostic	O
significance	O
in	O
early	O
breast	B-DS
cancer	I-DS
and	O
may	O
also	O
predict	O
response	O
to	O
hormonal	O
and	O
cytotoxic	O
therapies	O
,	O
although	O
this	O
latter	O
role	O
is	O
less	O
well	O
studied	O
.	O

Triple	O
-	O
negative	O
(	O
TN	O
)	O
breast	B-DS
cancers	I-DS
lack	B-Negative_regulation
estrogen	O
receptor	O
(	O
ER	B-GP
),	O
progesterone	O
receptor	O
(	O
PR	B-GP
),	O
and	O
HER2	O
/	O
neu	O
amplification	O
(	O
HER2	O
).	O

Treatment	O
of	O
MCF	B-DS
-	I-DS
7	O
cells	O
with	O
the	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
(	O
PPAR	O
)	O
gamma	O
agonists	O
ciglitazone	O
or	O
15	O
-	O
deoxy	O
-	O
Delta	O
12	O
,	O
14	O
-	O
prostaglandin	O
J2	O
resulted	O
in	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
decrease	B-Negative_regulation
of	O
cyclin	B-GP
D1	I-GP
and	O
estrogen	B-GP
receptor	I-GP
(	O
ER	O
)	O
alpha	O
proteins	O
,	O
and	O
this	O
was	O
accompanied	O
by	O
decreased	O
cell	O
proliferation	O
and	O
G	O
(	O
1	O
)-	O
G	O
(	O
0	O
)-->	O
S	O
-	O
phase	O
progression	O
.	O

In	O
conclusion	O
,	O
three	O
consecutive	O
microarray	O
(	O
CGH	O
,	O
cDNA	O
and	O
tissue	O
)	O
experiments	O
revealed	O
high	O
-	O
level	O
amplification	O
and	O
overexpression	B-Gene_expression
of	O
the	O
FGFR2	B-GP
in	O
a	O
breast	O
cancer	O
cell	O
line	O
,	O
but	O
only	O
a	O
low	O
frequency	O
of	O
involvement	O
in	O
primary	O
breast	B-DS
tumors	I-DS
.	O

Transfection	B-Gene_expression
of	O
HER2	B-GP
in	O
MCF7	O
breast	B-DS
cancer	I-DS
cells	O
that	O
express	O
HER3	O
caused	O
a	O
phosphoinoside	O
-	O
3	O
kinase	O
(	O
PI	O
-	O
3K	O
)-	O
dependent	O
activation	B-Positive_regulation
of	O
Akt	B-GP
,	O
and	O
was	O
associated	O
with	O
an	O
increased	O
resistance	O
of	O
the	O
cells	O
to	O
multiple	O
chemotherapeutic	O
agents	O
(	O
paclitaxel	O
,	O
doxorubicin	O
,	O
5	O
-	O
fluorouracil	O
,	O
etoposide	O
,	O
and	O
camptothecin	O
).	O

In	O
MCF	B-DS
-	I-DS
7	O
,	O
mimicking	O
E2	O
,	O
T3	O
stimulated	O
growth	O
in	O
a	O
dose	O
-	O
dependent	O
(	O
10	O
(	O
10	O
)	O
M	O
-	O
10	O
(-	O
8	O
)	O
M	O
)	O
manner	O
,	O
induced	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
progesterone	B-GP
receptor	I-GP
and	O
growth	B-GP
factor	I-GP
TGFalpha	I-GP
mRNAs	I-GP
and	O
inhibited	O
that	O
of	O
TGFbeta	O
mRNA	O
;	O
T3	O
also	O
increased	B-Positive_regulation
progesterone	O
binding	O
and	O
LDH5	B-GP
isozyme	I-GP
activities	O
.	O

10	O
(-	O
6	O
)	O
M	O
tamoxifen	O
(	O
TAM	O
)	O
reverted	O
growth	O
stimulation	O
,	O
suppressed	B-Negative_regulation
progesterone	B-GP
receptor	I-GP
and	O
TGFalpha	B-GP
mRNA	I-GP
induction	B-Positive_regulation
and	O
restored	B-Positive_regulation
TGFbeta	B-GP
mRNA	I-GP
to	O
control	O
levels	O
in	O
T3	O
-	O
treated	O
MCF	B-DS
-	I-DS
7	O
cells	O
.	O

Expression	O
of	O
C2GnT1	O
is	O
low	O
or	O
absent	O
in	O
around	O
50	O
%	O
of	O
breast	B-DS
cancers	I-DS
,	O
whereas	O
expression	B-Gene_expression
of	O
ST3Gal	B-GP
-	I-GP
I	O
is	O
consistently	O
increased	B-Positive_regulation
.	O

Thus	O
,	O
even	O
when	O
C2GnT1	O
is	O
expressed	O
,	O
the	O
O	O
-	O
glycans	O
added	O
to	O
MUC1	O
become	O
core	O
1	O
-	O
dominated	O
structures	O
,	O
provided	O
expression	B-Gene_expression
of	O
ST3Gal	B-GP
-	I-GP
I	O
is	O
increased	B-Positive_regulation
as	O
it	O
is	O
in	O
breast	B-DS
cancer	I-DS
.	O

HER2	B-GP
overexpression	B-Gene_expression
/	O
amplification	O
,	O
which	O
is	O
an	O
early	O
event	O
in	O
breast	B-DS
cancer	I-DS
development	O
,	O
is	O
associated	O
with	O
a	O
poor	O
prognosis	O
and	O
may	O
predict	O
response	O
to	O
therapy	O
.	O

The	O
cellular	B-GP
retinol	I-GP
binding	I-GP
protein	I-GP
I	I-GP
gene	I-GP
(	O
CRBP	B-GP
)	O
is	O
downregulated	B-Negative_regulation
in	O
a	O
subset	O
of	O
human	O
breast	O
cancers	O
and	O
in	O
MMTV	O
-	O
Myc	O
induced	O
mouse	O
mammary	B-DS
tumors	I-DS
.	O

Functional	O
studies	O
suggest	O
that	O
CRBP	B-GP
downregulation	B-Negative_regulation
contributes	O
to	O
breast	B-DS
tumor	I-DS
progression	O
.	O

The	O
insLQ	O
polymorphism	O
increases	B-Positive_regulation
LHR	B-GP
activity	O
,	O
thereby	O
shortening	O
breast	B-DS
cancer	I-DS
disease	O
-	O
free	O
survival	O
,	O
probably	O
by	O
increasing	O
estrogen	O
exposure	O
in	O
female	O
carriers	O
.	O

IFN	O
-	O
alpha	O
increased	B-Positive_regulation
the	O
cell	O
surface	O
expression	B-Gene_expression
of	O
DR	B-GP
antigen	I-GP
only	O
in	O
ZR	B-DS
-	I-DS
75	I-DS
-	I-DS
1	O
cells	O
.	O

IL	O
-	O
1	O
-	O
alpha	O
induced	B-Positive_regulation
a	O
moderate	O
level	O
of	O
HLA	O
class	O
I	O
antigen	O
in	O
ZR	O
-	O
75	O
-	O
1	O
,	O
BT	O
-	O
20	O
and	O
MDA	B-DS
-	I-DS
MB	I-DS
-	I-DS
468	I-DS
cells	O
,	O
and	O
HLA	B-GP
class	I-GP
II	I-GP
(	I-GP
DR	I-GP
)	O
expression	B-Gene_expression
only	O
in	O
ZR	O
-	O
75	O
-	O
1	O
cells	O
.	O

No	O
statistically	O
significant	O
association	O
was	O
found	O
between	O
increased	B-Positive_regulation
PTPase	B-GP
activity	O
and	O
either	O
c	B-GP
-	I-GP
erbB	I-GP
-	I-GP
2	O
overexpression	B-Gene_expression
or	O
grade	O
and	O
stage	O
of	O
disease	O
in	O
primary	O
human	O
mammary	B-DS
tumors	I-DS
.	O

Administration	O
of	O
exogenous	O
LTB4	O
(	O
1	O
-	O
10	O
nmol	O
/	O
L	O
)	O
was	O
able	O
to	O
stimulate	B-Positive_regulation
the	O
promoter	O
activity	O
of	O
FASN	B-GP
in	O
MCF	B-DS
-	I-DS
7	O
cells	O
.	O

In	O
aggregate	O
,	O
these	O
studies	O
support	O
the	O
notion	O
that	O
TGF	O
-	O
beta	O
plays	O
an	O
important	O
role	O
in	O
both	O
bone	O
-	O
and	O
lung	O
metastases	O
of	O
basal	O
-	O
like	O
breast	B-DS
cancer	I-DS
,	O
and	O
that	O
inhibiting	B-Negative_regulation
TGF	B-GP
-	I-GP
beta	I-GP
signaling	O
results	O
in	O
a	O
therapeutic	O
effect	O
independently	O
of	O
the	O
tissue	O
-	O
tropism	O
of	O
the	O
metastatic	O
cells	O
.	O

Herein	O
,	O
we	O
demonstrate	O
that	O
loss	B-Negative_regulation
of	O
Pfn1	B-GP
expression	B-Gene_expression
leads	O
to	O
slower	O
but	O
more	O
stable	O
lamellipodial	O
protrusion	O
thereby	O
enhancing	O
the	O
net	O
protrusion	O
rate	O
and	O
the	O
overall	O
motility	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
breast	B-DS
cancer	I-DS
cells	O
.	O

We	O
further	O
demonstrate	O
that	O
Pfn1	B-GP
downregulation	B-Negative_regulation
results	O
in	O
a	O
hyper	O
-	O
motile	O
phenotype	O
of	O
MDA	B-DS
-	I-DS
MB	I-DS
-	I-DS
231	I-DS
cells	O
in	O
an	O
Ena	O
/	O
VASP	O
-	O
dependent	O
mechanism	O
.	O

We	O
conclude	O
that	O
c	B-GP
-	I-GP
erbB	I-GP
-	I-GP
2	I-GP
protein	I-GP
overexpression	B-Gene_expression
assessed	O
by	O
IHC	O
is	O
a	O
superior	O
prognostic	O
indicator	O
in	O
operable	O
breast	B-DS
cancer	I-DS
compared	O
to	O
c	O
-	O
erbB	O
-	O
2	O
gene	O
amplification	O
analysed	O
by	O
the	O
dot	O
-	O
blot	O
technique	O
.	O

The	O
inhibition	B-Negative_regulation
of	O
aromatase	B-GP
activity	O
by	O
these	O
imidazole	O
derivatives	O
as	O
second	O
line	O
therapy	O
for	O
patients	O
with	O
hormone	O
dependent	O
breast	B-DS
cancer	I-DS
appears	O
to	O
be	O
a	O
favorable	O
alternative	O
form	O
of	O
hormone	O
ablative	O
therapy	O
and	O
holds	O
considerable	O
promise	O
for	O
the	O
treatment	O
of	O
this	O
malignancy	O
.	O

The	O
analysis	O
of	O
E	O
-	O
cadherin	O
glycoprotein	O
expression	O
is	O
a	O
powerful	O
tool	O
for	O
distinguishing	O
lobular	O
from	O
ductal	O
carcinomas	O
,	O
because	O
complete	O
loss	B-Negative_regulation
of	O
E	B-GP
-	I-GP
cadherin	I-GP
expression	B-Gene_expression
occurs	O
in	O
most	O
infiltrating	O
lobular	O
tumors	O
and	O
lobular	B-DS
carcinomas	I-DS
in	O
situ	O
,	O
but	O
not	O
in	O
ductal	O
tumors	O
.	O

We	O
show	O
,	O
for	O
the	O
first	O
time	O
in	O
a	O
transgenic	O
mouse	O
model	O
,	O
that	O
mammary	O
tumor	O
progression	O
is	O
associated	O
with	O
the	O
loss	B-Negative_regulation
of	O
ERalpha	B-GP
expression	B-Gene_expression
,	O
as	O
has	O
been	O
often	O
observed	O
in	O
human	O
breast	B-DS
cancers	I-DS
with	O
important	O
clinical	O
significance	O
.	O

A	O
strong	O
association	O
has	O
been	O
observed	O
between	O
reduced	B-Negative_regulation
expression	B-Gene_expression
of	O
the	O
nm23	B-GP
gene	I-GP
and	O
acquisition	O
of	O
metastatic	O
behaviour	O
in	O
some	O
tumour	O
cells	O
,	O
including	O
breast	B-DS
cancer	I-DS
and	O
melanoma	O
,	O
but	O
not	O
in	O
others	O
,	O
such	O
as	O
neuroblastoma	O
and	O
colon	O
,	O
cervical	O
and	O
thyroid	O
cancers	O
.	O

Here	O
,	O
we	O
show	O
that	O
overexpression	B-Gene_expression
of	O
BIRC5	B-GP
induces	O
a	O
high	O
proliferation	O
level	O
in	O
MCF	O
-	O
7	O
breast	B-DS
tumor	I-DS
cells	O
.	O

ErbB2	O
increases	B-Positive_regulation
vascular	B-GP
endothelial	I-GP
growth	I-GP
factor	I-GP
protein	I-GP
synthesis	B-Gene_expression
via	O
activation	O
of	O
mammalian	O
target	O
of	O
rapamycin	O
/	O
p70S6K	O
leading	O
to	O
increased	O
angiogenesis	O
and	O
spontaneous	O
metastasis	O
of	O
human	O
breast	B-DS
cancer	I-DS
cells	O
.	O

ErbB2	B-GP
overexpression	B-Gene_expression
in	O
breast	B-DS
tumors	I-DS
results	O
in	O
increased	O
metastasis	O
and	O
angiogenesis	O
and	O
reduced	O
survival	O
.	O

Here	O
we	O
show	O
that	O
heterozygous	O
inactivation	B-Negative_regulation
of	O
the	O
tumor	O
suppressor	O
gene	O
Pten	B-GP
leads	O
to	O
the	O
formation	O
of	O
basal	O
-	O
like	O
mammary	O
tumors	O
in	O
mice	O
,	O
and	O
that	O
loss	B-Negative_regulation
of	O
PTEN	B-GP
expression	B-Gene_expression
is	O
significantly	O
associated	O
with	O
the	O
BBC	O
subtype	O
in	O
human	O
sporadic	O
and	O
BRCA1	O
-	O
associated	O
hereditary	B-DS
breast	I-DS
cancers	I-DS
.	O

Here	O
,	O
we	O
defined	O
a	O
new	O
mechanism	O
for	O
IMC	O
-	O
C225	O
that	O
cross	O
-	O
links	O
integrins	O
with	O
EGFR	O
,	O
leading	O
to	O
activation	B-Positive_regulation
of	O
RhoA	B-GP
and	O
inhibition	O
of	O
breast	B-DS
cancer	I-DS
cell	O
invasion	O
irrespective	O
of	O
the	O
level	O
of	O
EGFR	O
in	O
the	O
cells	O
,	O
thus	O
providing	O
a	O
rationale	O
for	O
using	O
IMC	O
-	O
C225	O
in	O
the	O
metastatic	O
setting	O
independent	O
of	O
the	O
levels	O
of	O
EGFR	O
.	O

This	O
study	O
suggests	O
that	O
the	O
Asn	O
allele	O
in	O
the	O
SHBG	O
gene	O
may	O
be	O
related	O
to	O
a	O
reduced	O
risk	O
of	O
breast	B-DS
cancer	I-DS
among	O
postmenopausal	O
women	O
by	O
increasing	B-Positive_regulation
their	O
blood	O
SHBG	B-GP
levels	B-Gene_expression
.	O

Activated	B-Positive_regulation
STAT3	B-GP
correlated	O
with	O
elevated	B-Positive_regulation
cyclin	B-GP
D1	I-GP
protein	I-GP
in	O
primary	O
breast	B-DS
tumors	I-DS
and	O
breast	O
cancer	O
-	O
derived	O
cell	O
lines	O
.	O

Furthermore	O
,	O
knockdown	B-Negative_regulation
of	O
cyclin	B-GP
D1	I-GP
in	O
breast	B-DS
carcinoma	I-DS
cells	O
led	O
to	O
a	O
reduction	O
in	O
anchorage	O
-	O
independent	O
growth	O
.	O

The	O
EphA2	B-GP
receptor	I-GP
tyrosine	I-GP
kinase	I-GP
is	O
frequently	O
overexpressed	B-Gene_expression
in	O
invasive	B-DS
breast	I-DS
cancer	I-DS
cells	O
.	O

AGR2	B-GP
knockdown	B-Negative_regulation
induced	O
cell	O
death	O
in	O
ZR	B-DS
-	I-DS
75	I-DS
-	I-DS
1	O
and	O
T47	O
D	O
cells	O
,	O
and	O
also	O
downregulated	B-Negative_regulation
survivin	B-GP
and	O
c	B-GP
-	I-GP
Myc	I-GP
.	O

Increased	B-Positive_regulation
cellular	O
activity	O
of	O
ornithine	B-GP
decarboxylase	I-GP
(	O
ODC	B-GP
),	O
the	O
first	O
and	O
rate	O
-	O
limiting	O
enzyme	O
in	O
polyamine	O
(	O
PA	O
)	O
synthesis	O
,	O
is	O
an	O
independent	O
adverse	O
prognostic	O
factor	O
for	O
overall	O
survival	O
in	O
human	O
breast	B-DS
cancer	I-DS
,	O
thus	O
suggesting	O
an	O
important	O
role	O
for	O
PA	O
in	O
tumor	O
progression	O
.	O

Hyperactivation	B-Positive_regulation
of	O
the	O
insulin	B-GP
-	I-GP
like	I-GP
growth	I-GP
factor	I-GP
I	I-GP
receptor	I-GP
(	O
IGF	B-GP
-	I-GP
IR	I-GP
)	O
contributes	O
to	O
primary	O
breast	B-DS
cancer	I-DS
development	O
,	O
but	O
the	O
role	O
of	O
the	O
IGF	O
-	O
IR	O
in	O
tumor	O
metastasis	O
is	O
unclear	O
.	O

We	O
found	O
that	O
IGF	B-GP
-	I-GP
IR	I-GP
overexpression	B-Gene_expression
markedly	O
stimulated	O
aggregation	O
in	O
E	O
-	O
cad	O
-	O
positive	O
MCF	O
-	O
7	O
breast	B-DS
cancer	I-DS
cells	O
,	O
but	O
not	O
in	O
E	O
-	O
cad	O
-	O
negative	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
.	O

All	O
three	O
interferons	O
and	O
TPA	O
enhanced	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
the	O
Mr	O
180	O
,	O
000	O
carcinoembryonic	B-GP
antigen	I-GP
(	O
CEA	B-GP
)	O
and	O
CEA	B-GP
-	I-GP
related	I-GP
TAA	I-GP
recognized	O
by	O
monoclonal	O
antibody	O
B1	O
.	O
1	O
in	O
both	O
T47D	O
and	O
MCF	O
-	O
7	O
human	O
breast	B-DS
carcinoma	I-DS
cell	O
lines	O
.	O

In	O
general	O
,	O
IFN	O
-	O
gamma	O
was	O
more	O
effective	O
than	O
IFN	O
-	O
alpha	O
,	O
IFN	O
-	O
beta	O
or	O
TPA	O
in	O
augmenting	B-Positive_regulation
the	O
expression	O
of	O
TAA	O
,	O
CEA	O
and	O
BCA	O
-	O
225	O
,	O
and	O
HLA	B-GP
-	I-GP
DR	I-GP
expression	B-Gene_expression
in	O
T47D	O
and	O
MCF	B-DS
-	I-DS
7	O
cells	O
.	O

In	O
addition	O
,	O
Cd	O
enhanced	B-Positive_regulation
DNA	O
synthesis	O
and	O
pS2	B-GP
mRNA	I-GP
levels	O
in	O
estrogen	O
(	O
10	O
pM	O
estradiol	O
)	O
treated	O
T47D	B-DS
cells	O
.	O

E2	O
but	O
not	O
ICI	O
stimulated	B-Positive_regulation
BMP	B-GP
-	I-GP
6	O
reporter	O
activity	O
in	O
breast	B-DS
cancer	I-DS
cells	O
,	O
whereas	O
the	O
opposite	O
was	O
observed	O
in	O
osteoblast	O
-	O
like	O
cells	O
,	O
associated	O
with	O
lack	O
of	O
AF	O
-	O
2	O
dependence	O
of	O
the	O
response	O
,	O
and	O
absent	O
intranuclear	O
localization	O
of	O
ERalpha	O
,	O
suggesting	O
the	O
involvement	O
of	O
a	O
distinct	O
ERalpha	O
-	O
dependent	O
response	O
mechanism	O
in	O
osteoblasts	O
.	O

E2	O
,	O
but	O
not	O
ICI	O
,	O
stimulated	O
BMP	O
-	O
6	O
reporter	O
activity	O
by	O
approximately	O
100	O
%	O
in	O
MCF	B-DS
-	I-DS
7	O
,	O
T47	O
-	O
D	O
cells	O
,	O
and	O
HepG2	O
cells	O
when	O
transfected	B-Gene_expression
with	O
ERalpha	B-GP
.	O

We	O
report	O
that	O
transfection	B-Gene_expression
of	O
insulin	B-GP
-	I-GP
like	I-GP
growth	I-GP
factor	I-GP
-	I-GP
binding	I-GP
protein	I-GP
-	I-GP
3	O
(	O
IGFBP	B-GP
-	I-GP
3	O
)	O
cDNA	O
in	O
human	O
breast	B-DS
cancer	I-DS
cell	O
lines	O
expressing	O
either	O
mutant	O
p53	O
(	O
T47D	O
)	O
or	O
wild	O
-	O
type	O
p53	O
(	O
MCF	O
-	O
7	O
)	O
induces	O
apoptosis	O
.	O

In	O
MCF	B-DS
-	I-DS
7	O
,	O
an	O
increase	B-Positive_regulation
in	O
Bad	B-GP
and	O
Bax	B-GP
protein	I-GP
expression	B-Gene_expression
and	O
a	O
decrease	B-Negative_regulation
in	O
Bcl	B-GP
-	I-GP
x	I-GP
(	I-GP
L	I-GP
)	I-GP
protein	I-GP
and	O
Bcl	B-GP
-	I-GP
2	I-GP
protein	I-GP
and	O
mRNA	O
were	O
observed	O
.	O

In	O
T47D	B-DS
,	O
Bax	B-GP
and	O
Bad	B-GP
proteins	I-GP
were	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
;	O
Bcl	O
-	O
2	O
protein	O
is	O
undetectable	O
in	O
these	O
cells	O
.	O

Transfection	B-Gene_expression
of	O
IGFBP	B-GP
-	I-GP
3	O
increased	O
the	O
radiosensitivity	O
of	O
T47D	B-DS
and	O
increased	O
IR	O
-	O
induced	O
apoptosis	O
but	O
did	O
not	O
effect	O
a	O
rapid	O
G	O
(	O
1	O
)	O
arrest	O
.	O

Complete	O
response	O
of	O
brain	O
metastases	O
from	O
breast	B-DS
cancer	I-DS
overexpressing	B-Gene_expression
Her	B-GP
-	I-GP
2	I-GP
/	I-GP
neu	I-GP
to	O
radiation	O
and	O
concurrent	O
Lapatinib	O
and	O
Capecitabine	O
.	O

Increased	B-Positive_regulation
frequency	O
of	O
long	O
androgen	B-GP
receptor	I-GP
CAG	I-GP
repeats	I-GP
in	O
male	B-DS
breast	I-DS
cancers	I-DS
.	O

Stimulation	O
of	O
SKBR3	B-DS
cells	O
and	O
HCII	O
RI	O
#	O
11	O
mouse	O
mammary	O
epithelial	O
cells	O
expressing	O
the	O
human	O
erbB	O
-	O
2	O
with	O
EGF	O
led	O
to	O
an	O
increase	B-Positive_regulation
in	O
scFv	B-GP
(	O
FRP5	B-GP
)-	O
ETA	O
activity	O
,	O
showing	O
that	O
the	O
EGF	O
-	O
induced	O
activation	B-Positive_regulation
of	O
erbB	B-GP
-	I-GP
2	O
can	O
potentiate	O
the	O
action	O
of	O
the	O
erbB	O
-	O
2	O
-	O
directed	O
toxin	O
.	O

By	O
using	O
5	O
'	O
deletion	O
mutant	O
constructs	O
of	O
MMP	O
-	O
2	O
promoter	O
,	O
we	O
showed	O
that	O
deletion	O
of	O
the	O
region	O
containing	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
site	O
caused	O
the	O
greatest	O
reduction	O
of	O
MMP	O
-	O
2	O
promoter	O
activity	O
both	O
in	O
MKK6	O
-	O
and	O
H	O
-	O
Ras	O
-	O
activated	O
MCF10A	B-DS
cells	O
,	O
suggesting	O
that	O
the	O
AP	O
-	O
1	O
binding	O
site	O
is	O
critical	O
for	O
the	O
MMP	B-GP
-	I-GP
2	I-GP
promoter	I-GP
activation	B-Positive_regulation
.	O

Activation	B-Positive_regulation
of	O
ATF2	B-GP
,	O
which	O
depended	O
on	O
p38	O
activity	O
,	O
was	O
crucial	O
for	O
MMP	O
-	O
2	O
promoter	O
activity	O
as	O
well	O
as	O
induction	O
of	O
invasive	O
and	O
migrative	O
phenotypes	O
in	O
MCF10A	B-DS
cells	O
.	O

It	O
has	O
been	O
shown	O
recently	O
that	O
17beta	O
-	O
estradiol	O
(	O
E2	O
)	O
can	O
stimulate	B-Positive_regulation
the	O
Src	B-GP
/	I-GP
p21ras	I-GP
/	I-GP
mitogen	I-GP
-	I-GP
activated	I-GP
protein	I-GP
kinase	I-GP
pathway	O
in	O
breast	B-DS
cancer	I-DS
cells	O
,	O
and	O
this	O
effect	O
is	O
supposed	O
to	O
mediate	O
the	O
E2	O
-	O
induced	O
stimulation	O
of	O
breast	O
cancer	O
cell	O
proliferation	O
,	O
possibly	O
via	O
activation	B-Positive_regulation
of	O
the	O
c	B-GP
-	I-GP
fos	I-GP
and	O
c	B-GP
-	I-GP
jun	I-GP
early	I-GP
genes	I-GP
or	O
of	O
genes	O
involved	O
in	O
cell	O
cycle	O
control	O
.	O

It	O
has	O
,	O
however	O
,	O
been	O
reported	O
that	O
expression	B-Gene_expression
of	O
connexin26	B-GP
(	I-GP
Cx26	I-GP
)	I-GP
protein	I-GP
is	O
induced	B-Positive_regulation
in	O
human	O
ductal	B-DS
carcinomas	I-DS
of	O
the	O
breast	O
and	O
that	O
its	O
amount	O
increases	O
in	O
proportion	O
to	O
the	O
grade	O
of	O
malignancy	O
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
EMSY	B-GP
overexpression	B-Gene_expression
can	O
play	O
a	O
role	O
in	O
the	O
genesis	O
of	O
human	O
breast	B-DS
cancer	I-DS
.	O

In	O
this	O
study	O
we	O
show	O
that	O
oestradiol	O
decreased	B-Negative_regulation
secreted	O
sVEGFR	B-GP
-	I-GP
1	O
,	O
increased	B-Positive_regulation
secreted	O
VEGF	B-GP
,	O
and	O
decreased	O
the	O
ratio	O
of	O
sVEGFR	O
-	O
1	O
/	O
VEGF	O
in	O
MCF	O
-	O
7	O
human	O
breast	B-DS
cancer	I-DS
cells	O
.	O

Activation	B-Positive_regulation
of	O
PI3K	B-GP
/	I-GP
Akt	I-GP
signaling	O
and	O
hormone	O
resistance	O
in	O
breast	B-DS
cancer	I-DS
.	O

Recent	O
studies	O
show	O
that	O
aberrant	O
activation	B-Positive_regulation
of	O
Akt	B-GP
in	O
breast	B-DS
carcinoma	I-DS
is	O
associated	O
with	O
a	O
poor	O
prognosis	O
and	O
resistance	O
to	O
endocrine	O
therapy	O
and	O
chemotherapy	O
.	O

Our	O
findings	O
indicate	O
that	O
the	O
activation	B-Positive_regulation
of	O
Akt	B-GP
in	O
the	O
downstream	O
pathway	O
of	O
HER2	O
plays	O
an	O
important	O
role	O
in	O
resistance	O
to	O
endocrine	O
therapy	O
for	O
breast	B-DS
cancer	I-DS
.	O

Our	O
findings	O
suggest	O
that	O
pAkt	O
may	O
be	O
a	O
useful	O
predictor	O
of	O
resistance	O
to	O
endocrine	O
therapy	O
for	O
breast	B-DS
cancer	I-DS
,	O
while	O
also	O
suggesting	O
that	O
the	O
inhibition	B-Negative_regulation
of	O
Akt	B-GP
may	O
increase	O
the	O
efficacy	O
of	O
endocrine	O
therapy	O
.	O

Decreased	B-Negative_regulation
expression	B-Gene_expression
of	O
miR	B-GP
-	I-GP
342	I-GP
in	O
the	O
therapeutically	O
challenging	O
triple	O
-	O
negative	O
breast	B-DS
tumours	I-DS
,	O
increased	B-Positive_regulation
miR	B-GP
-	I-GP
342	I-GP
expression	B-Gene_expression
in	O
the	O
luminal	O
B	O
tumours	O
,	O
and	O
downregulated	B-Negative_regulation
miR	B-GP
-	I-GP
520g	I-GP
in	O
ER	O
and	O
PR	O
-	O
positive	O
tumours	O
indicates	O
that	O
not	O
only	O
is	O
dysregulated	O
miRNA	O
expression	O
a	O
marker	O
for	O
poorer	O
prognosis	O
breast	O
cancer	O
,	O
but	O
that	O
it	O
could	O
also	O
present	O
an	O
attractive	O
target	O
for	O
therapeutic	O
intervention	O
.	O

In	O
nuclear	O
run	O
-	O
on	O
assays	O
,	O
17beta	O
-	O
estradiol	O
(	O
E2	O
)	O
increased	B-Positive_regulation
the	O
rate	O
of	O
Tf	B-GP
gene	I-GP
expression	B-Gene_expression
approximately	O
3	O
-	O
fold	O
within	O
1	O
h	O
after	O
treatment	O
and	O
reporter	O
gene	O
activity	O
was	O
also	O
induced	O
in	O
MCF	B-DS
-	I-DS
7	O
cells	O
transfected	O
with	O
a	O
construct	O
containing	O
a	O
-	O
3600	O
to	O
+	O
39	O
Tf	O
gene	O
promoter	O
insert	O
.	O

Scavenger	B-GP
receptor	I-GP
class	I-GP
A	I-GP
,	I-GP
member	I-GP
3	O
(	O
SCARA3	B-GP
)	O
was	O
previously	O
found	O
to	O
be	O
overexpressed	B-Gene_expression
in	O
ovarian	O
/	O
primary	O
peritoneal	O
carcinoma	O
(	O
OC	O
/	O
PPC	O
)	O
compared	O
with	O
breast	B-DS
carcinoma	I-DS
effusions	O
by	O
global	O
gene	O
expression	O
analysis	O
.	O

miR	B-GP
-	I-GP
9	O
is	O
overexpressed	B-Gene_expression
in	O
several	O
cancer	O
forms	O
,	O
including	O
brain	O
tumours	O
,	O
hepatocellular	O
carcinomas	O
,	O
breast	B-DS
cancer	I-DS
and	O
Hodgkin	O
lymphoma	O
(	O
HL	O
).	O

It	O
was	O
found	O
that	O
there	O
were	O
both	O
significant	O
overexpression	B-Gene_expression
of	O
Wnt5A	B-GP
and	O
underexpression	O
of	O
Wnt10B	O
in	O
the	O
metastasis	O
-	O
derived	O
finite	O
life	O
-	O
span	O
breast	B-DS
cancer	I-DS
cells	O
when	O
they	O
were	O
compared	O
to	O
the	O
finite	O
life	O
-	O
span	O
normal	O
and	O
established	O
normal	O
and	O
breast	O
tumor	O
cells	O
.	O

Compared	O
with	O
that	O
of	O
the	O
vector	O
control	O
and	O
naïve	O
MCF7	B-DS
cell	O
group	O
,	O
there	O
was	O
a	O
significant	O
decrease	B-Negative_regulation
of	O
BCSG	B-GP
-	I-GP
1	I-GP
protein	I-GP
expression	B-Gene_expression
in	O
the	O
four	O
experimental	O
groups	O
by	O
immuno	O
-	O
histochemistry	O
staining	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

BCSG1	O
-	O
siRNA	O
down	B-Negative_regulation
-	I-Negative_regulation
regulates	I-Negative_regulation
the	O
expression	B-Gene_expression
of	O
BCSG1	B-GP
and	O
inhibits	O
effectively	O
growth	O
of	O
the	O
transplaned	O
human	O
breast	B-DS
cancer	I-DS
cell	O
line	O
in	O
nude	O
mice	O
.	O

We	O
have	O
previously	O
reported	O
that	O
glucocorticoids	O
markedly	O
increase	O
and	O
anti	O
-	O
glucocorticoids	O
(	O
such	O
as	O
RU	O
-	O
486	O
)	O
block	B-Negative_regulation
c	B-GP
-	I-GP
fms	I-GP
RNA	I-GP
and	O
protein	O
expression	B-Gene_expression
in	O
some	O
breast	B-DS
cancer	I-DS
cell	O
lines	O
,	O
but	O
not	O
in	O
others	O
,	O
and	O
that	O
this	O
increase	O
is	O
the	O
consequence	O
of	O
increased	O
transcription	O
from	O
the	O
first	O
,	O
epithelial	O
cell	O
-	O
specific	O
promoter	O
of	O
the	O
c	O
-	O
fms	O
gene	O
(	O
encoding	O
CSF	O
-	O
1R	O
,	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
receptor	O
).	O

In	O
MDA	B-DS
-	I-DS
MB	I-DS
-	I-DS
231	I-DS
,	O
TGF	O
-	O
beta1	O
had	O
no	O
effect	O
on	O
cell	O
proliferation	O
but	O
increased	B-Positive_regulation
uPA	B-GP
activity	O
and	O
PAI	B-GP
-	I-GP
1	I-GP
antigen	I-GP
level	O
;	O
sodium	O
butyrate	O
inhibited	B-Negative_regulation
both	O
cell	O
proliferation	O
and	O
uPA	B-GP
activity	O
but	O
had	O
no	O
effect	O
on	O
PAI	O
-	O
1	O
level	O
.	O

The	O
proliferation	O
of	O
certain	O
human	O
HER2	O
-	O
positive	O
breast	B-DS
cancer	I-DS
lines	O
also	O
requires	O
HSF1	O
,	O
as	O
its	O
knockdown	O
led	O
to	O
upregulation	B-Positive_regulation
of	O
p21	B-GP
and	O
/	O
or	O
decrease	O
in	O
survivin	O
,	O
precipitating	O
growth	O
arrest	O
.	O

Finally	O
,	O
ErbB2	O
-	O
amplified	O
breast	B-DS
cancer	I-DS
cells	O
expressing	O
a	O
specific	O
Pak	O
inhibitor	O
showed	O
delayed	O
tumor	O
formation	O
and	O
downregulation	B-Negative_regulation
of	O
Erk	B-GP
and	O
Akt	B-GP
signaling	O
in	O
vivo	O
.	O

Runx2	O
expression	O
in	O
C4	O
-	O
2B	O
PCa	O
cells	O
synergized	O
with	O
AR	O
to	O
promote	B-Positive_regulation
PIP	B-GP
expression	B-Gene_expression
,	O
whereas	O
its	O
knockdown	O
in	O
T47D	B-DS
BCa	O
cells	O
abrogated	O
basal	O
as	O
well	O
as	O
hormone	O
stimulated	O
PIP	O
expression	O
.	O

Similarly	O
,	O
neoadjuvant	O
studies	O
demonstrate	O
that	O
letrozole	O
substantially	O
inhibits	B-Negative_regulation
aromatase	B-GP
activity	O
in	O
both	O
malignant	O
and	O
nonmalignant	O
breast	O
tissues	O
,	O
and	O
markedly	O
suppresses	O
endogenous	O
estrogens	O
within	O
the	O
breast	B-DS
cancers	I-DS
.	O

After	O
a	O
median	O
follow	O
-	O
up	O
of	O
65	O
months	O
,	O
an	O
increase	B-Positive_regulation
in	O
TGF	B-GP
-	I-GP
beta	I-GP
1	O
over	O
1	O
year	O
was	O
the	O
only	O
significant	O
,	O
independent	O
predictor	O
of	O
a	O
shorter	O
survival	O
free	O
from	O
secondary	O
primary	O
breast	B-DS
cancer	I-DS
.	O

Estrogen	B-GP
receptor	I-GP
alpha	I-GP
46	I-GP
is	O
reduced	B-Negative_regulation
in	O
tamoxifen	O
resistant	O
breast	B-DS
cancer	I-DS
cells	O
and	O
re	O
-	O
expression	O
inhibits	O
cell	O
proliferation	O
and	O
estrogen	O
receptor	O
alpha	O
66	O
-	O
regulated	O
target	O
gene	O
transcription	O
.	O

We	O
observed	O
reduced	B-Negative_regulation
protein	O
expression	B-Gene_expression
of	O
an	O
N	O
-	O
terminally	O
truncated	O
ERalpha46	B-GP
in	O
endocrine	O
-	O
resistant	O
LCC2	O
,	O
LCC9	O
,	O
and	O
LY2	O
compared	O
to	O
MCF	O
-	O
7	O
breast	B-DS
cancer	I-DS
cells	O
.	O

Established	O
miR	O
-	O
21	O
targets	O
PTEN	O
and	O
PDCD4	B-GP
were	O
reduced	B-Negative_regulation
in	O
ERalpha46	O
-	O
transfected	O
,	O
E	O
(	O
2	O
)-	O
treated	O
MCF	B-DS
-	I-DS
7	O
cells	O
.	O

Obesity	O
and	O
HER	B-GP
2	O
overexpression	B-Gene_expression
:	O
a	O
common	O
factor	O
for	O
poor	O
prognosis	O
of	O
breast	B-DS
cancer	I-DS
.	O

Both	O
obesity	O
and	O
over	B-Gene_expression
-	I-Gene_expression
expression	I-Gene_expression
of	O
HER	B-GP
II	I-GP
are	O
associated	O
with	O
poor	O
prognosis	O
of	O
breast	B-DS
cancer	I-DS
.	O

One	O
of	O
these	O
kinases	O
,	O
Erk5	O
,	O
has	O
been	O
found	O
to	O
reside	O
in	O
the	O
nucleus	O
of	O
breast	B-DS
cancer	I-DS
cells	O
that	O
overexpress	B-Gene_expression
the	O
ErbB2	B-GP
receptor	I-GP
.	O

In	O
breast	B-DS
cancer	I-DS
cells	O
overexpressing	B-Gene_expression
ErbB2	B-GP
,	O
Erk5	O
dual	O
phosphorylation	O
required	O
ErbB2	O
tyrosine	O
kinase	O
activity	O
;	O
however	O
,	O
Erk5	O
nuclear	O
residency	O
did	O
not	O
require	O
ErbB2	O
activity	O
.	O

In	O
a	O
pivotal	O
phase	O
III	O
trial	O
,	O
the	O
addition	O
of	O
trastuzumab	O
to	O
chemotherapy	O
significantly	O
improved	O
response	O
rate	O
,	O
time	O
to	O
disease	O
progression	O
,	O
and	O
overall	O
survival	O
in	O
women	O
with	O
HER2	B-GP
overexpressing	B-Gene_expression
metastatic	B-DS
breast	I-DS
cancer	I-DS
.	O

The	O
growth	O
inhibition	O
of	O
human	O
breast	B-DS
cancer	I-DS
cells	O
by	O
a	O
novel	O
synthetic	O
progestin	O
involves	O
the	O
induction	B-Positive_regulation
of	O
transforming	B-GP
growth	I-GP
factor	I-GP
beta	I-GP
.	O

Moreover	O
,	O
we	O
examined	O
the	O
putative	O
impact	O
of	O
p53	O
MspI	O
1798G	O
>	O
A	O
,	O
which	O
is	O
completely	O
linked	O
to	O
p53PIN3	O
,	O
a	O
16	O
bp	O
insertion	O
/	O
duplication	O
that	O
has	O
been	O
associated	O
with	O
reduced	B-Negative_regulation
p53	B-GP
expression	O
,	O
on	O
familial	B-DS
breast	I-DS
cancer	I-DS
risk	O
.	O

From	O
a	O
clinical	O
perspective	O
,	O
we	O
suggest	O
that	O
if	O
chemically	O
stable	O
FASN	O
inhibitors	O
or	O
cell	O
-	O
selective	O
systems	O
able	O
to	O
deliver	O
RNAi	O
targeting	O
FASN	O
gene	O
demonstrate	O
systemic	O
anticancer	O
effects	O
of	O
FASN	B-GP
inhibition	B-Negative_regulation
in	O
vivo	O
,	O
additional	O
preclinical	O
studies	O
to	O
characterize	O
their	O
anti	O
-	O
breast	O
cancer	O
actions	O
should	O
be	O
of	O
great	O
interest	O
as	O
the	O
specific	O
blockade	B-Negative_regulation
of	O
FASN	B-GP
activity	O
may	O
also	O
provide	O
a	O
protective	O
means	O
against	O
endometrial	O
carcinoma	O
associated	O
with	O
tamoxifen	O
-	O
based	O
breast	B-DS
cancer	I-DS
therapy	O
.	O

Inhibition	B-Negative_regulation
of	O
aromatase	B-GP
is	O
an	O
important	O
approach	O
for	O
reducing	O
growth	O
stimulatory	O
effects	O
of	O
estrogens	O
in	O
hormone	O
-	O
dependent	O
breast	B-DS
cancer	I-DS
.	O

Functional	O
ablation	O
of	O
pRb	O
activates	B-Positive_regulation
Cdk2	B-GP
and	O
causes	O
antiestrogen	O
resistance	O
in	O
human	O
breast	B-DS
cancer	I-DS
cells	O
.	O

These	O
results	O
indicate	O
that	O
the	O
overexpression	B-Gene_expression
of	O
H	B-GP
-	I-GP
ras	I-GP
in	O
human	O
breast	B-DS
tumors	I-DS
is	O
not	O
correlated	O
with	O
alteration	O
of	O
the	O
protooncogene	O
.	O

Correlation	O
with	O
clinicopathological	O
data	O
showed	O
,	O
however	O
,	O
that	O
the	O
loss	B-Negative_regulation
of	O
one	O
H	B-GP
-	I-GP
ras	I-GP
-	I-GP
1	I-GP
allele	I-GP
in	O
breast	B-DS
carcinoma	I-DS
DNAs	O
is	O
significantly	O
linked	O
to	O
histological	O
Grade	O
III	O
tumors	O
,	O
the	O
lack	O
of	O
estrogen	O
and	O
/	O
or	O
progesterone	O
receptors	O
,	O
and	O
the	O
subsequent	O
occurrence	O
of	O
distal	O
metastasis	O
.	O

Increase	B-Positive_regulation
of	O
urokinase	B-GP
-	I-GP
type	I-GP
plasminogen	I-GP
activator	I-GP
gene	I-GP
expression	B-Gene_expression
in	O
human	O
lung	O
and	O
breast	B-DS
carcinomas	I-DS
.	O

Cyclin	O
D3	O
compensates	O
for	O
the	O
loss	B-Negative_regulation
of	O
cyclin	B-GP
D1	I-GP
during	O
ErbB2	O
-	O
induced	O
mammary	B-DS
tumor	I-DS
initiation	O
and	O
progression	O
.	O

The	O
lack	B-Negative_regulation
of	O
Cyclin	B-GP
D1	I-GP
was	O
associated	O
with	O
a	O
compensatory	O
upregulation	B-Positive_regulation
of	O
Cyclin	B-GP
D3	I-GP
,	O
which	O
explains	O
why	O
the	O
targeted	O
downregulation	B-Negative_regulation
of	O
Cyclin	B-GP
D1	I-GP
in	O
established	O
mammary	B-DS
tumors	I-DS
had	O
no	O
effect	O
on	O
cancer	O
cell	O
proliferation	O
.	O

Cyclin	B-GP
D1	I-GP
and	O
D3	O
are	O
overexpressed	B-Gene_expression
in	O
human	O
breast	O
cancer	O
cell	O
lines	O
and	O
primary	O
invasive	B-DS
breast	I-DS
cancers	I-DS
,	O
and	O
Cyclin	O
D3	O
frequently	O
exceeded	O
the	O
expression	O
of	O
Cyclin	O
D1	O
in	O
ErbB2	O
-	O
positive	O
cases	O
.	O

Collectively	O
,	O
the	O
results	O
of	O
this	O
study	O
suggest	O
that	O
only	O
the	O
combined	O
inhibition	B-Negative_regulation
of	O
Cyclin	B-GP
D1	I-GP
and	O
D3	O
might	O
be	O
a	O
suitable	O
strategy	O
for	O
breast	B-DS
cancer	I-DS
prevention	O
and	O
therapy	O
.	O

The	O
multidrug	B-GP
transporter	I-GP
breast	B-DS
cancer	I-DS
resistance	I-GP
protein	I-GP
(	O
BCRP	B-GP
/	I-GP
ABCG2	I-GP
)	O
is	O
strongly	O
induced	B-Positive_regulation
in	O
the	O
mammary	O
gland	O
during	O
pregnancy	O
and	O
lactation	O
.	O

Ovarian	B-DS
carcinoma	I-DS
and	O
breast	B-DS
carcinoma	I-DS
cells	O
which	O
are	O
multiply	O
drug	O
resistant	O
due	O
to	O
overexpression	B-Gene_expression
of	O
P	B-GP
-	I-GP
glycoprotein	I-GP
are	O
markedly	O
less	O
resistant	O
to	O
cryptophycin	O
than	O
they	O
are	O
to	O
vinblastine	O
,	O
colchicine	O
,	O
and	O
taxol	O
.	O

In	O
several	O
breast	B-DS
cancer	I-DS
cell	O
lines	O
,	O
trichostatin	O
A	O
(	O
TSA	O
),	O
a	O
potent	O
HDAC	O
inhibitor	O
,	O
strongly	O
decreases	B-Negative_regulation
ERalpha	B-GP
expression	B-Gene_expression
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

We	O
also	O
observed	O
a	O
reduction	B-Negative_regulation
of	O
UBR1	B-GP
protein	I-GP
levels	O
in	O
geldanamycin	O
-	O
treated	O
mouse	O
embryonic	O
fibroblasts	O
and	O
human	O
breast	B-DS
cancer	I-DS
cells	O
,	O
suggesting	O
that	O
UBR1	O
is	O
an	O
Hsp90	O
client	O
.	O

One	O
of	O
the	O
best	O
examples	O
of	O
a	O
correlation	O
between	O
high	O
levels	O
of	O
a	O
protease	O
in	O
a	O
primary	O
tumor	O
and	O
poor	O
prognosis	O
is	O
urokinase	B-GP
plasminogen	I-GP
activation	B-Positive_regulation
in	O
breast	B-DS
cancer	I-DS
.	O

Oestrogen	O
receptor	O
-	O
alpha	O
(	O
ERalpha	O
)	O
is	O
an	O
important	O
prognostic	O
marker	O
in	O
breast	B-DS
cancer	I-DS
and	O
endocrine	O
therapies	O
are	O
designed	O
to	O
inhibit	O
or	O
prevent	B-Negative_regulation
ERalpha	B-GP
activity	O
.	O

IGFBP2	B-GP
and	O
IGFBP5	B-GP
overexpression	B-Gene_expression
correlates	O
with	O
the	O
lymph	O
node	O
metastasis	O
in	O
T1	O
breast	B-DS
carcinomas	I-DS
.	O

Overexpression	B-Gene_expression
of	O
IGFBP2	B-GP
and	O
IGFBP5	B-GP
contributes	O
to	O
the	O
invasiveness	O
and	O
progression	O
of	O
several	O
human	O
cancers	O
,	O
but	O
their	O
roles	O
in	O
the	O
metastasis	O
of	O
breast	B-DS
cancer	I-DS
have	O
not	O
been	O
investigated	O
in	O
detail	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
confirmed	O
that	O
the	O
administration	O
of	O
cytostatics	O
used	O
for	O
breast	O
cancer	O
treatment	O
,	O
such	O
as	O
taxanes	O
and	O
cyclophosphamide	O
(	O
CPA	O
),	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
the	O
tumor	O
level	O
of	O
dThdPase	B-GP
in	O
mammary	B-DS
tumor	I-DS
models	O
as	O
well	O
.	O

The	O
preferential	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
PyNPase	B-GP
activity	O
in	O
the	O
tumor	O
by	O
CPA	O
administration	O
was	O
also	O
confirmed	O
in	O
mice	O
bearing	O
a	O
syngeneic	O
murine	O
mammary	B-DS
adenocarcinoma	I-DS
,	O
A755	O
.	O

Enhanced	B-Positive_regulation
Ha	B-GP
-	I-GP
ras	I-GP
expression	B-Gene_expression
was	O
documented	O
in	O
66	O
%	O
of	O
breast	O
and	O
100	O
%	O
of	O
colon	O
carcinomas	O
as	O
compared	O
with	O
their	O
normal	O
counterparts	O
,	O
with	O
levels	O
in	O
breast	B-DS
carcinomas	I-DS
ranging	O
from	O
10	O
.	O
1	O
to	O
50	O
.	O
4	O
pg	O
ras	O
p21	O
/	O
micrograms	O
protein	O
and	O
those	O
in	O
colon	O
carcinomas	O
ranging	O
from	O
18	O
.	O
4	O
to	O
51	O
.	O
7	O
pg	O
ras	O
p21	O
/	O
micrograms	O
protein	O
.	O

Artesunate	O
treatment	O
of	O
human	O
CCRF	O
-	O
CEM	O
leukemia	O
and	O
MCF7	O
breast	B-DS
cancer	I-DS
cells	O
induced	B-Positive_regulation
ABCB6	B-GP
expression	B-Gene_expression
but	O
repressed	B-Negative_regulation
ABCB7	B-GP
expression	B-Gene_expression
.	O

Using	O
multiple	O
primer	O
sets	O
and	O
controls	O
,	O
we	O
found	O
that	O
neither	O
mature	O
BORIS	O
transcripts	O
nor	O
spliced	O
variants	O
are	O
commonly	O
expressed	O
at	O
detectable	O
levels	O
in	O
malignant	O
breast	O
cells	O
or	O
tissues	O
,	O
although	O
endogenous	O
BORIS	B-GP
transcripts	I-GP
can	O
be	O
induced	B-Positive_regulation
in	O
MCF	B-DS
-	I-DS
7	O
cells	O
following	O
5	O
-	O
aza	O
-	O
2	O
'-	O
deoxycytidine	O
treatment	O
.	O

Several	O
of	O
the	O
analogues	O
elicit	O
stronger	O
growth	O
inhibitory	O
activity	O
against	O
prostate	O
(	O
PC	O
-	O
3	O
)	O
and	O
breast	O
(	O
MDA	B-DS
-	I-DS
MB	I-DS
-	I-DS
468	I-DS
)	O
carcinoma	O
cells	O
,	O
which	O
contain	O
elevated	B-Positive_regulation
basal	O
IKK	B-GP
activity	O
;	O
this	O
antiproliferative	O
activity	O
correlates	O
with	O
increased	O
inhibition	O
of	O
recombinant	O
IKKbeta	O
in	O
vitro	O
,	O
suggesting	O
that	O
the	O
anticancer	O
activities	O
of	O
these	O
AdArs	O
might	O
be	O
related	O
to	O
the	O
inhibition	B-Negative_regulation
of	O
IKK	B-GP
/	I-GP
NFkappaB	I-GP
signaling	O
.	O

Mutations	O
of	O
the	O
tumor	O
suppressor	O
gene	O
p53	O
have	O
been	O
identified	O
in	O
breast	O
cancer	O
cell	O
lines	O
,	O
and	O
some	O
breast	B-DS
carcinomas	I-DS
are	O
detectable	O
by	O
immunohistochemical	O
assay	O
because	O
of	O
p53	B-GP
protein	I-GP
accumulation	B-Positive_regulation
.	O

In	O
MDA	O
-	O
MB	O
-	O
231	O
breast	B-DS
carcinoma	I-DS
cells	O
,	O
Taxo	O
did	O
not	O
interfere	O
with	O
the	O
re	B-Positive_regulation
-	I-Positive_regulation
activation	I-Positive_regulation
of	O
E	B-GP
-	I-GP
cadherin	I-GP
and	O
maspin	B-GP
genes	I-GP
by	O
5	O
-	O
AZA	O
-	O
CdR	O
.	O

While	O
expression	B-Gene_expression
of	O
Bcl	B-GP
-	I-GP
2	O
,	O
Bcl	B-GP
-	I-GP
X	O
(	O
L	O
),	O
Hsp	B-GP
70	I-GP
and	O
90	O
was	O
increased	B-Positive_regulation
,	O
expression	O
of	O
Bax	O
and	O
caspases	O
8	O
and	O
3	O
was	O
significantly	O
lower	O
in	O
both	O
human	O
as	O
well	O
as	O
canine	O
mammary	B-DS
tumor	I-DS
tissues	O
compared	O
to	O
corresponding	O
adjacent	O
tissues	O
.	O

Many	O
advanced	O
human	O
tumors	O
including	O
breast	B-DS
cancer	I-DS
overproduce	B-Gene_expression
plasmin	B-GP
that	O
is	O
known	O
to	O
promote	O
angiogenesis	O
and	O
metastasis	O
.	O

MDA	B-DS
-	I-DS
MB231	I-DS
cell	O
membranes	O
induced	B-Positive_regulation
plasmin	B-GP
generation	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
while	O
those	O
from	O
MCF	O
-	O
7	O
cells	O
failed	O
to	O
convert	O
plasminogen	O
to	O
plasmin	O
.	O

GRB7	B-GP
protein	I-GP
over	B-Gene_expression
-	I-Gene_expression
expression	I-Gene_expression
and	O
clinical	O
outcome	O
in	O
breast	B-DS
cancer	I-DS
.	O

Experimentally	O
,	O
we	O
found	O
that	O
reducing	B-Negative_regulation
expression	B-Gene_expression
of	O
SCRIB	B-GP
by	O
short	O
-	O
hairpin	O
RNAs	O
(	O
shRNAs	O
)	O
reduces	O
the	O
growth	O
of	O
human	O
breast	B-DS
cancer	I-DS
cells	O
in	O
xenograft	O
assays	O
.	O

In	O
T	B-DS
-	I-DS
47D	I-DS
cells	O
,	O
PRG1	B-GP
mRNA	I-GP
was	O
rapidly	O
and	O
transiently	O
induced	B-Positive_regulation
by	O
progestins	O
,	O
expression	O
peaking	O
between	O
2	O
and	O
4	O
h	O
and	O
returning	O
to	O
control	O
levels	O
by	O
12	O
h	O
.	O

Both	O
elevated	B-Positive_regulation
protein	O
-	O
tyrosine	O
kinase	O
activity	O
of	O
pp60	B-GP
(	I-GP
c	I-GP
-	I-GP
src	I-GP
)	O
and	O
the	O
association	O
of	O
its	O
high	O
activity	O
with	O
a	O
short	O
disease	O
-	O
free	O
period	O
have	O
been	O
reported	O
in	O
patients	O
with	O
human	O
breast	B-DS
cancer	I-DS
.	O

In	O
60	O
%	O
of	O
breast	B-DS
cancers	I-DS
,	O
the	O
pp60	B-GP
(	I-GP
c	I-GP
-	I-GP
src	I-GP
)	O
level	O
was	O
increased	B-Positive_regulation
,	O
the	O
reaction	O
intensity	O
was	O
elevated	O
,	O
and	O
a	O
positive	O
reaction	O
was	O
seen	O
in	O
cytoplasma	O
and	O
in	O
the	O
nuclear	O
area	O
.	O

Selective	O
inhibition	B-Negative_regulation
of	O
human	B-GP
3β	I-GP
-	I-GP
hydroxysteroid	I-GP
dehydrogenase	I-GP
type	I-GP
1	O
as	O
a	O
potential	O
treatment	O
for	O
breast	B-DS
cancer	I-DS
.	O

We	O
showed	O
that	O
treatment	O
of	O
MCF	O
-	O
7	O
and	O
triple	O
-	O
negative	O
MDA	O
-	O
MB	O
-	O
231	O
human	O
breast	B-DS
cancer	I-DS
cells	O
with	O
a	O
GnRH	O
-	O
II	O
antagonist	O
results	O
in	O
apoptotic	O
cell	O
death	O
in	O
vitro	O
via	O
activation	B-Positive_regulation
of	O
stress	O
-	O
activated	O
MAPK	O
p38	B-GP
and	O
loss	O
of	O
mitochondrial	O
membrane	O
potential	O
.	O

CTEN	B-GP
(	I-GP
C	I-GP
-	I-GP
terminal	I-GP
tensin	I-GP
-	I-GP
like	I-GP
),	O
a	O
novel	O
oncogene	O
overexpressed	B-Gene_expression
in	O
invasive	B-DS
breast	I-DS
carcinoma	I-DS
of	O
poor	O
prognosis	O
.	O

The	O
DNA	O
-	O
binding	O
epidermal	O
growth	O
factor	O
-	O
receptor	O
inhibitor	O
PD153035	O
and	O
other	O
DNA	O
-	O
intercalating	O
cytotoxic	O
drugs	O
reactivate	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
the	O
retinoic	B-GP
acid	I-GP
receptor	I-GP
-	I-GP
beta	I-GP
tumor	I-GP
-	I-GP
suppressor	I-GP
gene	I-GP
in	O
breast	B-DS
cancer	I-DS
cells	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
EGFR	O
inhibitor	O
PD153035	O
specifically	O
induces	B-Positive_regulation
RAR	B-GP
-	I-GP
beta2	I-GP
,	O
but	O
not	O
the	O
other	O
two	O
isoforms	O
(	O
RAR	O
-	O
beta1	O
,	O
RAR	O
-	O
beta4	O
)	O
in	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
MDA	O
-	O
MB	O
-	O
453	O
human	O
breast	B-DS
cancer	I-DS
cells	O
.	O

MTA1	B-GP
overexpression	B-Gene_expression
correlates	O
significantly	O
with	O
tumor	O
grade	O
and	O
angiogenesis	O
in	O
human	O
breast	B-DS
cancers	I-DS
.	O

Osteopontin	B-GP
(	O
OPN	O
)	O
is	O
a	O
secreted	O
phosphoprotein	O
often	O
overexpressed	B-Gene_expression
at	O
high	O
levels	O
in	O
the	O
blood	O
and	O
primary	O
tumors	O
of	O
breast	B-DS
cancer	I-DS
patients	O
.	O

These	O
findings	O
support	O
the	O
assumption	O
that	O
induction	B-Positive_regulation
of	O
PGR	B-GP
by	O
estrogen	O
in	O
human	O
breast	B-DS
cancer	I-DS
is	O
mediated	O
by	O
a	O
mechanism	O
involving	O
nuclear	O
receptors	O
.	O

Activated	B-Positive_regulation
Src	B-GP
increases	B-Positive_regulation
adhesion	O
,	O
survival	O
and	O
alpha2	B-GP
-	I-GP
integrin	I-GP
expression	B-Gene_expression
in	O
human	O
breast	B-DS
cancer	I-DS
cells	O
.	O

We	O
have	O
shown	O
that	O
overexpression	B-Gene_expression
of	O
an	O
activated	O
form	O
of	O
the	O
Src	B-GP
tyrosine	I-GP
kinase	I-GP
suppressed	O
the	O
loss	O
of	O
adhesion	O
induced	O
by	O
dominant	O
-	O
negative	O
;	O
adenoviral	O
FAK	O
-	O
CD	O
and	O
decreased	O
the	O
apoptotic	O
response	O
in	O
BT474	O
and	O
MCF	O
-	O
7	O
breast	B-DS
cancer	I-DS
cell	O
lines	O
.	O

We	O
have	O
also	O
shown	O
that	O
expression	O
of	O
activated	B-Positive_regulation
Src	B-GP
in	O
breast	B-DS
cancer	I-DS
cells	O
increased	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
alpha2	B-GP
-	I-GP
integrin	I-GP
and	O
that	O
overexpression	B-Gene_expression
of	O
alpha2	B-GP
-	I-GP
integrin	I-GP
suppressed	O
FAK	O
-	O
CD	O
-	O
mediated	O
loss	O
of	O
adhesion	O
.	O

Thus	O
,	O
pharmacologically	O
-	O
induced	O
metabolic	O
restriction	O
(	O
via	O
treatment	O
with	O
glycolysis	O
inhibitors	O
)	O
may	O
be	O
a	O
promising	O
new	O
therapeutic	O
strategy	O
for	O
breast	B-DS
cancer	I-DS
patients	O
that	O
lack	B-Negative_regulation
stromal	O
Cav	B-GP
-	I-GP
1	O
expression	B-Gene_expression
.	O

Adipocyte	O
expression	B-Gene_expression
and	O
circulating	O
levels	O
of	O
leptin	B-GP
increase	B-Positive_regulation
in	O
both	O
gynaecological	O
and	O
breast	B-DS
cancer	I-DS
patients	O
.	O

We	O
conclude	O
that	O
13q34	O
amplification	O
may	O
be	O
of	O
relevance	O
in	O
tumor	O
progression	O
of	O
basal	O
-	O
like	O
breast	B-DS
cancers	I-DS
by	O
inducing	B-Positive_regulation
overexpression	B-Gene_expression
of	O
CUL4A	B-GP
and	O
TFDP1	O
,	O
which	O
are	O
both	O
important	O
in	O
cell	O
cycle	O
regulation	O
.	O

Myosin	B-GP
II	I-GP
co	I-GP
-	I-GP
chaperone	I-GP
general	I-GP
cell	I-GP
UNC	I-GP
-	I-GP
45	I-GP
overexpression	B-Gene_expression
is	O
associated	O
with	O
ovarian	B-DS
cancer	I-DS
,	O
rapid	O
proliferation	O
,	O
and	O
motility	O
.	O

Knockdown	B-Negative_regulation
of	O
GC	B-GP
UNC	I-GP
-	I-GP
45	I-GP
reduced	O
the	O
spreading	O
ability	O
of	O
ovarian	B-DS
cancer	I-DS
cells	O
whereas	O
it	O
was	O
enhanced	O
by	O
GC	B-GP
UNC	I-GP
-	I-GP
45	I-GP
overexpression	B-Gene_expression
.	O

In	O
sum	O
,	O
these	O
findings	O
implicate	O
elevated	B-Positive_regulation
GC	B-GP
UNC	I-GP
-	I-GP
45	I-GP
protein	I-GP
expression	B-Gene_expression
in	O
ovarian	B-DS
carcinoma	I-DS
proliferation	O
and	O
metastasis	O
.	O

Neurofibromin	B-GP
1	O
(	O
NF1	B-GP
)	O
defects	B-Negative_regulation
are	O
common	O
in	O
human	O
ovarian	B-DS
serous	I-DS
carcinomas	I-DS
and	O
co	O
-	O
occur	O
with	O
TP53	O
mutations	O
.	O

We	O
tested	O
the	O
in	O
vivo	O
effects	O
of	O
GSK690693	O
in	O
Lck	O
-	O
MyrAkt2	O
transgenic	O
mice	O
that	O
develop	O
lymphomas	O
,	O
heterozygous	O
Pten	O
(+/-)	O
knockout	O
mice	O
that	O
exhibit	O
endometrial	O
tumors	O
,	O
and	O
TgMISIIR	O
-	O
TAg	O
-	O
DR26	O
mice	O
that	O
develop	O
ovarian	B-DS
carcinomas	I-DS
,	O
all	O
of	O
which	O
exhibit	O
hyperactivation	B-Positive_regulation
of	O
Akt	B-GP
.	O

Overall	O
,	O
these	O
results	O
implicate	O
inhibition	B-Negative_regulation
of	O
DNA	B-GP
-	I-GP
PK	I-GP
as	O
a	O
component	O
of	O
TLK286	O
cytotoxicity	O
and	O
provide	O
a	O
rationale	O
for	O
its	O
use	O
in	O
the	O
clinical	O
management	O
of	O
cisplatin	O
-	O
resistant	O
ovarian	B-DS
cancer	I-DS
.	O

Antisense	O
blocking	B-Negative_regulation
of	O
BRCA1	B-GP
enhances	O
sensitivity	O
to	O
plumbagin	O
but	O
not	O
tamoxifen	O
in	O
BG	O
-	O
1	O
ovarian	B-DS
cancer	I-DS
cells	O
.	O

Loss	B-Negative_regulation
of	O
MKK4	B-GP
expression	B-Gene_expression
in	O
ovarian	B-DS
cancer	I-DS
:	O
a	O
potential	O
role	O
for	O
the	O
epithelial	O
to	O
mesenchymal	O
transition	O
.	O

MKK4	O
gene	O
knockdown	O
in	O
MDAH	B-DS
2774	I-DS
cells	O
over	B-Gene_expression
-	I-Gene_expression
expressing	I-Gene_expression
MKK4	B-GP
increased	O
invasion	O
activity	O
.	O

Interestingly	O
,	O
we	O
found	O
that	O
MKK4	B-GP
upregulation	B-Positive_regulation
caused	O
downregulation	O
of	O
phosphorylated	O
NF	O
-	O
κB	O
and	O
Twist	O
,	O
as	O
well	O
as	O
upregulation	B-Positive_regulation
of	O
E	B-GP
-	I-GP
cadherin	I-GP
,	O
in	O
TOVG	O
-	O
21G	O
and	O
SKOV3	B-DS
cells	O
.	O

This	O
promotes	O
Twist	O
over	O
-	O
expression	O
,	O
resulting	O
in	O
E	B-GP
-	I-GP
cadherin	I-GP
downregulation	B-Negative_regulation
that	O
induces	O
EMT	O
in	O
ovarian	B-DS
cancer	I-DS
.	O

From	O
these	O
23	O
patients	O
,	O
18	O
pts	O
were	O
referred	O
for	O
suspected	O
recurrence	O
of	O
ovarian	B-DS
carcinoma	I-DS
:	O
occult	O
recurrence	O
(	O
OR	O
)	O
defined	O
by	O
an	O
increase	B-Positive_regulation
in	O
serum	O
CA	B-GP
-	I-GP
125	I-GP
levels	O
with	O
negative	O
conventional	O
imaging	O
(	O
13	O
pts	O
)	O
or	O
equivocal	O
aspect	O
at	O
conventional	O
imaging	O
(	O
5	O
pts	O
).	O

We	O
also	O
found	O
that	O
:	O
(	O
1	O
)	O
luciferase	O
activity	O
mediated	O
by	O
the	O
VEGF	O
reporter	O
containing	O
a	O
mutation	O
of	O
the	O
HIF	O
-	O
1	O
binding	O
site	O
was	O
much	O
lower	O
than	O
that	O
of	O
the	O
reporter	O
containing	O
a	O
wild	O
-	O
type	O
HIF	O
-	O
1	O
binding	O
site	O
in	O
ovarian	B-DS
cancer	I-DS
cells	O
,	O
thus	O
confirming	O
that	O
HIF	O
-	O
1	O
is	O
a	O
major	O
transcriptional	O
regulator	O
of	O
VEGF	O
expression	O
;	O
and	O
that	O
(	O
2	O
)	O
CDDP	O
greatly	O
inhibited	B-Negative_regulation
VEGF	B-GP
reporter	O
activity	O
containing	O
the	O
wild	O
-	O
type	O
but	O
not	O
the	O
mutant	O
HIF	O
-	O
1	O
binding	O
site	O
.	O

These	O
results	O
suggest	O
a	O
novel	O
mechanism	O
of	O
CDDP	O
'	O
s	O
anti	O
-	O
tumor	O
activity	O
in	O
ovarian	B-DS
cancer	I-DS
cells	O
via	O
HIF	O
-	O
1	O
expression	O
and	O
VEGF	B-GP
transcriptional	O
activation	B-Positive_regulation
.	O

Loss	O
of	O
this	O
42	O
-	O
bp	O
sequence	O
was	O
associated	O
with	O
increased	B-Positive_regulation
ERCC1	B-GP
mRNA	I-GP
expression	B-Gene_expression
,	O
in	O
an	O
assessment	O
of	O
121	O
ovarian	B-DS
cancer	I-DS
specimens	O
(	O
p2	O
<	O
10	O
(-	O
6	O
)).	O

We	O
report	O
that	O
elevated	B-Positive_regulation
expression	B-Gene_expression
of	O
LPAAT	B-GP
-	I-GP
beta	I-GP
was	O
associated	O
with	O
reduced	O
survival	O
in	O
ovarian	B-DS
cancer	I-DS
and	O
earlier	O
progression	O
of	O
disease	O
in	O
ovarian	O
and	O
endometrial	O
cancer	O
.	O

Inhibition	B-Negative_regulation
of	O
LPAAT	B-GP
-	I-GP
beta	I-GP
also	O
enhanced	O
the	O
survival	O
of	O
mice	O
bearing	O
ovarian	B-DS
tumor	I-DS
xenografts	O
.	O

Consistently	O
,	O
loss	B-Negative_regulation
of	O
CD95	B-GP
in	O
mouse	O
models	O
of	O
ovarian	B-DS
cancer	I-DS
and	O
liver	O
cancer	O
reduces	O
cancer	O
incidence	O
as	O
well	O
as	O
the	O
size	O
of	O
the	O
tumours	O
.	O

Under	O
normoxic	O
conditions	O
,	O
treatment	O
of	O
both	O
ovarian	B-DS
cancer	I-DS
cell	O
lines	O
with	O
dmPGE	O
(	O
2	O
)	O
resulted	O
in	O
a	O
significant	O
increase	B-Positive_regulation
in	O
VEGF	B-GP
expression	B-Gene_expression
but	O
had	O
no	O
effect	O
on	O
HIF	O
-	O
1alpha	O
.	O

Consequently	O
,	O
Id	B-GP
-	I-GP
1	O
inhibition	B-Negative_regulation
in	O
the	O
future	O
might	O
be	O
of	O
benefit	O
for	O
patients	O
with	O
ovarian	B-DS
cancer	I-DS
.	O

The	O
overexpression	B-Gene_expression
of	O
the	O
colony	B-GP
-	I-GP
stimulating	I-GP
factor	I-GP
-	I-GP
1	O
(	O
CSF	B-GP
-	I-GP
1	O
)	O
by	O
epithelial	B-DS
ovarian	I-DS
cancer	I-DS
cells	O
enhances	O
invasiveness	O
and	O
metastatic	O
properties	O
,	O
contributing	O
to	O
the	O
poor	O
prognosis	O
of	O
the	O
patients	O
.	O

These	O
data	O
suggest	O
that	O
GAPDH	O
binding	O
to	O
CSF	O
-	O
1	O
ARE	O
sequence	O
prevents	O
CSF	O
-	O
1	O
mRNA	O
decay	O
and	O
subsequent	O
down	O
-	O
regulation	O
of	O
CSF	O
-	O
1	O
protein	O
translation	O
,	O
leading	O
to	O
CSF	B-GP
-	I-GP
1	O
overexpression	B-Gene_expression
and	O
increased	O
metastatic	O
properties	O
seen	O
in	O
ovarian	B-DS
cancer	I-DS
.	O

The	O
MMP	B-GP
-	I-GP
9	O
levels	B-Gene_expression
decreased	B-Negative_regulation
in	O
a	O
time	O
-	O
dependent	O
manner	O
(	O
3	O
,	O
8	O
,	O
24	O
h	O
)	O
and	O
the	O
addition	O
of	O
anti	O
-	O
IL	O
-	O
6	O
antibodies	O
to	O
SKOV	B-DS
-	I-DS
3	O
cell	O
cultures	O
significantly	O
decreased	O
their	O
capacity	O
to	O
secrete	O
MMP	O
-	O
9	O
,	O
particularly	O
after	O
8	O
h	O
of	O
incubation	O
.	O

Germline	O
and	O
somatic	O
mutations	O
,	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
),	O
and	O
epigenetic	O
events	O
such	O
as	O
promoter	O
hypermethylation	O
can	O
lead	O
to	O
decreased	B-Negative_regulation
expression	B-Gene_expression
of	O
BRCA1	B-GP
/	I-GP
2	O
in	O
ovarian	B-DS
cancers	I-DS
.	O

Eighteen	O
(	O
37	O
%)	O
of	O
the	O
ovarian	B-DS
carcinomas	I-DS
had	O
germline	O
or	O
somatic	O
BRCA1	O
mutations	O
,	O
or	O
epigenetic	O
loss	B-Negative_regulation
of	O
BRCA1	B-GP
.	O

Subtype	O
specific	O
elevated	B-Positive_regulation
expression	B-Gene_expression
of	O
hyaluronidase	B-GP
-	I-GP
1	O
(	O
HYAL	B-GP
-	I-GP
1	O
)	O
in	O
epithelial	B-DS
ovarian	I-DS
cancer	I-DS
.	O

Four	O
of	O
six	O
cancer	O
cell	O
lines	O
,	O
including	O
OVCAR	B-DS
-	I-DS
3	O
,	O
overexpressed	B-Gene_expression
cyclin	B-GP
D1	I-GP
protein	I-GP
relative	O
to	O
levels	O
in	O
IOSE	O
-	O
29	O
cells	O
.	O

LPA	O
treatment	O
increased	B-Positive_regulation
cyclin	B-GP
D1	I-GP
protein	I-GP
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
in	O
OVCAR	B-DS
-	I-DS
3	O
cells	O
but	O
not	O
in	O
IOSE	O
-	O
29	O
cells	O
.	O

In	O
addition	O
to	O
the	O
previously	O
characterized	O
indirect	O
mechanism	O
that	O
increases	O
angiogenesis	O
via	O
VEGF	O
,	O
LPA	O
may	O
directly	O
increase	B-Positive_regulation
the	O
level	O
of	O
cyclin	B-GP
D1	I-GP
in	O
ovarian	B-DS
cancer	I-DS
cells	O
,	O
increasing	O
their	O
proliferation	O
.	O

Cisplatin	O
decreased	B-Negative_regulation
XIAP	B-GP
protein	I-GP
levels	B-Gene_expression
and	O
induced	O
Akt	O
cleavage	O
and	O
apoptosis	O
in	O
chemosensitive	O
,	O
but	O
not	O
in	O
resistant	O
,	O
ovarian	B-DS
cancer	I-DS
cells	O
.	O

Treatment	O
of	O
HOSE	B-DS
or	O
OCa	O
cells	O
with	O
estrone	O
or	O
17beta	O
-	O
estradiol	O
at	O
10	O
(-	O
8	O
)	O
M	O
for	O
a	O
period	O
of	O
72	O
h	O
induced	O
significant	O
loss	B-Negative_regulation
of	O
PR	B-GP
-	I-GP
A	O
and	O
PR	B-GP
-	I-GP
B	I-GP
mRNA	I-GP
and	O
protein	O
expression	B-Gene_expression
,	O
with	O
the	O
regulation	O
primarily	O
controlled	O
at	O
the	O
transcriptional	O
level	O
.	O

The	O
expression	B-Gene_expression
of	O
programmed	B-GP
cell	I-GP
death	I-GP
6	O
(	O
PDCD6	B-GP
)	O
is	O
known	O
to	O
be	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	I-Negative_regulation
in	O
cancer	O
cell	O
lines	O
and	O
ovarian	B-DS
cancer	I-DS
tissues	O
compared	O
to	O
normal	O
cells	O
and	O
tissues	O
.	O

The	O
drug	O
-	O
resistant	O
cell	O
lines	O
include	O
ovarian	B-DS
cancer	I-DS
cell	O
lines	O
resistant	O
to	O
cisplatin	O
,	O
topotecan	O
,	O
adriamycin	O
and	O
paclitaxel	O
overexpressing	B-Gene_expression
class	B-GP
III	I-GP
beta	I-GP
-	I-GP
tubulin	I-GP
,	O
A2780TC1	O
and	O
A2780TC3	O
.	O

Expression	O
and	O
overexpression	B-Gene_expression
of	O
the	O
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP
(	O
EGFR	B-GP
)	O
have	O
been	O
described	O
in	O
several	O
solid	O
tumors	O
including	O
bladder	O
,	O
breast	O
,	O
colorectal	O
,	O
NSCLC	O
,	O
prostate	O
,	O
and	O
ovarian	B-DS
cancers	I-DS
.	O

The	O
malignant	O
ovarian	O
epithelial	O
phenotype	O
has	O
been	O
associated	O
with	O
(	O
1	O
)	O
autocrine	O
growth	O
stimulation	O
by	O
transforming	O
growth	O
factor	O
-	O
alpha	O
,	O
(	O
2	O
)	O
loss	O
of	O
autocrine	O
growth	O
inhibition	O
by	O
transforming	O
growth	O
factor	O
-	O
beta	O
,	O
(	O
3	O
)	O
mutation	O
or	O
amplification	O
of	O
ras	O
in	O
2	O
-	O
12	O
%	O
of	O
cases	O
,	O
(	O
4	O
)	O
amplification	O
of	O
myc	O
in	O
23	O
%	O
of	O
specimens	O
,	O
(	O
5	O
)	O
expression	O
of	O
fms	O
in	O
56	O
%	O
of	O
cases	O
with	O
potential	O
autocrine	O
stimulation	O
by	O
macrophage	O
colony	O
stimulating	O
factor	O
,	O
(	O
6	O
)	O
paracrine	O
stimulation	O
by	O
macrophage	O
products	O
including	O
interleukin	O
-	O
1	O
,	O
interleukin	O
-	O
6	O
and	O
tumor	O
necrosis	O
factor	O
,	O
(	O
7	O
)	O
overexpression	B-Gene_expression
of	O
c	B-GP
-	I-GP
erbB	I-GP
-	I-GP
2	O
(	O
HER	B-GP
-	I-GP
2	I-GP
/	I-GP
neu	I-GP
)	O
in	O
30	O
%	O
of	O
cases	O
,	O
and	O
(	O
8	O
)	O
mutation	O
with	O
consequent	O
overexpression	O
of	O
p53	O
in	O
50	O
%	O
of	O
advanced	O
ovarian	B-DS
cancers	I-DS
.	O

pshRNA	O
-	O
Survivin	O
could	O
reduce	B-Negative_regulation
the	O
expression	B-Gene_expression
of	O
Survivin	B-GP
gene	I-GP
,	O
and	O
induce	O
apoptosis	O
of	O
SKOV3	B-DS
and	O
SKOV3	O
/	O
ADM	O
cells	O
.	O

Three	O
recent	O
articles	O
support	O
a	O
model	O
in	O
which	O
,	O
in	O
the	O
absence	O
of	O
mutations	O
in	O
the	O
Hh	O
pathway	O
,	O
Hh	O
ligands	O
expressed	O
by	O
a	O
subset	O
of	O
epithelial	O
cancers	O
,	O
including	O
colon	O
,	O
pancreatic	O
,	O
and	O
ovarian	B-DS
cancer	I-DS
,	O
promote	O
tumor	O
growth	O
indirectly	O
by	O
activating	B-Positive_regulation
Hh	B-GP
signaling	O
in	O
the	O
surrounding	O
stroma	O
,	O
which	O
,	O
in	O
turn	O
,	O
provides	O
a	O
more	O
favorable	O
environment	O
for	O
tumor	O
growth	O
.	O

Reactive	O
oxygen	O
species	O
regulate	O
epidermal	O
growth	O
factor	O
-	O
induced	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1alpha	O
expression	O
through	O
activation	B-Positive_regulation
of	O
AKT	B-GP
and	O
P70S6K1	B-GP
in	O
human	O
ovarian	B-DS
cancer	I-DS
cells	O
.	O

The	O
epidermal	B-GP
growth	I-GP
factor	I-GP
(	O
EGF	B-GP
)	O
and	O
EGF	B-GP
receptor	I-GP
(	O
EGFR	B-GP
)	O
family	O
are	O
often	O
overexpressed	B-Gene_expression
in	O
various	O
human	O
cancers	O
including	O
ovarian	B-DS
cancer	I-DS
.	O

This	O
study	O
demonstrates	O
a	O
novel	O
mechanism	O
of	O
EGF	O
-	O
induced	O
VEGF	O
and	O
HIF	O
-	O
1alpha	O
expression	O
through	O
production	O
of	O
H2O2	O
and	O
activation	B-Positive_regulation
of	O
AKT	B-GP
and	O
p70S6K1	B-GP
in	O
human	O
ovarian	B-DS
cancer	I-DS
cells	O
.	O

Human	B-GP
folate	I-GP
receptor	I-GP
alpha	I-GP
(	O
FRalpha	B-GP
)	O
is	O
a	O
folate	O
-	O
binding	O
protein	O
that	O
is	O
selectively	O
overexpressed	B-Gene_expression
in	O
ovarian	B-DS
carcinoma	I-DS
and	O
has	O
been	O
regarded	O
as	O
a	O
suitable	O
target	O
antigen	O
for	O
immunotherapy	O
purposes	O
.	O

Transforming	O
growth	O
factor	O
beta	O
1	O
can	O
induce	B-Positive_regulation
CIP1	B-GP
/	I-GP
WAF1	I-GP
expression	O
independent	O
of	O
the	O
p53	O
pathway	O
in	O
ovarian	B-DS
cancer	I-DS
cells	O
.	O

OVCA420	B-DS
,	O
a	O
cell	O
line	O
that	O
is	O
dramatically	O
growth	O
inhibited	O
by	O
TGF	O
beta	O
1	O
,	O
significantly	O
induced	B-Positive_regulation
CIP1	B-GP
expression	B-Gene_expression
in	O
response	O
to	O
TGF	O
beta	O
1	O
.	O

GSK3	O
inhibition	O
using	O
6	O
-	O
bromoindirubin	O
-	O
3	O
'-	O
oxime	O
suppressed	B-Negative_regulation
hTERT	B-GP
expression	B-Gene_expression
,	O
telomerase	O
activity	O
and	O
telomere	O
length	O
in	O
several	O
cancer	O
cell	O
lines	O
and	O
growth	O
and	O
hTERT	O
expression	O
in	O
ovarian	B-DS
cancer	I-DS
xenografts	O
.	O

Single	O
-	O
chain	O
antibody	O
-	O
mediated	O
inhibition	B-Negative_regulation
of	O
Bcl	B-GP
-	I-GP
2	O
in	O
SKOV3	B-DS
cells	O
was	O
associated	O
with	O
increased	O
growth	O
rates	O
and	O
more	O
rapid	O
cell	O
cycle	O
progression	O
.	O

Treatment	O
with	O
cisplatin	O
resulted	O
in	O
more	O
cells	O
accumulating	O
in	O
S	O
phase	O
in	O
Bcl	O
-	O
2	O
-	O
overexpressing	O
SKOV3	B-DS
cells	O
,	O
while	O
the	O
inhibition	B-Negative_regulation
of	O
Bcl	B-GP
-	I-GP
2	O
abolished	O
delayed	O
entry	O
into	O
G2M	O
phase	O
without	O
affecting	O
cisplatin	O
-	O
induced	O
apoptosis	O
.	O

Serum	O
alphaFP	O
and	O
betaHCG	O
are	O
very	O
useful	O
in	O
the	O
preoperative	O
evaluation	O
and	O
management	O
of	O
nondysgerminomatous	O
ovarian	B-DS
germ	I-DS
cell	I-DS
tumors	I-DS
,	O
whereas	O
elevated	B-Positive_regulation
serum	O
inhibin	B-GP
levels	O
can	O
be	O
detected	O
in	O
patients	O
with	O
granulosa	O
cell	O
tumors	O
of	O
the	O
ovary	O
.	O

The	O
authors	O
report	O
one	O
case	O
in	O
a	O
43	O
-	O
year	O
-	O
old	O
woman	O
,	O
the	O
initial	O
interpretation	O
of	O
which	O
,	O
based	O
on	O
pleural	O
and	O
peritoneal	O
exudate	O
,	O
showed	O
suspected	O
latero	O
-	O
uterine	O
mass	O
and	O
significant	O
elevated	B-Positive_regulation
serum	O
CA	B-GP
125	I-GP
level	O
,	O
mimicking	O
disseminated	O
ovarian	B-DS
carcinoma	I-DS
.	O

Conversely	O
,	O
ectopic	O
Pak1	B-GP
overexpression	B-Gene_expression
enhanced	O
ovarian	B-DS
cancer	I-DS
cell	O
migration	O
and	O
invasion	O
in	O
a	O
kinase	O
-	O
dependent	O
manner	O
,	O
along	O
with	O
increased	B-Positive_regulation
p38	B-GP
activation	O
.	O

Amplification	O
or	O
overexpression	B-Gene_expression
of	O
the	O
c	B-GP
-	I-GP
erbB	I-GP
-	I-GP
2	I-GP
oncogene	I-GP
(	O
also	O
known	O
as	O
HER	O
-	O
2	O
,	O
neu	O
)	O
is	O
a	O
frequent	O
event	O
in	O
many	O
types	O
of	O
human	O
cancer	O
including	O
20	O
-	O
30	O
%	O
of	O
ovarian	B-DS
cancers	I-DS
where	O
it	O
characterizes	O
a	O
group	O
of	O
patients	O
with	O
poor	O
prognosis	O
(	O
1	O
,	O
2	O
).	O

The	O
HER2	B-GP
overexpressing	B-Gene_expression
human	O
SKOV	O
-	O
3	O
ovarian	B-DS
tumour	I-DS
cell	O
line	O
was	O
used	O
for	O
in	O
vitro	O
experiments	O
and	O
as	O
xenograft	O
model	O
in	O
nude	O
athymic	O
mice	O
.	O

Transfection	O
with	O
the	O
kinase	O
-	O
inactive	O
mutant	O
of	O
Akt	O
or	O
TM	O
of	O
FKHRL1	O
induced	B-Positive_regulation
the	O
activity	O
of	O
the	O
Fas	B-GP
ligand	I-GP
promoter	I-GP
in	O
Caov	B-DS
-	I-DS
3	O
cells	O
.	O

Tight	O
junction	O
proteins	O
claudin	B-GP
-	I-GP
3	O
and	O
claudin	B-GP
-	I-GP
4	O
are	O
frequently	O
overexpressed	B-Gene_expression
in	O
ovarian	O
cancer	O
but	O
not	O
in	O
ovarian	B-DS
cystadenomas	I-DS
.	O

Although	O
expressed	O
at	O
low	O
levels	O
in	O
some	O
normal	O
human	O
tissues	O
,	O
including	O
the	O
ovary	O
,	O
CLDN3	B-GP
and	O
CLDN4	B-GP
are	O
highly	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
in	O
epithelial	B-DS
ovarian	I-DS
cancers	I-DS
of	O
all	O
subtypes	O
.	O

These	O
results	O
show	O
that	O
CLDN3	B-GP
and	O
CLDN4	B-GP
are	O
frequently	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
in	O
ovarian	B-DS
tumors	I-DS
and	O
cell	O
lines	O
and	O
may	O
represent	O
novel	O
markers	O
for	O
this	O
disease	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
E3	O
ubiquitin	O
ligase	O
,	O
EDD	B-GP
,	O
a	O
regulator	O
of	O
DNA	O
damage	O
responses	O
,	O
is	O
amplified	O
and	O
overexpressed	B-Gene_expression
in	O
serous	O
ovarian	B-DS
carcinoma	I-DS
.	O

Although	O
EDD	O
expression	O
was	O
not	O
directly	O
correlated	O
with	O
relative	O
cisplatin	O
sensitivity	O
of	O
ovarian	B-DS
cancer	I-DS
cell	O
lines	O
,	O
sensitivity	O
to	O
cisplatin	O
was	O
partially	O
restored	O
in	O
platinum	O
-	O
resistant	O
A2780	O
-	O
cp70	O
ovarian	O
cancer	O
cells	O
following	O
siRNA	O
-	O
mediated	O
knockdown	B-Negative_regulation
of	O
EDD	B-GP
expression	B-Gene_expression
.	O

In	O
patients	O
with	O
recurrence	O
of	O
ovary	B-DS
tumor	I-DS
,	O
the	O
IAP	B-GP
levels	O
was	O
increased	B-Positive_regulation
to	O
compare	O
with	O
the	O
health	O
women	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
the	O
incidence	O
of	O
the	O
abnormal	O
value	O
was	O
100	O
%.	O

The	O
accumulation	B-Positive_regulation
of	O
p53	B-GP
protein	I-GP
was	O
analysed	O
immunohistochemically	O
in	O
ovarian	B-DS
cancer	I-DS
and	O
correlated	O
with	O
clinical	O
data	O
to	O
further	O
clarify	O
the	O
role	O
of	O
p53	O
mutations	O
for	O
prognosis	O
in	O
these	O
patients	O
.	O

Increased	B-Positive_regulation
p130cas	B-GP
expression	B-Gene_expression
is	O
associated	O
with	O
poor	O
clinical	O
outcome	O
in	O
human	O
ovarian	B-DS
carcinoma	I-DS
,	O
and	O
p130cas	O
gene	O
silencing	O
decreases	O
tumor	O
growth	O
through	O
stimulation	O
of	O
apoptotic	O
and	O
autophagic	O
cell	O
death	O
.	O

Concentrations	O
of	O
follicle	B-GP
stimulating	I-GP
hormone	I-GP
are	O
increased	B-Positive_regulation
in	O
ovarian	O
tumor	O
fluid	O
:	O
implications	O
for	O
the	O
management	O
of	O
ovarian	B-DS
cancer	I-DS
.	O

BRCA1	B-GP
expression	B-Gene_expression
is	O
decreased	B-Negative_regulation
or	O
absent	O
in	O
a	O
significant	O
proportion	O
of	O
sporadic	O
breast	O
and	O
ovarian	B-DS
cancers	I-DS
,	O
suggesting	O
a	O
wider	O
role	O
in	O
these	O
tumor	O
types	O
.	O

Epidermal	B-GP
growth	I-GP
factor	I-GP
(	O
EGF	B-GP
)	O
and	O
hepatocyte	B-GP
growth	I-GP
factor	I-GP
(	O
HGF	B-GP
)	O
are	O
often	O
both	O
overexpressed	B-Gene_expression
and	O
contribute	O
to	O
the	O
growth	O
of	O
ovarian	B-DS
cancer	I-DS
by	O
activating	O
autocrine	O
pathways	O
.	O

According	O
to	O
this	O
mechanism	O
the	O
deregulation	O
of	O
the	O
BRCA1	O
transcription	O
in	O
cancer	O
,	O
resulting	O
in	O
a	O
higher	O
proportion	O
of	O
translationally	O
inhibited	O
transcripts	O
containing	O
5	O
'-	O
UTRb	O
,	O
contributes	O
to	O
the	O
decrease	B-Negative_regulation
in	O
the	O
BRCA1	B-GP
protein	I-GP
observed	O
in	O
sporadic	O
breast	O
and	O
ovarian	B-DS
cancers	I-DS
.	O

Amplification	O
or	O
overexpression	B-Gene_expression
of	O
the	O
c	B-GP
-	I-GP
erbB	I-GP
-	I-GP
2	I-GP
gene	I-GP
have	O
been	O
reported	O
to	O
correlate	O
with	O
poor	O
patient	O
prognosis	O
in	O
human	O
breast	O
,	O
gastric	O
,	O
and	O
ovarian	B-DS
cancer	I-DS
.	O

We	O
propose	O
that	O
,	O
in	O
the	O
ovarian	B-DS
tumour	I-DS
microenvironment	O
,	O
interaction	O
between	O
tumour	O
cells	O
and	O
fibroblasts	O
may	O
enhance	B-Positive_regulation
fibroblast	O
production	B-Gene_expression
of	O
the	O
proMMP	B-GP
-	I-GP
2	O
and	O
TIMP	B-GP
-	I-GP
2	O
.	O

Collagen	O
I	O
,	O
also	O
present	O
in	O
the	O
ovarian	B-DS
tumours	I-DS
,	O
then	O
induces	O
these	O
fibroblasts	O
to	O
activate	B-Positive_regulation
proMMP	B-GP
-	I-GP
2	O
even	O
in	O
the	O
presence	O
of	O
TIMP	O
-	O
2	O
.	O

We	O
previously	O
showed	O
that	O
the	O
expressing	B-Gene_expression
level	O
of	O
FSH	B-GP
receptor	I-GP
(	O
FSHR	B-GP
)	O
increased	B-Positive_regulation
from	O
ovarian	O
epithelial	O
inclusions	O
(	O
OEIs	O
)	O
to	O
benign	O
ovarian	B-DS
epithelial	I-DS
tumors	I-DS
(	O
OETs	O
)	O
and	O
to	O
borderline	O
OETs	O
,	O
whereas	O
FSHR	O
levels	O
decreased	O
with	O
an	O
increase	O
in	O
carcinoma	O
grade	O
.	O

In	O
addition	O
,	O
the	O
higher	O
PA1	B-DS
cell	O
responsiveness	O
to	O
endogenous	O
compared	O
with	O
exogenous	O
activin	O
,	O
suggests	O
that	O
activin	B-GP
overexpression	B-Gene_expression
in	O
PA1	O
cells	O
may	O
up	B-Positive_regulation
-	I-Positive_regulation
regulate	I-Positive_regulation
an	O
activin	B-GP
signaling	O
component	O
,	O
or	O
down	O
-	O
regulate	O
an	O
activin	O
signaling	O
inhibitor	O
.	O

Blocking	B-Negative_regulation
of	O
IL	B-GP
-	I-GP
1	I-GP
alpha	I-GP
activity	O
in	O
HOC	B-DS
-	I-DS
7	O
cells	O
with	O
either	O
IL	O
-	O
1	O
receptor	O
antagonist	O
(	O
IL	O
-	O
1ra	O
)	O
or	O
a	O
neutralizing	O
antibody	O
directed	O
against	O
IL	O
-	O
1	O
alpha	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
decrease	O
of	O
IL	O
-	O
8	O
release	O
by	O
ATRA	O
,	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
1	O
alpha	O
treated	O
HOC	O
-	O
7	O
cells	O
.	O

Four	O
out	O
of	O
the	O
twelve	O
cancer	O
tissue	O
specimens	O
,	O
one	O
specimen	O
of	O
cancer	O
ascites	O
cells	O
and	O
the	O
NIH	O
:	O
OVCAR	B-DS
-	I-DS
3	O
cancer	O
cell	O
line	O
showed	O
elevated	B-Positive_regulation
amplification	O
of	O
c	B-GP
-	I-GP
Ki	I-GP
-	I-GP
ras	I-GP
,	O
as	O
compared	O
to	O
the	O
human	O
fibroblast	O
cell	O
line	O
FS4	O
and	O
normal	O
ovarian	O
tissues	O
.	O

Six1	B-GP
overexpression	B-Gene_expression
in	O
ovarian	B-DS
carcinoma	I-DS
causes	O
resistance	O
to	O
TRAIL	O
-	O
mediated	O
apoptosis	O
and	O
is	O
associated	O
with	O
poor	O
survival	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
developmental	O
regulator	O
Six1	B-GP
is	O
overexpressed	B-Gene_expression
in	O
ovarian	B-DS
carcinoma	I-DS
cell	O
lines	O
(	O
OCC	O
)	O
compared	O
with	O
normal	O
ovarian	O
surface	O
epithelium	O
.	O

In	O
addition	O
,	O
Six1	B-GP
overexpression	B-Gene_expression
renders	O
OCC	O
resistant	O
to	O
tumor	O
necrosis	O
factor	O
-	O
related	O
apoptosis	O
inducing	O
ligand	O
(	O
TRAIL	O
)-	O
mediated	O
apoptosis	O
,	O
and	O
Six1	B-GP
knockdown	B-Negative_regulation
in	O
the	O
TRAIL	O
-	O
resistant	O
SKOV3	O
ovarian	B-DS
carcinoma	I-DS
line	O
dramatically	O
sensitizes	O
the	O
cells	O
to	O
TRAIL	O
.	O

Six1	B-GP
was	O
overexpressed	B-Gene_expression
in	O
50	O
%	O
of	O
the	O
early	O
-	O
stage	O
(	O
stage	O
I	O
)	O
and	O
63	O
%	O
of	O
the	O
late	O
-	O
stage	O
(	O
stages	O
II	O
,	O
III	O
,	O
and	O
IV	O
)	O
ovarian	B-DS
carcinomas	I-DS
examined	O
,	O
with	O
late	O
-	O
stage	O
carcinomas	O
expressing	O
approximately	O
3	O
-	O
fold	O
higher	O
Six1	O
mRNA	O
levels	O
on	O
average	O
compared	O
with	O
early	O
-	O
stage	O
tumors	O
.	O

We	O
have	O
previously	O
shown	O
that	O
acquisition	O
of	O
cisplatin	O
resistance	O
by	O
OAW42	O
-	O
R	O
ovarian	B-DS
carcinoma	I-DS
cells	O
was	O
associated	O
with	O
the	O
loss	B-Negative_regulation
of	O
ERK	B-GP
activation	O
in	O
response	O
to	O
cisplatin	O
.	O

Downmodulation	B-Negative_regulation
of	O
caveolin	B-GP
-	I-GP
1	O
expression	B-Gene_expression
in	O
human	O
ovarian	B-DS
carcinoma	I-DS
is	O
directly	O
related	O
to	O
alpha	B-GP
-	I-GP
folate	I-GP
receptor	I-GP
overexpression	B-Gene_expression
.	O

Conversely	O
,	O
cav	B-GP
-	I-GP
1	O
transfection	B-Gene_expression
in	O
IGROV1	B-DS
cells	O
led	O
to	O
downregulated	O
alphaFR	O
expression	O
,	O
together	O
with	O
formation	O
of	O
caveolar	O
structures	O
and	O
reduction	O
of	O
growth	O
capability	O
.	O

Moreover	O
,	O
cav	B-GP
-	I-GP
1	O
expression	B-Gene_expression
was	O
induced	B-Positive_regulation
in	O
IGROV1	B-DS
cells	O
by	O
transfection	O
with	O
intracellular	O
anti	O
-	O
alphaFR	O
antibodies	O
to	O
downmodulate	B-Negative_regulation
alphaFR	B-GP
expression	B-Gene_expression
.	O

Attenuating	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)-	O
1α	O
expression	O
via	O
small	O
interference	O
RNA	O
resulted	O
in	O
a	O
significantly	O
decreased	B-Negative_regulation
hCG	B-GP
expression	B-Gene_expression
in	O
OVCAR	B-DS
-	I-DS
3	O
,	O
which	O
indicated	O
that	O
the	O
effect	O
of	O
hypoxia	O
on	O
hCG	O
expression	O
was	O
mediated	O
through	O
HIF	O
-	O
1α	O
.	O

Expression	B-Gene_expression
level	O
of	O
vascular	O
marker	O
and	O
HIF	B-GP
-	I-GP
1α	I-GP
in	O
OVCAR	B-DS
-	I-DS
3	O
increased	B-Positive_regulation
in	O
response	O
to	O
hCG	O
treatment	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Taken	O
together	O
,	O
these	O
studies	O
suggest	O
that	O
IL	O
-	O
1	O
may	O
kill	O
ovarian	O
NIH	O
:	O
OVCAR	B-DS
-	I-DS
3	O
tumor	O
cells	O
by	O
inducing	O
a	O
blockade	O
at	O
G1	O
/	O
S	O
of	O
the	O
cell	O
cycle	O
,	O
down	B-Negative_regulation
-	I-Negative_regulation
regulating	I-Negative_regulation
c	B-GP
-	I-GP
myc	I-GP
gene	I-GP
and	O
inducing	O
p53	O
-	O
dependent	O
apoptosis	O
.	O

Cyclin	B-GP
E	O
is	O
overexpressed	B-Gene_expression
in	O
breast	O
,	O
lung	O
,	O
skin	O
,	O
gastrointestinal	O
,	O
cervical	O
,	O
and	O
ovarian	B-DS
cancers	I-DS
.	O

MonoHER	O
suppressed	O
DOX	O
-	O
dependent	O
activation	O
of	O
the	O
mitochondrial	O
apoptotic	O
pathway	O
in	O
normal	O
and	O
A2780	B-DS
cells	O
as	O
illustrated	O
by	O
p53	B-GP
accumulation	B-Positive_regulation
and	O
activation	O
of	O
caspase	O
-	O
9	O
and	O
-	O
3	O
cleavage	O
.	O

The	O
levels	O
of	O
TAT	B-GP
and	O
FDP	O
were	O
significantly	O
higher	B-Positive_regulation
in	O
patients	O
with	O
ovarian	B-DS
cancer	I-DS
compared	O
to	O
the	O
control	O
group	O
(	O
both	O
:	O
p	O
less	O
than	O
0	O
.	O
01	O
),	O
and	O
these	O
levels	O
were	O
higher	O
than	O
in	O
other	O
gynecological	O
malignancies	O
.	O

TAT	B-GP
and	O
FDP	B-GP
were	O
increased	B-Positive_regulation
following	O
cancer	O
dissemination	O
,	O
and	O
the	O
recovery	O
of	O
coagulative	O
and	O
fibrinolytic	O
factors	O
(	O
TAT	O
,	O
FDP	O
)	O
with	O
effective	O
treatment	O
was	O
correlated	O
to	O
the	O
prognosis	O
for	O
patients	O
with	O
ovarian	B-DS
cancer	I-DS
.	O

Transfection	B-Gene_expression
of	O
HER	B-GP
-	I-GP
2	I-GP
siRNA	I-GP
was	O
conducted	O
with	O
lipofectamine	O
2000	O
in	O
ovarian	B-DS
carcinoma	I-DS
cell	O
line	O
SKOV3	O
.	O

Decreased	B-Negative_regulation
p21Cip1	B-GP
expression	B-Gene_expression
is	O
related	O
to	O
several	O
indicators	O
of	O
aggressiveness	O
in	O
ovarian	B-DS
adenocarcinomas	I-DS
and	O
seems	O
to	O
be	O
differentially	O
regulated	O
in	O
LMP	O
tumors	O
and	O
adenocarcinomas	O
.	O

Expression	O
of	O
BRCA1	O
protein	O
in	O
benign	O
,	O
borderline	O
,	O
and	O
malignant	O
epithelial	O
ovarian	B-DS
neoplasms	I-DS
and	O
its	O
relationship	O
to	O
methylation	O
and	O
allelic	O
loss	B-Negative_regulation
of	O
the	O
BRCA1	B-GP
gene	I-GP
.	O

These	O
findings	O
suggest	O
that	O
reduced	B-Negative_regulation
expression	B-Gene_expression
of	O
BRCA1	B-GP
protein	I-GP
along	O
with	O
genetic	O
and	O
epigenetic	O
changes	O
of	O
the	O
BRCA1	B-GP
gene	I-GP
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
sporadic	O
ovarian	B-DS
carcinomas	I-DS
,	O
particularly	O
those	O
of	O
serous	O
histology	O
.	O

Preoperatively	O
,	O
an	O
elevated	B-Positive_regulation
thyroglobulin	B-GP
(	O
Tg	O
)	O
level	O
,	O
laboratory	O
or	O
clinical	O
evidence	O
of	O
hyperthyroidism	O
,	O
or	O
ultrasonography	O
appearance	O
of	O
""""	O
struma	O
pearl	O
""""	O
should	O
prompt	O
referral	O
to	O
oncologist	O
for	O
surgical	O
management	O
of	O
a	O
possibly	O
malignant	B-DS
ovarian	I-DS
teratoma	I-DS
.	O

ZEB2	O
expression	O
was	O
negatively	O
correlated	O
with	O
CDH1	O
expression	O
in	O
advanced	O
stage	O
samples	O
,	O
whereas	O
ZEB2	B-GP
knockdown	B-Negative_regulation
in	O
ovarian	B-DS
adenocarcinoma	I-DS
SKOV3	O
cells	O
resulted	O
in	O
an	O
increase	B-Positive_regulation
in	O
CDH1	B-GP
expression	B-Gene_expression
.	O

p53	B-GP
overexpression	B-Gene_expression
,	O
identified	O
by	O
immunohistochemistry	O
,	O
and	O
p53	O
mutations	O
,	O
identified	O
by	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
DNA	O
sequencing	O
,	O
have	O
been	O
described	O
in	O
ovarian	B-DS
cancers	I-DS
.	O

p53	B-GP
overexpression	B-Gene_expression
has	O
been	O
correlated	O
with	O
poor	O
outcome	O
for	O
women	O
with	O
ovarian	B-DS
cancer	I-DS
in	O
some	O
studies	O
.	O

No	O
correlation	O
could	O
be	O
seen	O
between	O
the	O
histology	O
of	O
the	O
ovarian	B-DS
tumours	I-DS
and	O
the	O
elevation	B-Positive_regulation
of	O
MMP	B-GP
-	I-GP
2	I-GP
/	I-GP
9	O
activity	O
.	O

More	O
interestingly	O
,	O
however	O
,	O
MMP	B-GP
-	I-GP
9	O
expression	B-Gene_expression
and	O
fibronectin	O
concentration	O
were	O
significantly	O
elevated	B-Positive_regulation
and	O
the	O
activated	O
forms	O
of	O
both	O
MMP	O
-	O
9	O
and	O
MMP	O
-	O
2	O
were	O
more	O
frequent	O
in	O
ovarian	B-DS
cancer	I-DS
patients	O
who	O
developed	O
recurrent	O
disease	O
.	O

Angiopoietin	B-GP
-	I-GP
1	O
and	O
Ang	B-GP
-	I-GP
2	O
levels	B-Gene_expression
were	O
significantly	O
elevated	B-Positive_regulation
in	O
serum	O
samples	O
of	O
patients	O
with	O
ovarian	B-DS
carcinoma	I-DS
compared	O
with	O
healthy	O
controls	O
(	O
P	O
=	O
0	O
.	O
0005	O
and	O
P	O
<	O
0	O
.	O
0005	O
,	O
respectively	O
).	O

In	O
addition	O
,	O
Ang	B-GP
-	I-GP
2	O
levels	B-Gene_expression
were	O
significantly	O
higher	B-Positive_regulation
in	O
patients	O
with	O
ovarian	O
carcinoma	O
compared	O
with	O
patients	O
with	O
benign	O
(	O
P	O
<	O
0	O
.	O
0005	O
)	O
or	O
borderline	B-DS
ovarian	I-DS
tumors	I-DS
(	O
P	O
=	O
0	O
.	O
011	O
).	O

Anti	O
-	O
androgen	O
use	O
early	O
in	O
the	O
course	O
of	O
ovarian	B-DS
cancer	I-DS
is	O
more	O
likely	O
to	O
be	O
effective	O
as	O
these	O
data	O
suggest	O
that	O
androgen	B-GP
receptor	I-GP
expression	B-Gene_expression
decreases	B-Negative_regulation
with	O
exposure	O
to	O
chemotherapy	O
and	O
this	O
may	O
explain	O
the	O
low	O
response	O
rates	O
seen	O
in	O
clinical	O
trials	O
of	O
patients	O
heavily	O
pre	O
-	O
treated	O
with	O
multiple	O
courses	O
of	O
chemotherapy	O
.	O

Carbohydrate	O
antigen	O
expression	O
in	O
primary	O
tumors	O
,	O
metastatic	O
lesions	O
,	O
and	O
serous	O
effusions	O
from	O
patients	O
diagnosed	O
with	O
epithelial	B-DS
ovarian	I-DS
carcinoma	I-DS
:	O
evidence	O
of	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
Tn	B-GP
and	O
Sialyl	B-GP
Tn	I-GP
antigen	I-GP
expression	B-Gene_expression
in	O
effusions	O
.	O

Ovarian	B-DS
carcinoma	I-DS
cells	O
in	O
effusions	O
show	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
Tn	B-GP
and	O
Sialyl	B-GP
Tn	I-GP
,	O
possibly	O
representing	O
a	O
transient	O
phenotypic	O
alteration	O
facilitating	O
metastasis	O
.	O

Significantly	O
decreased	O
,	O
or	O
complete	O
loss	B-Negative_regulation
of	O
,	O
protein	O
expression	B-Gene_expression
of	O
the	O
TSLC1	B-GP
gene	I-GP
was	O
observed	O
in	O
59	O
%	O
ovarian	B-DS
carcinomas	I-DS
,	O
45	O
%	O
borderline	O
tumors	O
,	O
and	O
7	O
%	O
cystadenomas	O
,	O
but	O
in	O
none	O
of	O
the	O
normal	O
ovaries	O
(	O
0	O
%).	O

In	O
ovarian	B-DS
carcinomas	I-DS
,	O
decreased	B-Negative_regulation
TSLC1	B-GP
expression	B-Gene_expression
was	O
significantly	O
correlated	O
with	O
lymph	O
node	O
metastasis	O
(	O
pN	O
,	O
P	O
=	O
0	O
.	O
001	O
),	O
distant	O
metastasis	O
(	O
pM	O
,	O
P	O
=	O
0	O
.	O
028	O
),	O
and	O
more	O
advanced	O
International	O
Federation	O
of	O
Gynecology	O
and	O
Obstetrics	O
stages	O
(	O
P	O
=	O
0	O
.	O
008	O
).	O

By	O
univariate	O
survival	O
analysis	O
on	O
the	O
ovarian	B-DS
carcinoma	I-DS
cohorts	O
,	O
decreased	B-Negative_regulation
TSLC1	B-GP
protein	I-GP
expression	B-Gene_expression
was	O
significantly	O
associated	O
with	O
shortened	O
patient	O
survival	O
(	O
mean	O
:	O
26	O
.	O
9	O
months	O
in	O
tumors	O
with	O
complete	O
loss	O
of	O
TSLC1	O
vs	O
63	O
.	O
1	O
months	O
in	O
tumors	O
with	O
significantly	O
decreased	B-Negative_regulation
TSLC1	B-GP
vs	O
94	O
.	O
3	O
months	O
in	O
tumors	O
with	O
normal	O
levels	O
of	O
TSLC1	O
;	O
P	O
<	O
0	O
.	O
001	O
).	O

Decreased	B-Negative_regulation
protein	O
expression	B-Gene_expression
of	O
the	O
TSLC1	B-GP
gene	I-GP
might	O
be	O
important	O
in	O
conferring	O
a	O
more	O
aggressive	O
behavior	O
in	O
ovarian	B-DS
carcinoma	I-DS
.	O

Genetic	O
downregulation	O
of	O
pregnancy	O
-	O
associated	O
plasma	O
protein	O
-	O
A	O
(	O
PAPP	O
-	O
A	O
)	O
by	O
bikunin	O
reduces	B-Negative_regulation
IGF	O
-	O
I	O
-	O
dependent	O
Akt	O
and	O
ERK1	B-GP
/	I-GP
2	O
activation	O
and	O
subsequently	O
reduces	O
ovarian	B-DS
cancer	I-DS
cell	O
growth	O
,	O
invasion	O
and	O
metastasis	O
.	O

NTN1	B-GP
was	O
found	O
overexpressed	B-Gene_expression
in	O
76	O
%	O
of	O
ovarian	B-DS
cancer	I-DS
specimens	O
(	O
13	O
/	O
17	O
)	O
as	O
compared	O
to	O
normal	O
(	O
0	O
/	O
10	O
,	O
p	O
<	O
0	O
.	O
004	O
)	O
and	O
benign	O
(	O
1	O
/	O
8	O
,	O
p	O
<	O
0	O
.	O
008	O
)	O
samples	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
NTN1	O
may	O
be	O
involved	O
in	O
ovarian	B-DS
cancer	I-DS
as	O
the	O
expression	B-Gene_expression
of	O
NTN1	B-GP
mRNA	I-GP
is	O
strongly	O
upregulated	B-Positive_regulation
in	O
ovarian	O
malignant	O
tumors	O
but	O
not	O
in	O
benign	O
tumors	O
.	O

Quantitative	O
reverse	O
transcription	O
-	O
PCR	O
and	O
Western	O
blot	O
analyses	O
showed	O
that	O
GRB7	B-GP
and	O
GRB7v	B-GP
were	O
frequently	O
upregulated	B-Positive_regulation
in	O
ovarian	B-DS
cancer	I-DS
samples	O
.	O

The	O
overexpressed	B-Gene_expression
GRB7	B-GP
(	O
P	O
=	O
0	O
.	O
009	O
)	O
and	O
GRB7v	O
(	O
P	O
=	O
0	O
.	O
017	O
)	O
were	O
significantly	O
correlated	O
with	O
high	O
-	O
grade	O
ovarian	B-DS
cancer	I-DS
.	O

Immunohistochemical	O
analysis	O
on	O
ovarian	B-DS
cancer	I-DS
tissue	O
array	O
confirmed	O
that	O
the	O
upregulated	B-Positive_regulation
GRB7	B-GP
was	O
significantly	O
correlated	O
with	O
high	O
-	O
grade	O
ovarian	O
cancer	O
(	O
P	O
=	O
0	O
.	O
001	O
).	O

Matrilysin	O
(	O
MMP	O
-	O
7	O
)	O
promotes	O
invasion	O
of	O
ovarian	B-DS
cancer	I-DS
cells	O
by	O
activation	B-Positive_regulation
of	O
progelatinase	B-GP
.	O

We	O
report	O
that	O
MMP	B-GP
-	I-GP
7	O
is	O
overexpressed	B-Gene_expression
in	O
ovarian	B-DS
cancer	I-DS
cell	O
lines	O
and	O
EOC	O
surgical	O
specimens	O
.	O

DOV13	B-DS
cells	O
incubated	O
with	O
active	O
rhMMP	O
-	O
7	O
significantly	O
increased	O
cellular	O
invasion	O
and	O
proMMP	B-GP
-	I-GP
2	O
activation	B-Positive_regulation
.	O

TIMP	O
-	O
2	O
or	O
the	O
generic	O
MMP	O
inhibitor	O
-	O
GM6001	O
inhibited	O
both	O
the	O
activation	B-Positive_regulation
of	O
proMMP	B-GP
-	I-GP
2	O
and	O
the	O
increased	O
invasion	O
of	O
DOV13	B-DS
cells	O
promoted	O
by	O
rhMMP	O
-	O
7	O
.	O

Despite	O
these	O
differences	O
,	O
ovarian	B-DS
carcinoma	I-DS
cells	O
show	O
substantial	O
accumulation	B-Positive_regulation
of	O
araCTP	B-GP
from	I-GP
extracellular	I-GP
araC	I-GP
.	O

Increase	B-Positive_regulation
in	O
nitric	B-GP
oxide	I-GP
synthase	I-GP
activity	O
might	O
be	O
related	O
to	O
the	O
growth	O
and	O
malignant	O
behavior	O
of	O
ovarian	B-DS
cancer	I-DS
.	O

Our	O
findings	O
suggest	O
that	O
LH	O
/	O
hCG	O
influences	O
the	O
chemosensitivity	O
of	O
ovarian	B-DS
cancer	I-DS
cells	O
through	O
an	O
apoptosis	O
-	O
inhibitory	O
signal	O
possibly	O
via	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
IGF	B-GP
-	I-GP
1	O
expression	O
.	O

Mesothelin	B-GP
is	O
a	O
glycosyl	O
-	O
phosphatidyl	O
inositol	O
(	O
GPI	O
)-	O
linked	O
membrane	O
protein	O
of	O
40	O
kDa	O
over	B-Gene_expression
-	I-Gene_expression
expressed	I-Gene_expression
in	O
all	O
pancreatic	O
adenocarcinoma	O
and	O
mesothelioma	O
,	O
in	O
>	O
70	O
%	O
of	B-DS
ovarian	I-DS
adenocarcinoma	I-DS
,	O
and	O
in	O
non	O
-	O
small	O
cell	O
lung	O
and	O
colorectal	O
cancers	O
.	O

Estradiol	O
stimulates	B-Positive_regulation
cell	O
growth	O
and	O
secretion	O
of	O
procathepsin	B-GP
D	O
and	O
a	O
120	O
-	O
kilodalton	O
protein	O
in	O
the	O
human	O
ovarian	B-DS
cancer	I-DS
cell	O
line	O
BG	O
-	O
1	O
.	O

LPA	O
increased	B-Positive_regulation
COX	B-GP
-	I-GP
2	I-GP
protein	I-GP
expression	B-Gene_expression
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
in	O
two	O
of	O
three	O
immortalized	O
borderline	O
ovarian	O
epithelial	O
cells	O
as	O
well	O
as	O
in	O
four	O
of	O
six	O
ovarian	B-DS
cancer	I-DS
cell	O
lines	O
.	O

In	O
patients	O
with	O
ovarian	B-DS
cancer	I-DS
,	O
the	O
increased	B-Positive_regulation
leptin	B-GP
levels	B-Gene_expression
were	O
associated	O
with	O
higher	O
circulating	O
follicle	O
-	O
stimulating	O
hormone	O
(	O
FSH	O
).	O

We	O
previously	O
reported	O
that	O
LTBP	B-GP
-	I-GP
1L	I-GP
is	O
overexpressed	B-Gene_expression
in	O
some	O
patients	O
with	O
ovarian	B-DS
cancer	I-DS
.	O

Interestingly	O
,	O
ovarian	B-DS
cancer	I-DS
patients	O
(	O
n	O
=	O
42	O
)	O
with	O
G	O
-	O
A	O
/	O
G	O
-	O
A	O
homozygous	O
genotype	O
had	O
increased	B-Positive_regulation
expression	B-Gene_expression
of	O
LTBP	B-GP
-	I-GP
1	O
and	O
apparently	O
poorer	O
survival	O
than	O
those	O
with	O
other	O
genotypes	O
(	O
P	O
=	O
0	O
.	O
02	O
).	O

Intriguingly	O
,	O
the	O
loss	B-Negative_regulation
of	O
MKP3	B-GP
protein	I-GP
was	O
associated	O
with	O
ubiquitination	O
/	O
proteosome	O
degradation	O
mediated	O
by	O
high	O
intracellular	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
accumulation	O
such	O
as	O
hydrogen	O
peroxide	O
in	O
ovarian	B-DS
cancer	I-DS
cells	O
.	O

Functionally	O
,	O
short	O
hairpin	O
RNA	O
knock	O
down	O
of	O
endogenous	O
MKP3	O
resulted	O
in	O
increased	B-Positive_regulation
ERK1	B-GP
/	I-GP
2	O
activity	O
,	O
cell	O
proliferation	O
rate	O
,	O
anchorage	O
-	O
independent	O
growth	O
ability	O
and	O
resistance	O
to	O
cisplatin	O
in	O
ovarian	B-DS
cancer	I-DS
cells	O
.	O

Conversely	O
,	O
enforced	B-Positive_regulation
expression	B-Gene_expression
of	O
MKP3	B-GP
in	O
MKP3	O
-	O
deficient	O
ovarian	B-DS
cancer	I-DS
cells	O
significantly	O
reduced	B-Negative_regulation
ERK1	B-GP
/	I-GP
2	O
activity	O
and	O
inhibited	O
cell	O
proliferation	O
,	O
anchorage	O
-	O
independent	O
growth	O
ability	O
and	O
tumor	O
development	O
in	O
nude	O
mice	O
.	O

Hyaluronan	O
-	O
CD44	O
interaction	O
with	O
neural	O
Wiskott	O
-	O
Aldrich	O
syndrome	O
protein	O
(	O
N	O
-	O
WASP	O
)	O
promotes	O
actin	O
polymerization	O
and	O
ErbB2	B-GP
activation	B-Positive_regulation
leading	O
to	O
beta	O
-	O
catenin	O
nuclear	O
translocation	O
,	O
transcriptional	O
up	O
-	O
regulation	O
,	O
and	O
cell	O
migration	O
in	O
ovarian	B-DS
tumor	I-DS
cells	O
.	O

Coordinate	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
TMEM97	B-GP
and	O
cholesterol	B-GP
biosynthesis	I-GP
genes	I-GP
in	O
normal	O
ovarian	O
surface	O
epithelial	O
cells	O
treated	O
with	O
progesterone	O
:	O
implications	O
for	O
pathogenesis	O
of	O
ovarian	B-DS
cancer	I-DS
.	O

Our	O
findings	O
indicate	O
that	O
:	O
(	O
I	O
)	O
VDR	B-GP
expression	B-Gene_expression
is	O
increased	B-Positive_regulation
in	O
ovarian	B-DS
carcinomas	I-DS
as	O
compared	O
to	O
normal	O
ovarian	O
tissue	O
.	O

(	O
II	O
)	O
Up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
VDR	B-GP
in	O
ovarian	B-DS
carcinomas	I-DS
is	O
not	O
exclusively	O
induced	O
by	O
an	O
increase	O
of	O
proliferation	O
,	O
but	O
by	O
different	O
unknown	O
mechanisms	O
.	O

Transfection	B-Gene_expression
with	O
GSK	B-GP
-	I-GP
3betaS9A	I-GP
to	O
upregulate	B-Positive_regulation
the	O
GSK	B-GP
-	I-GP
3beta	I-GP
activity	O
resulted	O
in	O
the	O
increase	B-Positive_regulation
of	O
BrdU	B-GP
incorporation	O
in	O
SKOV3	B-DS
cells	O
compared	O
with	O
that	O
in	O
the	O
control	O
vector	O
.	O

On	O
the	O
contrary	O
,	O
transfection	B-Gene_expression
with	O
GID5	B-GP
-	I-GP
6	O
to	O
downregulate	O
GSK	O
-	O
3beta	O
activity	O
decreased	O
the	O
BrdU	O
incorporation	O
in	O
SKOV3	B-DS
cells	O
,	O
compared	O
with	O
that	O
in	O
GID5	O
-	O
6LP	O
,	O
which	O
is	O
a	O
control	O
vector	O
of	O
GID5	O
-	O
6	O
.	O

Targeting	O
and	O
down	O
-	O
regulation	O
of	O
ErbB2	B-GP
,	O
a	O
member	O
of	O
EGF	O
receptor	O
family	O
,	O
is	O
regarded	O
as	O
one	O
of	O
the	O
key	O
aspect	O
for	O
cancer	O
treatment	O
because	O
it	O
is	O
often	O
overexpressed	B-Gene_expression
in	O
breast	O
and	O
ovarian	B-DS
cancer	I-DS
cells	O
.	O

Quantitative	O
PCR	O
revealed	O
decreased	B-Negative_regulation
Notch	B-GP
1	O
mRNA	O
in	O
ovarian	B-DS
adenocarcinomas	I-DS
compared	O
with	O
adenomas	O
.	O

Progression	O
of	O
benign	O
prostate	B-DS
cancer	I-DS
to	O
malignant	O
metastasis	O
is	O
linked	O
to	O
increased	B-Positive_regulation
production	B-Gene_expression
of	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	B-GP
),	O
a	O
powerful	O
mitogen	O
.	O

In	O
this	O
study	O
,	O
using	O
in	O
vitro	O
model	O
system	O
we	O
show	O
that	O
DPPIV	O
loss	O
is	O
associated	O
with	O
increased	B-Positive_regulation
bFGF	B-GP
production	B-Gene_expression
in	O
metastatic	B-DS
prostate	I-DS
cancer	I-DS
cells	O
.	O

DPPIV	O
reexpression	O
in	O
prostate	B-DS
cancer	I-DS
cells	O
blocks	O
nuclear	O
localization	O
of	O
bFGF	O
,	O
reduces	B-Negative_regulation
bFGF	B-GP
levels	O
,	O
inhibits	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)-	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
1	O
/	O
2	O
activation	O
,	O
and	O
decreases	O
levels	O
of	O
urokinase	O
-	O
type	O
plasminogen	O
activator	O
,	O
known	O
downstream	O
effectors	O
of	O
bFGF	O
signaling	O
pathway	O
.	O

Our	O
findings	O
suggest	O
that	O
blockage	B-Negative_regulation
of	O
osteopontin	B-GP
and	O
/	O
or	O
COX	O
-	O
2	O
is	O
a	O
promising	O
therapeutic	O
approach	O
for	O
the	O
inhibition	O
of	O
prostate	B-DS
tumor	I-DS
progression	O
and	O
angiogenesis	O
.	O

Elevated	B-Positive_regulation
expression	B-Gene_expression
of	O
Met	B-GP
has	O
been	O
shown	O
in	O
advanced	O
cases	O
of	O
carcinoma	B-DS
of	I-DS
the	I-DS
prostate	I-DS
,	O
stomach	O
,	O
pancreas	O
,	O
and	O
thyroid	O
.	O

Androgens	O
repress	B-Negative_regulation
Bcl	B-GP
-	I-GP
2	O
expression	B-Gene_expression
via	O
activation	O
of	O
the	O
retinoblastoma	O
(	O
RB	O
)	O
protein	O
in	O
prostate	B-DS
cancer	I-DS
cells	O
.	O

The	O
oncogene	O
Bcl	B-GP
-	I-GP
2	O
is	O
upregulated	B-Positive_regulation
frequently	O
in	O
prostate	B-DS
tumors	I-DS
following	O
androgen	O
ablation	O
therapy	O
,	O
and	O
Bcl	B-GP
-	I-GP
2	O
overexpression	B-Gene_expression
may	O
contribute	O
to	O
the	O
androgen	O
-	O
refractory	O
relapse	O
of	O
the	O
disease	O
.	O

Finally	O
,	O
androgen	O
treatment	O
of	O
LNCaP	B-DS
cells	O
upregulated	B-Positive_regulation
specifically	O
levels	O
of	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitors	O
(	O
CDKIs	O
)	O
p15INK4B	O
and	O
p27KIP1	B-GP
.	O

Prostate	B-DS
cancer	I-DS
cells	O
transfected	B-Gene_expression
with	O
EP4	B-GP
-	I-GP
siRNA	I-GP
and	O
treatments	O
with	O
EP4	O
antagonist	O
suggest	O
a	O
link	O
between	O
EP4	O
,	O
and	O
Snail	O
activation	O
,	O
potentially	O
via	O
p	O
-	O
Akt	O
.	O

Combined	O
blockade	B-Negative_regulation
of	O
RANK	O
/	O
RANKL	O
axis	O
and	O
BMP	B-GP
pathway	O
resulted	O
in	O
reduced	O
tumor	O
burden	O
and	O
decreased	O
bone	O
loss	O
compared	O
to	O
inhibition	O
of	O
either	O
individual	O
pathway	O
alone	O
in	O
osteolytic	O
prostate	B-DS
cancer	I-DS
lesion	O
in	O
bone	O
.	O

Induction	B-Positive_regulation
of	O
androgen	B-GP
receptor	I-GP
by	O
1alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
and	O
9	O
-	O
cis	O
retinoic	O
acid	O
in	O
LNCaP	O
human	O
prostate	B-DS
cancer	I-DS
cells	O
.	O

The	O
decrease	B-Negative_regulation
in	O
survivin	B-GP
gene	I-GP
expression	B-Gene_expression
by	O
transfection	O
of	O
siRNA	O
was	O
accompanied	O
by	O
the	O
inhibition	O
of	O
cell	O
proliferation	O
of	O
PCa	O
cells	O
(	O
31	O
%	O
and	O
25	O
%	O
decreased	O
in	O
LNCaP	B-DS
and	O
PC	O
-	O
3	O
cells	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

Antisense	O
oligodeoxynucleotides	O
,	O
designed	O
to	O
block	B-Negative_regulation
production	B-Gene_expression
of	O
epidermal	B-GP
-	I-GP
FABP	I-GP
(	O
a	O
marker	O
for	O
normal	O
prostate	O
cells	O
),	O
caused	O
increased	O
proliferation	O
in	O
DU	O
145	O
prostate	B-DS
cancer	I-DS
cells	O
.	O

In	O
vivid	O
contrast	O
,	O
antisense	O
oligodeoxynucleotides	O
to	O
L	B-GP
-	I-GP
FABP	I-GP
(	O
overexpressed	B-Gene_expression
in	O
prostate	B-DS
cancer	I-DS
)	O
decreased	O
proliferation	O
and	O
caused	O
apoptosis	O
.	O

Furthermore	O
,	O
elevated	O
[	O
Ca2	O
+]	O
o	O
triggered	O
activation	B-Positive_regulation
of	O
the	O
Akt	B-GP
signaling	O
pathway	O
and	O
enhanced	O
PC	B-DS
-	I-DS
3	O
cell	O
attachment	O
.	O

The	O
transcriptional	O
co	O
-	O
activator	O
cAMP	O
response	O
element	O
-	O
binding	O
protein	O
-	O
binding	O
protein	O
is	O
expressed	O
in	O
prostate	B-DS
cancer	I-DS
and	O
enhances	B-Positive_regulation
androgen	O
-	O
and	O
anti	O
-	O
androgen	O
-	O
induced	O
androgen	B-GP
receptor	I-GP
function	O
.	O

NP	O
manifested	O
no	O
immunoreactivity	O
,	O
whereas	O
Pca	O
and	O
BPH	B-DS
showed	O
significantly	O
increased	B-Positive_regulation
HIF	B-GP
-	I-GP
1alpha	I-GP
protein	I-GP
expression	B-Gene_expression
.	O

Our	O
findings	O
of	O
increased	B-Positive_regulation
HIF	B-GP
-	I-GP
1alpha	I-GP
protein	I-GP
expression	B-Gene_expression
in	O
BPH	B-DS
and	O
Pca	O
specimens	O
suggests	O
the	O
potential	O
role	O
of	O
this	O
protein	O
in	O
BPH	O
and	O
Pca	O
.	O

The	O
same	O
concentration	O
of	O
R1881	O
resulted	O
in	O
a	O
decrease	O
in	O
intracellular	O
glutathione	O
concentrations	O
and	O
an	O
increase	B-Positive_regulation
in	O
gamma	B-GP
-	I-GP
glutamyl	I-GP
transpeptidase	I-GP
activity	O
in	O
LNCaP	B-DS
cells	O
.	O

Treatment	O
with	O
the	O
oxidizing	O
agents	O
H2O2	O
and	O
menadione	O
produced	O
an	O
increase	B-Positive_regulation
in	O
gamma	B-GP
-	I-GP
glutamyl	I-GP
transpeptidase	I-GP
activity	O
in	O
LNCaP	B-DS
cells	O
,	O
whereas	O
treatment	O
with	O
the	O
antioxidant	O
compound	O
ascorbic	O
acid	O
(	O
100	O
mM	O
)	O
reduced	O
the	O
oxidative	O
stress	O
produced	O
in	O
LNCaP	O
cells	O
by	O
1	O
nM	O
R1881	O
and	O
completely	O
blocked	B-Negative_regulation
the	O
gamma	B-GP
-	I-GP
glutamyl	I-GP
transpeptidase	I-GP
activity	O
.	O

For	O
patients	O
with	O
metastatic	B-DS
prostate	I-DS
cancer	I-DS
,	O
treatment	O
is	O
primarily	O
palliative	O
,	O
relying	O
mainly	O
on	O
the	O
suppression	B-Negative_regulation
of	O
systemic	O
androgen	B-GP
hormone	I-GP
levels	O
.	O

Phenylbutyrate	O
attenuates	B-Negative_regulation
the	O
expression	B-Gene_expression
of	O
Bcl	O
-	O
X	O
(	O
L	O
),	O
DNA	O
-	O
PK	O
,	O
caveolin	O
-	O
1	O
,	O
and	O
VEGF	B-GP
in	O
prostate	B-DS
cancer	I-DS
cells	O
.	O

These	O
findings	O
indicate	O
that	O
FoxM1	B-GP
depletion	B-Negative_regulation
causes	O
cell	O
death	O
due	O
to	O
mitotic	O
catastrophe	O
and	O
that	O
inhibiting	O
FoxM1	O
represents	O
a	O
therapeutic	O
strategy	O
to	O
target	O
breast	B-DS
cancer	I-DS
.	O

Long	O
-	O
term	O
culture	O
of	O
MCF	B-DS
-	I-DS
7	O
cells	O
in	O
estrogen	O
deprived	O
medium	O
(	O
LTED	O
)	O
mimics	O
aromatase	B-GP
inhibition	B-Negative_regulation
in	O
patients	O
.	O

Its	O
stimulation	O
on	O
breast	B-DS
cancer	I-DS
cell	O
lines	O
induces	B-Positive_regulation
β1	B-GP
integrin	I-GP
and	O
promotes	O
tumor	O
invasiveness	O
.	O

P1	O
,	O
a	O
high	B-GP
mobility	I-GP
group	I-GP
-	I-GP
like	I-GP
protein	I-GP
is	O
depressed	B-Negative_regulation
in	O
human	O
breast	B-DS
adenocarcinoma	I-DS
.	O

We	O
showed	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
knockdown	O
of	O
PDI	O
in	O
MCF	O
-	O
7	O
human	O
breast	B-DS
cancer	I-DS
cells	O
with	O
RNA	O
interference	O
down	O
-	O
regulates	O
ERalpha	O
protein	O
but	O
up	B-Positive_regulation
-	I-Positive_regulation
regulates	I-Positive_regulation
ERbeta	B-GP
protein	I-GP
,	O
resulting	O
in	O
a	O
drastic	O
increase	O
in	O
ERbeta	O
/	O
ERalpha	O
ratio	O
,	O
which	O
is	O
a	O
crucial	O
determinant	O
of	O
different	O
cellular	O
responses	O
to	O
estrogens	O
.	O

A	O
higher	O
increase	B-Positive_regulation
of	O
the	O
expression	B-Gene_expression
and	O
maximal	O
pixel	O
intensity	O
of	O
ICAM	B-GP
-	I-GP
1	O
,	O
VCAM	O
-	O
1	O
and	O
P	O
-	O
selectin	O
was	O
observed	O
in	O
endothelial	O
cells	O
cocultured	O
with	O
c	O
-	O
erbB2	O
-	O
positive	O
breast	B-DS
carcinoma	I-DS
cells	O
as	O
compared	O
to	O
endothelial	O
cells	O
cocultured	O
with	O
c	O
-	O
erbB2	O
-	O
negative	O
cell	O
line	O
.	O

In	O
addition	O
,	O
even	O
a	O
transient	O
,	O
siRNA	O
-	O
mediated	O
p21	B-GP
suppression	B-Negative_regulation
in	O
fibroblasts	O
sufficiently	O
stimulates	O
MCF7	O
and	O
MDA	B-DS
-	I-DS
MB	I-DS
-	I-DS
231	I-DS
growth	O
in	O
vivo	O
.	O

The	O
observed	O
relationship	O
between	O
the	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
Bcl	B-GP
-	I-GP
2	O
and	O
induction	O
of	O
apoptosis	O
was	O
not	O
causal	O
because	O
stable	O
overexpression	O
of	O
Bcl	O
-	O
2	O
resulted	O
in	O
protection	O
of	O
MCF	B-DS
-	I-DS
7	O
cells	O
from	O
the	O
cytotoxic	O
morphological	O
changes	O
and	O
growth	O
-	O
inhibitory	O
effects	O
of	O
butyrate	O
(	O
15	O
%	O
growth	O
inhibition	O
compared	O
to	O
60	O
%	O
growth	O
inhibition	O
in	O
the	O
parental	O
cells	O
).	O

The	O
non	O
-	O
receptor	O
PTK	O
termed	O
breast	O
tumor	O
kinase	O
(	O
Brk	B-GP
/	I-GP
PTK6	I-GP
)	O
is	O
overexpressed	B-Gene_expression
in	O
approximately	O
86	O
%	O
of	O
human	O
breast	B-DS
tumors	I-DS
.	O

Brk	O
-	O
dependent	O
signaling	O
to	O
p38	O
MAPK	O
was	O
recapitulated	O
by	O
Brk	B-GP
overexpression	B-Gene_expression
in	O
the	O
HC11	O
murine	O
mammary	O
epithelial	O
cell	O
(	O
MEC	O
)	O
line	O
and	O
human	O
MEC	O
,	O
while	O
Brk	O
knock	O
-	O
down	O
in	O
breast	B-DS
cancer	I-DS
cells	O
blocked	O
EGF	O
-	O
stimulated	O
p38	O
signaling	O
.	O

Intercellular	B-GP
adhesion	I-GP
molecule	I-GP
1	I-GP
(	I-GP
ICAM	I-GP
-	I-GP
1	O
)	O
was	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	I-Negative_regulation
in	O
MCF10A	B-DS
cells	O
using	O
short	O
hairpin	O
RNA	O
.	O

The	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
ICAM	B-GP
-	I-GP
1	O
by	O
short	O
hairpin	O
RNA	O
in	O
MCF10A	B-DS
cells	O
led	O
to	O
the	O
induction	B-Positive_regulation
of	O
psoriasin	O
,	O
calgranulin	B-GP
-	I-GP
A	O
,	O
calgranulin	O
-	O
B	O
,	O
and	O
MUC1	O
,	O
and	O
we	O
demonstrated	O
that	O
these	O
up	O
-	O
regulations	O
were	O
not	O
ROS	O
dependent	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
ICAM	B-GP
-	I-GP
1	O
in	O
mammary	O
epithelial	O
cells	O
may	O
contribute	O
both	O
to	O
the	O
high	O
expression	O
of	O
psoriasin	O
seen	O
in	O
some	O
high	O
-	O
grade	O
DCIS	B-DS
tumors	O
and	O
to	O
the	O
induction	B-Positive_regulation
of	O
MUC1	B-GP
.	O

RT	O
-	O
PCR	O
and	O
Western	O
blot	O
showed	O
that	O
the	O
expressions	B-Gene_expression
of	O
only	O
c	O
-	O
Met	O
and	O
STAT3	B-GP
decreased	B-Negative_regulation
obviously	O
in	O
colon	O
and	O
breast	B-DS
cancer	I-DS
cells	O
exposed	O
to	O
LS	O
-	O
7	O
.	O

These	O
compounds	O
decreased	B-Negative_regulation
ERalpha	B-GP
in	O
MCF	B-DS
-	I-DS
7	O
cells	O
at	O
both	O
mRNA	O
and	O
protein	O
levels	O
,	O
and	O
suppressed	O
estrogen	O
-	O
stimulated	O
genes	O
.	O

Oestradiol	O
acutely	O
increases	B-Positive_regulation
PI3	O
-	O
kinase	O
and	O
Akt	B-GP
activities	O
in	O
MCF	B-DS
-	I-DS
7	O
cells	O
.	O

The	O
Src	O
inhibitor	O
,	O
PP1	O
,	O
prevents	O
hormone	O
stimulation	B-Positive_regulation
of	O
Akt	B-GP
and	O
PI3	O
-	O
kinase	O
activities	O
in	O
MCF	B-DS
-	I-DS
7	O
cells	O
.	O

In	O
turn	O
,	O
stimulation	O
of	O
Src	O
activity	O
is	O
abolished	O
in	O
ERalpha	O
-	O
expressing	O
NIH	O
3T3	O
fibroblasts	O
by	O
co	B-Gene_expression
-	I-Gene_expression
transfection	I-Gene_expression
of	O
the	O
dominant	B-GP
-	I-GP
negative	I-GP
p85alpha	I-GP
and	O
in	O
MCF	B-DS
-	I-DS
7	O
cells	O
by	O
the	O
PI3	O
-	O
kinase	O
inhibitor	O
,	O
LY294002	O
.	O

Our	O
findings	O
suggest	O
loss	B-Negative_regulation
of	O
E	B-GP
-	I-GP
cadherin	I-GP
expression	B-Gene_expression
in	O
some	O
breast	B-DS
cancers	I-DS
may	O
be	O
due	O
to	O
dominant	O
repression	O
of	O
the	O
trans	O
-	O
acting	O
pathways	O
that	O
regulate	O
E	O
-	O
cadherin	O
transcription	O
.	O

Heregulin	O
and	O
agonistic	O
anti	O
-	O
p185	O
(	O
c	O
-	O
erbB2	O
)	O
antibodies	O
inhibit	O
proliferation	O
but	O
increase	O
invasiveness	O
of	O
breast	B-DS
cancer	I-DS
cells	O
that	O
overexpress	B-Gene_expression
p185	B-GP
(	O
c	O
-	O
erbB2	O
):	O
increased	O
invasiveness	O
may	O
contribute	O
to	O
poor	O
prognosis	O
.	O

PKC	O
-	O
zeta	O
is	O
required	O
for	O
angiotensin	O
II	O
-	O
induced	O
activation	B-Positive_regulation
of	O
ERK	B-GP
and	O
synthesis	O
of	O
C	O
-	O
FOS	O
in	O
MCF	B-DS
-	I-DS
7	O
cells	O
.	O

When	O
the	O
epidermal	B-GP
growth	I-GP
factor	I-GP
-	I-GP
receptor	I-GP
(	O
EGFR	O
)	O
tyrosine	O
kinase	O
activity	O
was	O
inhibited	B-Negative_regulation
by	O
the	O
use	O
of	O
its	O
inhibitor	O
AG1478	O
,	O
Ang	O
II	O
was	O
still	O
able	O
to	O
induce	B-Positive_regulation
ERK1	O
/	O
2	O
phosphorylation	O
and	O
c	B-GP
-	I-GP
fos	I-GP
expression	O
,	O
therefore	O
proving	O
that	O
the	O
transactivation	O
of	O
EGFR	O
was	O
not	O
required	O
for	O
these	O
Ang	O
II	O
effects	O
in	O
MCF	B-DS
-	I-DS
7	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
in	O
MCF	B-DS
-	I-DS
7	O
cells	O
Ang	O
II	O
activates	O
multiple	O
signalling	O
pathways	O
involving	O
PKC	O
-	O
zeta	O
,	O
PI3K	O
and	O
MAPK	O
;	O
of	O
these	O
pathways	O
only	O
PKC	O
-	O
zeta	O
appears	O
responsible	O
for	O
the	O
induction	B-Positive_regulation
of	O
c	B-GP
-	I-GP
fos	I-GP
.	O

In	O
the	O
former	O
group	O
,	O
ErbB2	B-GP
overexpression	B-Gene_expression
was	O
strongly	O
associated	O
with	O
increased	O
risk	O
of	O
recurrence	O
(	O
RR	O
=	O
4	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
1	O
-	O
10	O
.	O
4	O
)	O
and	O
breast	B-DS
cancer	I-DS
death	O
(	O
RR	O
=	O
5	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
3	O
-	O
12	O
.	O
6	O
).	O

Transfecting	B-Gene_expression
A2780	B-DS
cells	O
with	O
active	O
Notch	B-GP
1	I-GP
-	I-GP
IC	I-GP
resulted	O
in	O
a	O
proliferative	O
and	O
colony	O
formation	O
advantage	O
compared	O
to	O
mock	O
transfected	O
cells	O
.	O

Immunoblotting	O
analysis	O
demonstrated	O
that	O
PRB	B-GP
protein	I-GP
expression	B-Gene_expression
was	O
markedly	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
in	O
OVCAR	B-DS
-	I-DS
3	O
,	O
whereas	O
the	O
PRA	O
and	O
PRB	O
isoforms	O
both	O
appeared	O
to	O
be	O
increased	O
in	O
NOV	O
-	O
31	O
.	O

These	O
results	O
suggest	O
that	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
PRA	B-GP
is	O
associated	O
with	O
the	O
development	O
of	O
ovarian	B-DS
epithelial	I-DS
carcinoma	I-DS
.	O

Overexpression	B-Gene_expression
of	O
p185	O
(	O
c	O
-	O
erbB2	O
)	O
(	O
p185	B-GP
/	I-GP
NEU	I-GP
/	I-GP
HER2	I-GP
)	O
by	O
tumor	O
cells	O
is	O
associated	O
with	O
a	O
poor	O
prognosis	O
in	O
many	O
but	O
not	O
all	O
studies	O
of	O
breast	O
and	O
ovarian	B-DS
cancer	I-DS
.	O

Moreover	O
,	O
the	O
poor	O
prognosis	O
of	O
breast	O
and	O
ovarian	B-DS
cancers	I-DS
that	O
overexpress	B-Gene_expression
p185	B-GP
(	O
c	O
-	O
erbB2	O
)	O
could	O
relate	O
in	O
part	O
to	O
enhanced	O
invasiveness	O
rather	O
than	O
to	O
increased	O
proliferative	O
capacity	O
.	O

This	O
study	O
showed	O
that	O
IL	B-GP
-	I-GP
18	I-GP
serum	O
levels	O
were	O
elevated	B-Positive_regulation
in	O
ovarian	B-DS
cancer	I-DS
patients	O
and	O
were	O
correlated	O
with	O
overall	O
survival	O
,	O
although	O
they	O
were	O
shown	O
not	O
to	O
be	O
an	O
independent	O
prognostic	O
factor	O
.	O

Overexpression	B-Gene_expression
of	O
TUBB3	B-GP
protein	I-GP
was	O
observed	O
in	O
56	O
(	O
85	O
%)	O
of	O
the	O
66	O
ovarian	B-DS
cancers	I-DS
,	O
and	O
was	O
significantly	O
associated	O
with	O
aggressive	O
tumor	O
behavior	O
(	O
advanced	O
stage	O
,	O
presence	O
of	O
ascites	O
,	O
suboptimal	O
cytoreduction	O
at	O
surgery	O
and	O
presence	O
of	O
lymph	O
node	O
metastasis	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

In	O
2	O
cell	O
lines	O
with	O
weak	O
expression	O
of	O
TUBB3	O
protein	O
(	O
OVCAR	B-DS
-	I-DS
3	O
and	O
JHOC	O
-	O
8	O
),	O
TUBB3	B-GP
induction	B-Positive_regulation
was	O
independently	O
induced	O
by	O
treatment	O
with	O
5	O
-	O
Aza	O
-	O
CdR	O
(	O
JHOC	O
-	O
8	O
)	O
or	O
PBA	O
(	O
OVCAR	O
-	O
3	O
),	O
while	O
neither	O
agent	O
markedly	O
altered	O
TUBB3	O
mRNA	O
/	O
protein	O
expression	O
in	O
a	O
strongly	O
TUBB3	O
-	O
expressing	O
cell	O
line	O
(	O
JHOC	O
-	O
5	O
).	O

A	O
CpG	O
island	O
of	O
another	O
cell	O
line	O
showing	O
faint	O
expression	O
of	O
TUBB3	O
protein	O
(	O
OVCAR	B-DS
-	I-DS
3	O
),	O
in	O
which	O
a	O
significant	O
gain	O
of	O
TUBB3	B-GP
expression	B-Gene_expression
was	O
induced	B-Positive_regulation
by	O
treatment	O
with	O
PBA	O
but	O
not	O
with	O
5	O
-	O
Aza	O
-	O
CdR	O
,	O
was	O
hypomethylated	O
,	O
similarly	O
to	O
a	O
cell	O
line	O
(	O
JHOC	O
-	O
5	O
)	O
showing	O
constitutive	O
expression	O
of	O
TUBB3	O
.	O

p53	B-GP
accumulation	B-Positive_regulation
in	O
ovarian	B-DS
carcinomas	I-DS
and	O
its	O
prognostic	O
implications	O
.	O

These	O
results	O
suggest	O
that	O
p53	B-GP
accumulation	B-Positive_regulation
occurs	O
more	O
frequently	O
in	O
tumors	O
with	O
aggressive	O
behavior	O
and	O
that	O
p53	O
immunoreactivity	O
may	O
have	O
a	O
prognostic	O
role	O
in	O
certain	O
subsets	O
of	O
patients	O
with	O
ovarian	B-DS
carcinoma	I-DS
.	O

Induction	B-Positive_regulation
of	O
MDR1	B-GP
-	I-GP
gene	I-GP
expression	B-Gene_expression
by	O
antineoplastic	O
agents	O
in	O
ovarian	B-DS
cancer	I-DS
cell	O
lines	O
.	O

Induction	B-Positive_regulation
of	O
gamma	B-GP
-	I-GP
glutamyl	I-GP
transpeptidase	I-GP
mRNA	I-GP
by	O
platinum	O
complexes	O
in	O
a	O
human	O
ovarian	B-DS
carcinoma	I-DS
cell	O
line	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
sublines	O
of	O
human	O
ovarian	B-DS
carcinoma	I-DS
cell	O
line	O
A2780	O
,	O
which	O
exhibited	O
low	O
levels	O
of	O
resistance	O
to	O
oxaliplatin	O
,	O
showed	O
elevated	B-Positive_regulation
steady	O
state	O
levels	O
of	O
mRNA	O
and	O
activity	O
of	O
gamma	B-GP
-	I-GP
glutamyl	I-GP
transpeptidase	I-GP
(	O
gamma	O
-	O
GT	O
,	O
EC	O
2	O
.	O
3	O
.	O
2	O
.	O
2	O
),	O
but	O
not	O
of	O
gamma	O
-	O
glutamylcysteine	O
synthetase	O
(	O
gamma	O
-	O
GCS	O
,	O
EC	O
6	O
.	O
3	O
.	O
2	O
.	O
2	O
)	O
[	O
El	O
-	O
akawi	O
et	O
al	O
.,	O
Cancer	O
Lett	O
.	O
105	O
:	O
5	O
-	O
14	O
;	O
1966	O
].	O

Thus	O
,	O
ING1	O
mutation	O
is	O
very	O
rare	O
in	O
breast	O
or	O
ovarian	B-DS
cancers	I-DS
,	O
however	O
,	O
repression	B-Negative_regulation
of	O
ING1	B-GP
expression	B-Gene_expression
frequently	O
accompanies	O
tumour	O
development	O
of	O
breast	O
cancer	O
.	O

Pronounced	O
increases	B-Positive_regulation
in	O
the	O
concentration	O
of	O
an	O
ovarian	B-DS
tumor	I-DS
marker	O
,	O
CA	B-GP
-	I-GP
125	I-GP
,	O
in	O
serum	O
of	O
a	O
healthy	O
subject	O
during	O
menstruation	O
.	O

[	O
Antitumor	O
effect	O
of	O
endothelial	O
progenitor	O
cells	O
with	O
TRAIL	B-GP
gene	I-GP
transfection	B-Gene_expression
on	O
ovarian	B-DS
carcinoma	I-DS
xenografts	O
in	O
nude	O
mice	O
].	O

Lewis	O
y	O
overexpression	O
led	O
to	O
an	O
increase	B-Positive_regulation
in	O
both	O
mRNA	O
and	O
protein	O
expression	O
levels	O
of	O
cyclin	B-GP
A	O
,	O
cyclin	O
D1	O
and	O
cyclin	O
E	O
in	O
ovarian	B-DS
cancer	I-DS
cells	O
,	O
decrease	O
in	O
both	O
mRNA	O
and	O
protein	O
expression	O
levels	O
of	O
p16	O
and	O
p21	O
,	O
and	O
decrease	B-Negative_regulation
of	O
p27	B-GP
at	O
only	O
the	O
protein	O
expression	O
level	O
without	O
change	O
in	O
its	O
mRNA	O
level	O
.	O

Abdominopelvic	O
tuberculosis	O
simulating	O
disseminated	O
ovarian	B-DS
carcinoma	I-DS
with	O
elevated	B-Positive_regulation
CA	B-GP
-	I-GP
125	I-GP
level	O
:	O
report	O
of	O
two	O
cases	O
.	O

Ovarian	B-DS
cancer	I-DS
patients	O
with	O
elevated	B-Positive_regulation
CA	B-GP
125	I-GP
levels	O
after	O
three	O
chemotherapy	O
courses	O
have	O
a	O
poor	O
prognosis	O
.	O

The	O
antisense	O
oligonucleotides	O
targeting	O
VEGF	O
-	O
A	O
significantly	O
decreased	B-Negative_regulation
VEGF	B-GP
-	I-GP
A	I-GP
protein	I-GP
and	I-GP
mRNA	I-GP
expression	B-Gene_expression
and	O
inhibited	O
cell	O
migration	O
in	O
SKOV3	O
ovarian	B-DS
cancer	I-DS
cells	O
.	O

Patients	O
with	O
invasive	O
ovarian	B-DS
cancer	I-DS
were	O
found	O
to	O
have	O
significantly	O
higher	B-Positive_regulation
median	O
c	B-GP
-	I-GP
erbB	I-GP
-	I-GP
2	I-GP
oncoprotein	I-GP
expression	B-Gene_expression
than	O
patients	O
with	O
either	O
benign	O
ovarian	O
cyst	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
or	O
control	O
groups	O
(	O
P	O
=	O
0	O
.	O
001	O
).	O

Overexpression	B-Gene_expression
of	O
c	B-GP
-	I-GP
erbB	I-GP
-	I-GP
2	I-GP
oncoprotein	I-GP
was	O
found	O
in	O
seven	O
(	O
21	O
.	O
9	O
%)	O
of	O
32	O
epithelial	B-DS
ovarian	I-DS
cancers	I-DS
.	O

CCBE1	B-GP
is	O
expressed	O
in	O
normal	O
ovary	O
,	O
but	O
is	O
reduced	B-Negative_regulation
in	O
ovarian	B-DS
cancer	I-DS
cell	O
lines	O
and	O
primary	O
carcinomas	O
.	O

